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7.0 ADDENDUM
7.1 Introduction
This addendum provides further justification for the
use of microgravity for the Blood Storage Experiments.
The addendum is comprised of five portions: I) signifi-
cance, 2) working hypothesis, 3) storage lesions at
earth's gravity, 4) biomaterials and 5) sugary.
7,2.
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Significance ,
The possibility of conducting experiments with the
formed elements of the blood under conditions of
microgravity opens up important opportunities to improve
our understanding of basic formed element physiology as
well as contribute to imvroved preservation of the
formed elements for use in transfusion. In attemptin_
to identify the possible effects of reduced gravita-
tional attraction on formcd elements during preserva-
tion, it is essential to recognize that I) the formed
elements - red cells, white cells and platelets - are
complex living systems which depend upon multiple
interactions with their extracellular environment, of
which gravitational force is but one component; and 2)
the surivial within the circulation and the functional
capacity of stored formed elements after transfusion are
markedly diminished when compared to cells from fresh
blood.
Multiple factors affect blood cells during storage such
as sedimentation, diffusion of nutrients and metab-
olites, gas tran_ort, mechanical trauma due to mixing
and leaching of chemical compounds from the container
materinl. Storage under standard blood bank conditions
invariably exposes blood to Earth's gravity, and leads
to injuries, i.e. storage lesions (see below) to the
stored formed elements.
Exposure of the blood at microgravity in the space
shuttle is expected to result in a greatly reduced
perturbation of cell functions and permit the separation
of sedimentation, mixing and container lesions which are
associated with terrestrial blood storage.
Information gained from storage experi_m.nts under
microgravity as proposed will add a new and important
dimension to our understanding of blood cell membrane
functions and the storage defects, and serve as a
guideline for design of the improved methodology for
blood storage on Earth. Further, the knowledge gained
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can serve as a guide not only for tht polymer indultry
to develop alternative blood bags but also for the
pharmaceutical industry to study drug effects on cell
membranes,
7.3 An Experimental Hypothesis
The objective of this proposal is a comparative evalua-
tion of the physiological, biochemical and physical
changes of the membrane of the erythrocyte, platelet,
and leukocyte during storage under two specific condi-
tions: standard blood bank conditions and microgravity,
utilizing three plastic formulations.
GiVen the complexity of living biolozical systems, the
wide range of possible measurements _ich could be made
and the limited set of measurements which have been
chosen in the first set of experiments, the followdn_
are some of the results we expect from our studies:
Studies comparing the state of human blood following
prolonzed preservation at a) Earth's gravity, and b)
the microgravity within the shuttle, should shed
important new light on the fundamental cell physio-
logy of each type of blood cells, and, if we are
fortunate in our choice of measurements, should
provide significant new clues to improved preserv-
ation of these important materials on earth.
For cells preserved at microgravity, the adverse
effects of sedimentation and mixing should be less
apparent against the background of container lesions
and aging lesions.
Red cells preserved at microgravity should exhibit
improved pH control and more nearly physiologicnl
levels of important metabolites such as ATP and 2,3
DPG.
Platelets and leukocytes which are more sensitive
than red cells to harmful effects from cell-cell
interactions, should show superior indices of cell
viability and potential to function after storage at
microgrsvity in comparison to controls kept on Earth.
Adverse effects of synthetic polymers vhlch originate
from cell-surface interactions should be reduced
during microgravity preservation.
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7.4 Storage Lesions at Earth's Cravity
In this portion, the discussion is divided into four
sections: 1) storage lesions overview, 2) red cell
storage on Earth, 3) platelet storage on Earth, and 4)
leukocyte storage on Earth.
7.4.I Storage Lesion Overview
In discussin_ the science of blood formed element
preservation, it has proved useful to classify observed
results into several categories of effects, termed
lesions• It e_ust be noted, however, that this does not
necessarily mean that we can identify a specific area of
physical damage or injury with each lesion.
7.4.1.1 Sedimentation Lesions
The sedimentation leslon results from the dense packing
• of the formed elements, with resulting intensity of
injurious cell-cell and cell-container surface inter-
actions. Under these circumstances, metabolic injury
can occur as cells are deprived of their substrates or
as cell wastes concentrate in the immediate vicinity
rathcr than being dissipated and removed as in the
physiological state.
Within the blood stream, erythrocytes, leukocytes and
platelets, like all cells, are metabolically active.
They are supplied with energy in the form of small
organic molecules (substrates), which are contained in
the fluid medium, the plasma, which surrounds them, and
they depend upon the plasma to accept the waste products
of their metabolism. If these waste products, partic-
ularly carbon dioxide, are not removed, they can quickly
alter the extracellular environment and injure the cell.
The blood cells utilize energy to carry out their
physiological functions, and to maintain their own
integrity• Thus, the red cell requires a constant
supply of energy derived primarily from the metabolism
of glucose to maintain its unique biconcave dibcoid
shape. If the metabolic system fails, the cells
invariably die.
The rationale of preservation of the red blood cell, the
formed element about which we know the most, takes
advantage of what is known about red cell metabolism. A
preservative diluent solution provides glucose, the main
energy source, and other chemical intermediates needed
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to foster a viable metabolic system. Another constit-
uent of the diluent lowers the pH of the red cell
suspension. And finally, and most important, the
temperature is reduced from 37.5"C to between I and 6"C.
Under these conditions, the metabolic system is put into
a quasi-hibernative state, in which it survives remark-
ably veil. Glucose utilization proceeds at a very slow
rate, as does carbon dioxide production; and no oxygen
is required.
It follows that an experiment at microRrsvity will shed
light on cellular metabolism and other varameters of
cellular viability which are most sensitive to the
harmful effects of gravitational fosce.
7.4.1.2 Aging Lesions
Agin_ lesions arise from the simple fact of biologic
a_inR which all biologicel cells are subject to. Red
Cells, for example, normally live for 120 days in the
circulating blood. Thus, if preserved outside the body,
• red cells may continue to age. In the blood bank, at
l-6"C, this aging contributes to the time limit for
preservation. The specific cause of biologic aging is
not knovn but is thought to include membrane changes of
cells.
The ability of blood cells (red cells, platelets and
leukocytes) to maintain their size and shape against the
stress of gravity requires the expenditure of energy.
Reduction or elimination of this stress in microgravity
will lead to marked energy conservation. As a result,
the characteristics of the aging processes of blood
cells can be better defined.
7.4.1.3 Container Lesions
Container lesions are defined as those effects brought
about by exposure of the blood or its formed elements to
foreign surfaces such as _lass tubes, metal needles and
plastic bags. These include but are not limited to
cell-foreign surface effects and cell-foreign surface
constituent effects. A vhole field of endeavor is
concerned with cell-foreign surface effects; these being
particularly important in respect to implanted prosthe-
tic devices, such as artificial heart valves, prosthetic
aortas, etc. In these cases, biocompatibility is
probably determined by physical forces at the interface
between the solid and liquid phases of the blood forces
which may adsorb and rupture formed elements, or which
may damage the complex composition of lipids and
proteins in the cell membrane.
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An example of a cell-forelgn surface constituent effect
is the leaching of the organic chemical plasticizer,
DEHP, from the plastic blood ba8 onto the red cell
surface.
7.4.1.4 Mixing Lesions
Mixing lesions represent the fourth type of storage
lesions _ich are encountered in blood preservation.
These result from the use of mixing procedures to
improve the preservation of separated formed elements.
In a simplistic view, mixing is us_ally used to prevent
th_ deleterious effects of sedimentation.
Mixing ostensibly reduces the deleterious effects of
"crowding" of cells, results in the accessibility of
essential nutrients to the cell, and eliminates the
undesirable effects on the cell of accumulated waste
products.
But mixing unfortunately can introduce undesired effects
as well. Mixin_ subjects cells to enerzetic forces of
turbulence, cell-container surface and cell-cell
interactions. Not surprisingly, the mixing can produc_
variable effects which are often brought to light when
mixing is carried out in different polymer bags and
modes of movement (see Table I in section 7.4.3.1.).
Microgravity which maintains the cells in suspension,
provides a unique way of avoiding both the sedimentation
and the mixing lesions.
7.4.2 Red Cell Storage on Earth
7.4.2.1 Sedimentation Effects on Red Cell Storage
Storage of whole blood under standard blood bank
conditions leads to sedimentation of the ceils _ich
produces storage lesions because metabolites accumulate
around the cells, pH decreases, and substrates are
depleted. These lesions develop as a result.of the
limitation of diffusion which in turn is determined by
the thickness of sedimented cell layers.
Recently, Beutler etal. (I) compared 2_-hour post-
transfusion survival and hemolysis of red cell concen-
trates collected into CPD-A2 (anticoagulant with
increased glucose) and stored for 42 days either
standing vertically or lying horizontally. It was
reasoned that the horizontal position would facilitate
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diffusion by increasing the plasma to cell surface
ratio. They found that hemolysis was significantly
greater and survival significantly lover in the concen-
trates stored in the vertical position than those stored
in the horizontal position.
The significant differences in hemolysis may be due to
the inability of substrates to diffuse from the over-
lying plasma into the deeper layers of the sedimented
cells in the vertical position during the storage
period. However, the percent of hemolysis in the units
stored in the horizontal sedimented position was st£11
unacceptably high (>IZ).
Mi_ing Injury of Red Cells During Storage
Sedimentation can be prevented on Earth by continuous
mixing. Dern eL el. (2) studied the effect of inter-
mittent mixing (5 times weekly), sin£1e mixing (once
midway through storage) and non-mixing on the storage of
CPD whole blood for 28 days. They demonstrated that
intermittent mixing gave the best in vivo and in vitro
results after storage, followed by single mixing and
then non-mixing. Units with intermittent mixing showed
an increase in ATP level and in post-infusion survival
but a decrease in plasma hemoglobin when compared to the
single- or non-mixing units.
However, injury caused by agitation (or mixing) to red
cells was described as early as 1884 by Meltzer etal.
(3). These authors observed that agitation of whole
blood in glass tubes produced the release of hemoglobin
from red cells and demonstrated that this was dependent
on shear stress and on interactions between red cells
and container wall aurfaces.
Although the mechanism of the mixing lesion is poorly
defined, it has been shown that mechanical mixing can
result in loss of membrane lipid (4), reduction in the
surface to volume ratio (5), increase in cation perme-
ability (6) and decrease in deformability which corre-
lates with poor post-infusion survival (7).
7.4.3.1 Platelet Storage on Earth: Mixing Injury
Storage of platelet concentrates under standard blood
bank conditions requires continuous mixing. Work from
several laboratories has shown that mixing of platelets
during storage prevented extensive deterioration of
platelet functions as measured by activation, yield and
survival (8-11). for example, Murphy et el. (8) studied
the effect of mixing on the survival of 48 hour stored
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platelet concentrates. The mean survival (TI/2) was 3.6
days for the mixed, 2.6 days for the non-.mixed concen-
trates, and 4.2 days for fresh platelets. Morphology of
platelets and the pH of the concentrate were also better
maintained in the mixed units (9).
Several commercial mixing devices are currently avail-
able for storage of platelet concentrates. There are
two general types, flatbed (horizontal) and rotary.
Results from storage of platelet concentrates using two
different five-day bags and four different mixing
devices are summarized in Table I. As illustrated in
Table I, the mode of agitation is extremely important
for both in viva and in vitro function of platelets. At
the present time, the mechanism asato why only minor
vadiatlons in the mode of mixing should have such
significant effect on platelet storage has not been
defined. It should be emphasized, however, that even
with continuous mixing, the recovery, survival and
function of stored platelets are decreased when compared
to fresh platelets.
7.4.3.2 Contact Activation of Platelets
It is well established that platelet-platelet contact as
well as platelet-contsiner surface contact can cause
altezation and activation of these cells. In other
words, contact among platelets themselves and between
platelets and foreign surfaces can induce platelet
injury. Continuous mixing during storage facilitates
contact activation of platelets. This may be one of the
mechanisms _ich leads to decreased recovery, survival
and function of stored platelets.
7.4 .& Leukocyte Storage on Earth
To date, it is necessary to transfuse leukocytes as soon
as possible after collection (less than 6 hours) because
these cells rapidly lose their integrity and function
during storage. There are many unsolved _roblems with
regard to leukocyte storage (18-21). For example,
leukocyte collection under standard blood bank condi-
tions invariably contains a large number of platelets
and red cells. Interactions among these cells during
sedimentation result in s fall in pH lack of diffusion
of nutrients and clumping of leukocytes by platelet
activation.
Little is known about the effect of mixing on leukocytes
during storage. McCullough etal. (18) reported that
mixing during storage, although it had no effect on the
bacterial killing function of leukocytes, caused a
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reduction in chemotaxis (migration of leukocytes to a
noxious stimulus such as bacterise). The chemotactic
response of leukocytes, an energy-dependent process,
deteriorates first end to the greatest extent during
storage when compared to other functions (19-21).
We have previously proposed that storage of blood at
microgravity leads to marked energy conservation (see
section 7.4.1.2.). Therefore, microgravity will better
maintain energy-dependent functions of leukocytes, e.g.
chemotaxis. Leukoctye function is maintained through a
narrow pH range (7.0 to 7.5) (18). Storage at micro-
gravity whlch prevents sedimentation would reduce the
steep pH gradients to which leukoc_tes are subjected
under standard blood bank conditions may in fact improve
the viability of leukocytes.
7.5.1
.Biomaterials and Blood Storage on Earth
A phthalste plasticizer is currently employed in the
manufacture of blood bags. The evidence of the harmful
consequence of the phthalate plasticlzer has been
reviewed in our original proposal (section 2.1._,
Biomaterials). Accordingly, industry has been engaged
in extensive studies to develop alternative polymers.
In comparison to the standard PVC-DEHP blood bags,
all alternative polymers developed to date have been
deleterious to the red cell in that: I) there is
increased hemolysis; 2) the red cell potassium does not
leak out to the same degree as the hemoglobin; 3) there
is increased osmotic fragility; 4) the red cell survival
at 21 days in CPD anticoagulant is reduced and 5) the
red cell survival in all new polymer formulations
utillzing CPD adenine anticoagulant is less than 70%
(FDA Regulations require greater than 70% survival)
after 35 days storage. These factors point to a
selective membrane alteration. A11 attempts to define
the mechanism of this alteration on earth have failed.
7.5.2 Biomaterials and Microgravity Blood Storage
The interaction of bio=aterials and blood cells during
storage is one of the multipIe variables that can affect
blood storage on earth (see above). Microgravity as
provided by the space shuttle would eliminate the effect
of two most important variables, i.e. sedimentation and
the mechanical mixing injury to stored blood cells (see
previous section), and is the only means by which the
separation of the sedimentation, container and mechan-
ical mixing lesions can be achieved. A comparison of
........ _o _e membrane changes of blood cells stored in different
• g\_ a., },"
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polymer formulations at microgravity viii give new
InslRht into the membrane characterlstlca of blood cells
upon storage.
In this project, we will utilize three FDA approved
blood bags, one, the currently used PVC-DEKP bag, and
two alternative polymer formulations, the PVC-TOTM and
polyolefin bags. PVC-DEHP and PVC-TOTR contain the
plastizers phthalate and trimellitate, respectively,
whereas, polyolefin bags do not contain a plasticizer.
The studies summarized below have been carried out in
the Blood Bank Research Laboratory at Children's
Hopspital (under the leadership of Drs. S. Kevy and M.
Jacobson) as part of a cooperative program with industry
for the in vitro and in viva evaluation of alternative
polymer formulations. Our results demonstrate the
existence of a membrane abnormality due to the inter-
action of the polymer with the membrane of both the red
cell and platelet as well as the affinity of the
plasticizer for lipid.
Leaching of Plasticizer
The leaching of DEHP from VC during blood storage is
dependent on diffusion mn_ is directly proportional to
the lipoprotein concentration. Two aspects of diffusion
are involved: I) migration through the plastic to the
internal surface of the container, and 2) diffusion of
lipoprotein molecules toward and away from the container
wall. Although only a fraction of the leached DERP is
associated with the red ceil, this plasticizer has a
membrane stabilizing effect (see below). In a previous
study, we compared the degree of leaching of TOTN and
DEHP and their effect on human flbroblast tissue
culture. The leaching of TOTH by plasma is one-
hundredth that of DERP and is independent (unlike DEHP)
of lipoprotein concentration. Furthermore, results from
tissue culture studies showed that TOTH did not inhibit
the growth of human fibroblasts, whereas DERP was a
potent inhibitor (22).
7.5.4 Lipid Association of Plasticizer
During storage there is an active exchange between the
plasma and erythrocyte membrane lipids (23). It is
thought that the neutral llpids other than cholesterol
are not an integral part of the red cell membrane but
represent small amounts of plasma llpoprotein material
adsorbed to the surface of the membrane (24). Utilizing
polyvinyl chloride plasticized with 14C-carbonyl labeled
DEUP we were able to determine that the degree of
leaching was limited by the llpoprotein concentration.
Ultracentrifugation studies revealed that 93Z of the
-ll-
DEHPfound in plasma was in the llpoprotein fraction. As
aho_n in Table II, agarose gel chromatography demon-
strated that the low density component bound more
plasticizer than either the very low or high density
components (25). There was little bound to albumin. The
plasticizer is probably solubilized and transported in
plasma in a manner similar to that of the triglycerides.
Table If. Association of 14C-DERP with Lipoprotein
Components of Plasma
% of Total Recovery
J
DEHP Addition VLDL LDL RDL
23.3 mglml 19 47 27
*VLDL: very low density lipoprotein; LDL: low density
lipoprotein; HDL: hiRh density lipoprotein; Vi:
non-lipoprotein fraction
vi*
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7.5.5 Membrane Stabilization Effect of DEHP
Red blood cells when exposed to DEHP are more resistent
to hemolysis as compared to those cells which are stored
in non-DEHP containers (26). The mechanism of the
"protective" effect of DEHP on hemolysis is unknown.
However, Seeman (27) demonstrated that there is a 50%
inhibition of hemolysis when the membrane area of the
intact erythrocyte expands by 2 to 3Z. Possible
mechanisms by which compounds could expand the membrane
area are: l) occupation of space within the membrane,
2) disordering and expansion of the lipid regions of the
membrane, 3) induction of conformational changes in
membrane proteins, and 4) adsorption to the membrane,
thus altering the amount of water in contact with the
membrane. Furthermore, Roth and Seeman (28) demon-
strated that lipophilic anesthetics stabilize the red
cell membrane against hypotonic hemolysis while drugs
with low lipid solubility had no effect. It is con-
ceivable, therefore, that DEHP, due to its lipophilic
nature may stabilize the red cell membrane in a like
manner.
7.5.6 Red Cell Studies
Storage of blood in alternative polymer containers
(PVC-TOTH, the polyoleflns, and etc.) resulted in
increased hemolysis and osmotic fragility and decreased
post-infusion survival as compared to PVC-DEBP bags. In
-12-
this section additional data from studies of hemolysis
and osmotic fragility are included whereas the survival
data have been reviewed in our original'proposal.
7.5.6.1 Hemolysis Studies
The rate of hemolysis in stored blood is generally
accepted as the primary initial screening procedure to
indicate blocompatibility with the erythrocyte. In
1954, Gibson and Thorn (29) compared blood stored in
glass and plasticized polyvinyl chloride containers, and
demonstrated that the plasma hemoglobin level and the
susceptibility to hemolysis in hypatonic 0.6Z saline was
evident at one week and markedly increased during the
third week of storage in the "inert" glass container as
compared to polyvinyl chloride formulations, whereas all
other biochemical parameters measured were identical.
Paired studies were carried out in our laboratory to
compare plasma hemoglobin, osmotic fragility, red cell
electrolytes and glycolytic intermediates in blood
stored in PVC-DEHP bags and alternative polymers. The
average plasma hemoglobin level at one week was markedly
different for PVC-DERP and polyolefin but similar for
the polyolefin and a polyolefin copolymer. By 3 weeks
the plasma hemoglobin level for the polyolefin bag was
64.2 mg/dl with its PVC-DEHP control at 34.1 mg/dl; the
polyolefin co-polymer had a level of 44.0 mgldl with its
PVC control at 27.5 mgldl (means of 5 paired studied).
Similar results were obtained with 5 other polyolefin
derivatives. All exhibited significant differences by
one week.
Studies were also performed comparing PVC-DEHP with an
identical PVC formulation using a TOTM plasticizer. The
average plasma hemoglobin for the PVC-DEHP controls was
33.4 mg/dl and the PVC-TOTM was 66.5 mg/dl. The rate of
hemolysis of the PVC-DEHP and PVC-TOTM packs were quite
different. This was evident within the first week of
storage.
7.5.6.2 Osmotic Fragility Studies
Results from paired studies on osmotic fragility are
shown in Fi_s. I and 2. We demonstrated that signifi-
cant losses in stability as measured by hypotonic
hemolysis occurred in red cells stored in containers
fabricated with non-plasticized polymers and TOTM as
compared to the PVC-DERP containers (Figs. I and 2),
Fragillty curves were generated for each sample but only
the percent hemolysis in 0.61 NaCI is shown. By the end
of four weeks the percent hemolysis is II for FVC-DEHP
-13-
and 27.5 and 29.5, respectively for two of the exper-
imental polymers (Fig. I) . After 3 weeks of storage
the PVC-DE_P units had 12.5% hemolysls and after four
weeks 18.5% hemolysis whereas the PVC-TOTM units had
23.5 and 34.8 percent hemolysis at the corresponding
storage times (Fig. 2). It should be emphasized that as
early as one week after storage, significant differences
were noted,
In the same paired studies, red cell electrolytes and
glycolytic intermediate levels were identical for all
polymers tested, All the aforementioned polymers have
excellent gas transfer and two of them have been
approved for 5 day platelet storage.
7.5.7 Platelet Studies
Therapeutic effectiveness of platelets is judged by
three parameters: 1) Yield or Recovery: This is the
term applied to the percent of the platelets that
circulate following transfusion. 2) Survival: The
duration in days that the platelets circulate. 3)
Correction of the patient's bleeding time.
Previous studies from our laboratory has demonstrated
that varying formulations of PVC bags plasticized with
DERP exert a profound effect on platelet yield and
lurvival during storage (Table III). As shown in Table
III, polymers #2 and #3 were suitable for storage up to
72 hours with normal survival whereas polymers #1 and #4
had markedly decreased survival within 48 hours. Both
polymers 2 and 3 are currently used in blood banks for
platelet storage up to 72 hours. It should be emphas-
ized, however, that platelet recovery in the two latter
polymers was only 40% of that of fresh platelets.
-14- 1
Table II1. Effect of Four PVC-DERP Formulations
on Platelet Recovery and Survival
(n-10)
Plastic Storage Recovery Survival
Pack Temp ('C) Hrs. (%) Days
#l 22 0 51.2 + 1.5 8.6
#2 22 0 61.3 _ 2.2 8.5
#3 22 0 58.6 _" 2.7 8.3
#4 22 0 42.5 _" 3.1 7.9
#1 22 48 43.5 _ 2.9 2.9 a#2 22 48 52.5 _.2 7.5
#3 22 48 54.8 _ 2.1 6.9
#4 22 48 41.I _ 2.6 1.8 a
#2 22 72 35.0 + 1.6 7.2
#3 22 72 35.2 ÷ _.4 7.1
aThe 72-hour recovery and survival were not determined due to poor
survival at 48 hours.
7.6 Summary
Clearly, from the above discussion storage of whole
blood, platelet concentrates and leukocytes under
earth's gravity, either in the sedimented state or with
continuous mixing is not optimal. Storage of blood at
microgravlty in the space shuttle is expected to result
in a greatly reduced perturbation of cell function. The
continuous suspension of blood during storage in the
shuttle at a microgravity environment will more closely
mimic the relationship of the cells ¢o the plasma in the
circulatory system than does ground storcge of blood.
Continuous suspension of blood will I) eliminate the
accumulation of metabolites i_ediately surrounding
blood cells, 2) increase the availability of substrates,
3) increase gas transport, 4) better maintain pH, and 5)
reduce or eliminate.the chances of contact activation
for platelets.
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Initial Blood Storage Experiment
Experimental Protocol
i.0 INTRODUCTION
The Initial Blood Storage Experiment (IBSE) will involve pre and post flight
biomedical operations. Blood will be collected from a group of blood donors,
and sterile suspensions of blood cells will be separated into sealed plastic
blood bags. The bags will be placed in temperature controlled environmental
stainless steel dewars. The dewars will be housed in three modified middeck
lockers. Two lockers comprise the flight payload; the third dewar and a func-
tional IBSE unit will be held on the ground in the laboratory facility.
This experimental protocol details the procedures that will be performed at
the onsite facility, Central Florida Blood Bank, and base laboratories. All
procedures, where applicable, are in accordance with the American Association
of Blood Banks Technical Standards, Eleventh Edition and the Good Manufactur-
ing Practices for Blood and Blood Components of the Code of Federal Regula-
tions.
2.0
2. i
2.1.2
BLOOD COLLECTION
Blood will be drawn from a group of 36 volunteer donors under standard
operating procedures and aegis of the Central Florida Blood Bank (CFBB),
which will be responsible for collection and preparation of the com-
ponents used in the experiment. A member of the IBSE team will be
present.
The donors will be preselected by CFBB according to the following
guidelines:
a.) having successfully donated blood previously for transfusion
b.) having previously been shown to be negative for HBsAg
c.) having previously been shown to be negative for irregular
antibodies against red cell antigens
d.) being of a single ABO and Rh type or at the discretion of the
CFBB, two blood groups 12 units of one ABO and Rh for use as whole
blood and 24 units of a second ABO and Rh for use as platelets and
buffy coats.
e.) having not ingestedlaspirin the day of blood collection or 5
days previous.
f.) non-transfused males.
g.) having previously been shown to be negative for anti-HTLV III
antibodies, ie. sUSpected AIDS virus antibodies.
IBSEProtocol
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FDA approved standard CPD anticoagulant blood bags will be used.
CFBB criteria will govern the acceptance or rejection of all donors
at the time of phlebotomy; as well as the disposition of any units
found to be unsatisfactory for any reason.
2.1.5
2.1.6
2.1.7
Standard CFBB laboratory testing will be conducted by CFBB after the
collection, from pilot samples obtained at the time of phlebotomy,
i.e. ABO, Rh, antibody screening, syphilis testing, hepatitis
testing and anti-HTLV III testing. All testing will be complete
prior to pooling. All donor and donation records will be retained
by CFBB.
Units collected as whole blood and not intended for component pre-
paration will be stored at 1-6 C until the time of pooling and
aliquoting.
Units intended for production of components will be stored at room
temperature (20-24 C) for no more than six hours.
3.0
3.1
3.2
COMPONENT" PREPARATION
All component preparation will be completed by the CFBB according to
their standard operating procedures with the exception of the final
plasma volume of platelet concentrates. These concentrates will be
resuspended to volume of 65 ml.
The red cells and plasma from the units used for platelet and bully coat
preparation w111 be stored at 1-6 C for 21 days.
RECORDS
Pooling Records:
A Pooling Data Sheet is prepared prior to pooling each blood component.
The accuracy of all data must be verified by a second person, who
initials the sheet, before pooling. The following information must be
documented:
- Component (whole blood, platelets, or leukocytes)
- Collection date
- Pooling date and time
- Temperature of pooling area (room tamp, 5°C, etc.)
- Lot number and description of pooling bag
- Whole blood number of each component
- ABO and Rh type of each component
- Identity of person pooling
- Identity of person verifying records.
The time pooling is completed will be documented.
Component:
Whole Blood
Platelets
Leukocytes
Collection Date:
Initial Blood Storage Experiment
POOLING DATA SHEET
Pooling Bag Description:
Lot Number:
Whole Blood
Number ABO/Rh
Technic ian
Pool Ina
v
Temp.
Pooling Date:
Time Begun: ,,
Time Completed:
of Pooling Area: .....
Technician
Reviewlne
v
[Remerk5
Initial Blood Storage Experiment
PRE-FLIGHT ALIOUOTING DATA SHEET
Whole Blood 250 ml
Polymer Code: PVC-DEHP = D
PVC-TOTM = T
Polyolefln = PO
Date:
Time Begun:
Time Completed:
Temperature of Aliquoting Area:
Order
I
2
}
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Bag ID
Code#
I
8
15
2
9
16
3
10
17
4
11
!8
5
12
19
6
I}
20
7
14
21
Polymer
T
PO
P
T
PO
P
T
T
PO
T,
Pg
D
T
PQ
D
T
PO
Gross Net
Weiaht(e) Weiaht(e) Tech. Review
v v v
Remerks
Spare Bme
Spare Bae
Spare Bae
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PRE-FLIGHT ALIOUOTING DATA SHEET
Leukocytes 75 ml
Polymer Code: PVC-DEHP = D
PVC-TOTM = T
Polyolefin = PO
Date:
Time Begun:
Time Completed:
Temperature of Allquoting Area:
Bag ID
Order .Code# Polymer
Gross
Weight(e)
v w
Net , t"
Weiaht Ca)
I 22
2 . 29
3 36.
4 23
.5 30
• 6 37
_7 24
6 31
9 3 8i
_10 25
11 3Z
12 39
13 26
14 33
15 40
16 27
17 34
18 41
.19 28
20 35
21 42
.D
T.
PO,
PO
O
T
PO
D
T
PO,,
D
T
PQ
D
T
PO
D
T
PO
i ,
Tech. Review Remark s
Spare Baa
,, i,
Spare Bag
_D_re B_
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PRE-FL I(3FFFAL IOUOTI _IGDATA SHEE'T
Platelets 65 ml
Polymer Code: PVC-DEHP = D
PVC-TOTM = T
Polyolefin = PO
Date:
Time Begun:
Time Completed:
Temperature of Aliquoting Area:,
Order
I
2
3
, 4 _,
Bag ID
Code#
4}
50
57
4_
Polymer
D
T
PO
,. D
Gross
Weieht(e)
v v
Net
Wei_ht(e ) Tech
51 T
6 58 PO
7 4_ D
B 52 T.
9 59 PO
10 _6 D.
11 53 T
12 . 60 PO
13 47 g.
.14 54 T
.15 61 PO
16 _8 D.
17 55 T
18 62 . PO,
19 49 D
2O 56 T
21 63 PO
22 98 T
• Review Remarks
_pare Bag
Scare Bae
SDare Bao
,, , , ,
SPare Bae
v
PRECEDING PAGE BLA_K NOT FILMED
4.2
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Records of Pre-flight Aliquoting of Pools:
A Pre-Flight Aliquoting Data Sheet is prepared prior to aliquoting each
pool into the coded experiment blood bags. The order in which the bags
are to filled is pre-deterimined on the data sheet. The aliquoting
technician will verify the labeled bags as being of the correct polymer
and having the correct code. After the aliquoting, a second person will
review the records and initial to verify accuracy.
5.0
5.1.0
5.1.1
5.1.2
5.1.3
5.1.4
5.1.5
5.1.6
5.1.7
POOLING
All pooling and aliquoting will be performed using aseptic techniques.
All bench area will be washed down with a 10% bleach solution prior to
use and after any blood spills.
Whole Blood Pool
12 units of whole blood will be pooled in groups of 6 units to make
two pools. The two pools will then be mixed together to make one
pool. Whole blood pooling may be carried out at room temperature,
but after aliquoting the bags should be placed immediately at I-
6oc.
Remove the segments from each of the units of whole blood. Place
the segments from each unit in separate plastic bags labeled with
the corresponding whole blood number and store between I-6oC for
21 days.
Using the Dupont Sterile Connection Device (SCD), connect the
integral tubing from a unit of whole blood to the tubing of a
cytoagglomerator bag. Allow the whole blood to empty into the
cytoagglomerator bag. Once the bag is empty, clamp the tubing
with a hemostat and heat seal the integral tubing in three places
close to the port of the whole blood bag.
Disconnect tubing at the center seal. Repeat with 5 more units of
whole blood.
Repeat the above procedure with the remaining 6 units of whole
blood and a second cytoagglomerator bag.
Once the second bag is filled, the two pooling bags must be mixed
together. Using the SCD, connect the two cytoagglomerator bags.
Hang one bag above the other. Allow the blood in the hanging bag to
flow into the second bag, mixing gently until the hanging bag is
empty. This should take about i0 minutes.
Reverse positions of the two bags and repeat until the the two bags
are mixed a total of ten times.
5.1.8 Store whole blood pool at I-6°C until ready to aliquot.
IBSE Protocol
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5.2 Platelets
All platelet concentrates must rest for 1 hour and 15 minutes and be
rotated for a minimum of 1 hour and 15 minutes prior to pooling. All
platelet pooling will be performed at room temperature.
5.2.1 Pool 24 units of platelet concentrates into a 2 liter plasma
transfer pack.
5.2.2 Using the SCD, connect a 2 liter plasma transfer pack with a unit
of platelet concentrate. Hang the platelet unit above the trans-
fer pack and allow the platelets to gravity feed into the transfer
pack. When the platelet bag is empty, clamp the integral tubing
with a hemostat. Heat seal the integral tubing 3 times close to
the port of the platelet bag. Disconnect at the center seal.
5.2.3 Repeat until all 24 platelet units have been pooled.
5.2.4 Mix by inversion.
5.2.5 Store pooled platelets at room temperature until ready to aliquot.
5.3 Leukocyte Pool
Preparation of leukocytes will be performed under a laminar flow hood.
5.3.1 24 units of buffy coats will be sedimented with dextran to separate
the leukocytes. Suspensions of leukocyte will be washed in plasma
transfer packs. See white cell protocol, Section 14.3.
5.3.2 Connect a 2 liter plasma transfer bag to a unit of leukocytes,
using the SCD. Hang the leukocytes above the plasma transfer pack
and allow the leukocytes to gravity feed into the transfer pack.
When the leukocyte bag is empty, clamp the integral tubing with a
hemostat. Heat seal the integral tubing 3 times close to the port
of the leukocyte bag. Disconnect the 2 bags at the center seal.
5.3.3 Repeat until all leukocytes have been pooled.
5.3.4 Mix by inversion.
5.3.5 Store pooled leukocytes at I-6oC until ready to pool.
5.4 Plasma
5.4.1 Select 8 units of plasma from units used for platelet preparations
for pooling into a 2 liter plasma transfer pack. The pooled
plasma will be used for tests on platelets.
5.4.2 Using the SCD, connect a unit of plasma to a 2 liter plasma trans-
fer pack. Hang the plasma above the transfer pack and allow the
plasma to gravity feed into the transfer pack. When the plasma
bag is empty, hemostat the integral tubing. Heat seal the tubing
5.4.3
5.4.4
5.4.5
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close to the port of the plasma bag. Disconnect the 2 bags at the
center seal.
Repeat until 8 bags of plasma have been pooled.
Mix by inversion.
Store pooled plasma at I-6°C until needed.
6.0 ALIOUOTING
Each product pool will be aliquoted into 3 different, FDA OoB approved
plastic formulations: PVC-DEHP, PVC-TOTM, and Polyolefin. Each whole
blood and leukocyte pool will be aliquoted into 21 samples in 300 ml
bags. The platelet pool will be aliquoted in 23 samples in 3DO ml bags.
There will be 7 bags of each plastic formulation for each whole blood
and leukocyte pool. For the platelet pool, there will be 7 bags PVC-
DEf_ and 7 bags polyolefin and 9 bags PVC-TOTM. The total number of
bags will be sixty-five. The volumes vary according to each product.
6.1 Prelsbeling of bags
Each bag will be given a unique number which will identify the blood
component, the type of plastic, the dewar and locker used for storage.
PVC-DEHP PVC-TOTM Polyolefin
Whole Blood 1-7 8-14 15-21
Leukocytes 22-28 29-35 36-42
Platelets 43-49 50-56,98,99 57-63
Spare bags are: Whole Blood: 7,12,18
Leukocytes: 27,30,42
Platelets: 49,52,57
IBSE Protocol
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6.1.2 Code for location and storage condition
ORBI TER EARTH
LEUK WB LEUK _ LEUK WB LEUK _ LEUK WB LEUK
A 6 22 10 29 20 37 D 4 40 13 32 15 28
B 8 41 17 26 5 35 E 11 24 19 38 2 33
C 21 34 3 39 14 23 F 16 31 1 25 9 36
P 56 48 P, 60 50
L L
A 62 53 A 47 98
T T
E 43 58 E 51 63
L L
E 54 99 E 59 46
T T
S 44 61 S 45 55
FRONT BACK FRONT BACK
(TOP) (BOTTOM) (TOP) (BOTTOM)
Letter codes are dewars. A and B are cold dewars stored in one orbiter
locker. C is a cold dewar and PLATELETS is a warm dewar stored in the orbiter
locker. D and E are cold dewars stored in one earth locker. F is a cold
dewar and PLATELETS* is a warm dewar stored in the other earth locker.
6.2 Wnole Blood
6.2.1 Whole blood will be aliquoted in 250 ml volumes in the following
prelabeled 300 ml bags and stored at I-6°C until loaded in the
dewars:
I. PVC DEIIP 7 bags
2. Polyolefin 7 bags
3. PVC TOTM 7 bags
6.3 Platelets
6.3.1 Platelets will be aliquoted in 65 ml volumes in the following
prelabeled 300 ml bags and stored at room temperature (20-24°C)
until loaded in dewar:
1. PVC DEHP 7 bags
2. Polyolefin 7 bags
3. PVC TOTM 9 bags
IBSE Protocol
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6.4 Leukocytes
6.4.1 Leukocytes will be aliquoted in 75 ml volumes in the following
prelabeled 300 ml bags and stored at 1-6oC until loaded in the
dewars:
I. PVC DEHP 7 bags
2. PVC TOTM 7 bags
3. Polyolefin 7 bags
6.5 Procedure for aliquoting
6.5.1 Whole blood
6.5.1.2 Mix the whole blood pool well prior to aliquoting end again
between each bag.
6.5.1.3 Place a 300 ml bag to be filled on scale and tare for the
weight of the bag.
6.5.1.4 Using the SCD, connect one cytoagglomerator bag containing
whole blood pool with the 300 ml bag for aliquoting.
6.5.1.5 Allow 250 g of whole blood to flow into the above prelabeled
bag.
6.5.1.6 When bag is filled with the appropriate volume, clamp with a
hemostat. Heat seal tubing 3 times close to the port of the
aliquoted bag. Disconnect the 2 bags at the center seal.
6.5.1.7 Repeat with each prelabeled bag for whole blood until Ii bags
are filled or cytoagglomerator bag is empty.
6.5.1.8 Using the sterile docking device connect second cytoagglomer-
ator bag to a bag for aliquoting. Repeat steps 6.5.1.2-
6.5.1.7.
6.5.1.9 The blood remaining in the cytoagglomerator bag will be
aliquoted into plastic tubes for use in baseline studies.
See 7.0.
6.5.1.10 Store whole blood aliquots at I-6°C until ready to load in the
dewar.
6.5.2 Platelets
6.5.2.1 Mix platelet pool well before aliquoting end between each bag
during aliquoting.
6.5.2.2 Place bag for aliquot on scale end tare for the weight of the
bag.
6.5.2.3 Using the SCD, connect the platelet pool with a prelabeled bag
for aliquoting.
IBSE Protocol
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6.5.2.4 Allow 65 g of platelet suspension to flow into aliquoting bag.
Clamp with hamostats when the appropriate volume has been
aliquoted. Heat seal the integral tubing 3 times, close to
the port of the aliquot bag. Disconnect bags at the center
seal.
6.5.2.5 Repeat until all 23 bags are filled.
6.5.2.6 The platelet suspension remaining in the pooled bag will be
aliquoted into tubes for baseline studies. See 7.0.
6.5.2.7 Aliquoted platelets will be stored at room temperature (20-
24oc) until loaded in the dewar.
6.5.3 Leukocytes
6.5.3.1 Hlx leukocyte pool well before aliquoting and between each bag
during aliquoting.
6.5.3.2 Place bag for aliquot on scale and tare for the weight of the
bag.
6.5.3.3 Using the SCD, connect the leukocyte pool with a prelabeled
bag for aliquoting.
6.5.3.4 Allow 75 g of leukocytes to flow into aliquoting bag. Clamp
with hemostats when the appropriate volume has been aliquot-
ed. Heat seal the integral tubing 3 times, close to the port
of the aliquot bag. Disconnect bags at the center seal.
6.5.3.5 Repeat until all 21 bags are filled.
6.5.3.6 The leukocyte suspension remaining in the pooled bag will be
aliquoted into tubes for baseline studies. See 7.0.
6.5.3.7 Aliquoted leukocytes will be stored at 1-6 until loaded in the
dewar.
7.0 SAMPLES FOR BASELINE STUDIES
Time zero samples are those taken at the time of aliquoting. Their
purpose is to verify the condition of the products pre flight. All
assays outlined in the protocol will be performed on time zero samples.
Each investigator will receive samples according to the description
below.
7.1 Whole blood
Whole blood pool must be mixed well prior to aliquoting.
7.1.1 Using a hemostat, clamp the integral tubing of the cytoagglomerator
bag. Cut the end of the tubing. Place the tubing in a prelabeled
7.1.2
# of
Tubes
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centrifuge tube. Release the hemostat and allow the require
volume (listed in 7.1.2) to flow into the tube. When the tube is
filled with the require volume reclamp the hemostat and repeat
until all whole blood tubes are filled.
Whole blood will be aliquoted into the following tubes labeled
whole blood and place on ice or to maintain a temperature of i-
6oC.
Tube Volume Investigator
Volume Needed
3 50 ml 50 ml
I 50 ml 30 ml
2 15 ml i0 ml
2 i0 ml i0 ml
2 15 ml 5 ml
M. Jacobson (A.B.[I])
I. Szymanski
M. Jacobson
D. Ausprunk
M. Jacobson (A.S.)
M. Jacobson (S.K.)
W. Curby
7.2 Platelets -"
Platelets must be well mixed prior to any aliquoting.
7.2.1 Using a hemostat, clamp the integral tubing of the platelet bag.
Cut the end of the tubing. Place the tubing in a prelabeled cen-
trifuge tube. Release the hemostat and allow the require volume
(listed in 7.2.2) to flow into the tube. When the tube is filled
with the require volume reclamp the hemostat and repeat until all
platelet tubes are filled.
7.2.2 Platelets will be aliquoted into the following tubes labeled plate-
lets and left at room temperature:
# of Tube Volume Investigator
Tubes Volume Needed
1 3 ml syringe 1.5 ml M. Jacobson
1 50 ml 30 ml F. Chao
1 50 ml 15 ml F. Chao
1 15 ml 5 ml I. Szymanski
1 15 ml 4 ml D. Ausprunk
1 15 ml 3 ml M. Jacobson
1 15 ml 1 ml W. Curby
7.3 Leukocytes
Leukocyte pool must be well mixed prior to aliquoting.
7.3.1 Using a hemostat, clamp the integral tubing of the leukocyte bag.
Cut the end of the tubing. Place the tubing in a prelabeled cen-
trifuge tube. Release the hemostat and allow the require volume
7.3.2
# of
Tubes
IBSE Protocol
Page 12
(listed in 7.3.2) to flow into the tube. When the tube is filled
with the require volume reclamp the hemostat and repeat until all
whole blood tubes are filled.
Leukocytes will be aliquoted into the following tubes labeled
leukocytes and place on ice or to maintained at a temperature
between I-6°C:
Tube Volume Investigator
Volume Needed
50 ml 30 ml F. Lionetti
15 ml 5 ml D. Ausprunk
2 ml 1 ml W. Curby
PACKAGING AND SHIPMENT OF BLOOD
Whole blood, red blood cells, leukocyte preparations and plasma will be
packed and shipped on wet ice to maintain at a temperature of I-6oC.
Platelets will be packed in IBSE shipping racks and shipped at 20-24°C.
A member of the IBSE team will observe the packing of blood components
prior to shipment. This person will accompany the blood in the heli-
copter to KSC. A second person will accompany the ground stored blood
to Boston.
9.0 STORAGE OF ALIQUOTED POOLED SAMPLES
Of the sixty-three aliquoted bags, fifty-six will be used in the
experiment. One extra bag of each plastic and each component will be
available in the event a replacement is required. There are 2 dewars to
each locker and 4 lockers total. 2 lockers will remain in the labor-
atory and 2 lockers will be placed on the orbiter. The following table
is a the description of how the products and the specific bag types will
be divided.
Earth stored aliquots Orbiter stored aliquots
Whole blood:
3 PVC-DEHP
3 PVC-TOTM
3 Polyolefin
3 PVC-DEHP
3 PVC-TOTM
3 Polyolefin
Leukocytes:
3 PVC-DEHP
3 PVC-TOTM
3 Polyolefin
3 PVC-DEHP
3 PVC-TOTM
3 Polyolefin
IBSE Protocol
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Platelets:
3 PVC-DEHP
4 PVC-TOTM
3 Polyolefin
3 PVC-DEHP
4 PVC-TOTM
3 Polyolefin
A total of 56 bags, 18 whole blood, 18 leukocytes and 20 platelets.
9.1 Whole blood and leukocytes
Whole blood and leukocytes will be stored in a total of 6 cold dewars.
Three of the cold dewars will be left in the laboratory under controlled
conditions and three will be placed on the orbiter. Each cold dewar
will contain 3 whole blood aliquots and three leukocyte aliquots in the
configuration described in 6.1.2.
9.2 Platelets
Platelets will be stored in a total of 2 warm dewars (22oc). One warm
dewar will be left in the laboratory under controlled conditions and one
will be placed on the orbiter. Each dewar will contain 9 platelet
aliquots and one "dummy" bag in the configuration described in 6.1.2.
The "dummy" bag will contain platelets from the pool and aliquoted into
a PVC-TOTMbag.
I0.0 LOADING OF DEWARS
10.1 This activity requires 3 IBSE staff members (2 CBR and I ADL staff) to
manipulate the hardware. These three individuals will work in a res-
ricted area, 0 + C Building, room 2249 or 2251, until all dewars are
loaded and ADL closeout of the lockers is complete. All clerical
entries will be verified and initialed by a second person.
10.2 Two Curby cranes for suspending IBSE hardware over the lockers will be
in place for the loading procedure.
10.3 Each dewar will be prelabeled by ADL (A-D for Orbiter, E-H for Earth-
stored dewar). The bag types, blood components, and temperature of each
dewar by label are defined in section 6.2.
10.4 The microgravity-stored dewars will be loaded at KSC and the ground
stored will be loaded simultaneously in Boston. The procedure is
identical for microgravity and Earth-stored dewars.
10.5 Selection of blood components:
10.5.1 Prior to loading the dewars, filled, coded bags will be separated
into 6 identical groups for whole blood and leukocytes, each con-
taining 3 whole blood units (one in each type of plastic bag), 3
leukocyte units (one in each type of plastic bag), and 2 identical
groups for platelet units.
IBSE Protocol
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10.5.2 Before loading commences, the code number of each bag to go in the
dewar will be recorded on the appropriate worksheet.
10.5.3 A plastic protective drape will be placed over the lower locker
assembly to prevent spillage into the hardware in the unlikely
event of a broken blood bag during the loading procedure.
10.6 Loading will begin with platelet bags since they are stored at room
temperature.
10.6.1 Platelet bags will be secured in vertical mm holders as
described in section __, arranged by bag type as designated in
6.1.1. The final position of each coded bag will be recorded on
the appropriate worksheet.
10.6.2 The platelet holders will be joined by rubber bands maintaining the
relative positions defined in section 6.1, and the entire unit
slipped into the 22 + IoC dewar compartment.
10.7 Cold-stored components intended for a single dewar (3 whole blood and 3
leukocytes) will be removed from refrigerated storage and brought to the
dewar loading site. Each bag will be removed from its protective
plastic overwrap and wiped dry with towelling to remove condensation
prior to loading.
10.7.1 Whole blood and leukocytes will be loaded alternately in the
arrangement described in section 6.1.2, beginning at the bottom of
the 5 + IoC dewar.
w
10.7.2 Each bag must be folded at the top, label side up, maintaining
maximum surface area against the air flow grid surface. The top
of the bag is folded back onto the label and is positioned at the
top of the individual compartment.
10.7.3 The folded blood bag is placed horizontally in a parallel folded
Teflon sheet which facilitates placement of the blood bag into the
hardware without sliding the bag across any rough surfaces. Then,
while the blood bag is held in place from the opposite side, the
teflon sheet "envelope" is withdrawn. Corners of the plastic bag
may not protrude out of the prescribed area in order for the
hardware to lower properly into the locker.
10.7.4 To fully contain any protruding bag corners and to ensure ease of
lowering, each loaded bag will be encircled in the hardware by
Kapton tape (Connecticut Hard Rubber). Whole blood will be
encircled by i" tape and leukocytes will be encircled by I/2"
tape. Precut strips of tape will be attached to a vertical metal
bar in the hardware and circled in the direction of the 3 adjacent
bars and finally around the open space allowed for loading.
I0.8 The 2-dewar unit is ready for ADL closeout. Repeat with Earth-stored
lockers and dewars.
ii.0
II.I
IBSEProtocol
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SUMMARY OF PRE-FLIGHT TIMELI_
The launch is scheduled for 7 a.m., 1985. The IBSE lockers
must be turned over to NASA 12 hours prior to that, 7 p.m.,
1985. In order to minimize pre-flight exposure to I x g, the donor
blood will be collected early on the morning before and all subsequent
preparations are defined within that 12-13 hour period.
Day Prior to Launch
6:00 - 9:00 a.m.
6:00 - 8:00
8:00 - 9:00
Collection of blood from CFBB donors.
24 donors for plateletand leukocyte production.
12 donors for whole blood.
8:00 - 10:30 Platelet concentrates rest and rotate.
8:00 - ii:00 Leukocytes prepared from bully coats at CFBB.
9:00 - 2:00 p.m. Whole blood units pooled and divided into coded IBSE
bags, at CFBB, i person.
10:30 - 2:00 Platelets and leukocytes pooled and divided into
coded IBSE bags, at CFBB, 2 people.
2:00 - 3:30 Prepared Blood components and 11BSE staff trans-
ported to KSC by helicopter. Other IBSE personnel
needed for loading the dewars at KSC must travel by
car.
3:30 - 7:00 Load orbiter and ground dewars.
ADL closeout of orbiter and ground lockers.
** 7:00 p.m. Turn over orbiter dewars to NASA.
12.0
12.1
ADL FLIGHT PREPARATIONS
The experiment requires eight nearly identical environmental chambers.
During the preflight preparatory phase, suspensions of human blood
formed elements will be prepared, introduced and sealed into plastic
bags (containers), which will then be mounted in fixed positions within
the environmental chambers as described above. These chambers will then
be closed, the associated environmental control systems (temperature
control and air supply) will be activated and the entire system will be
enclosed in modified NASA storage lockers for flight. The environment-
al chambers must then operate continuously from the time of insertion
and closure of the blood preparation into the chambers until the locker
assembly has been removed from the orbiter and returned to IBSE
personnel.
The design of the chambers and their associated environmental control
systems must assure that the following environmental specifications will
be met from the point of preflight loading and closure to the termina-
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tion of flight and the lockers have been turned over to the IBSE
personnel (see 12.1 Table I).
12.1 TABLE I
Chambers needed Whole Blood Platelets Leukocytes
Capacity 250mi 65mi 75mi
Thickness of
bags with blood
3. Ocm O. 5cm 1.5cm
Temperature
Range
Air
5 ° + loC 22 ° + loC 5 ° + loC
Cabin air Cabin air Cabin air
Orientation of
the bag during
take off
Horizontal Vertical Horizontal
The air flow through the chambers will be a minimum of 85 cc/min.
12.2 All blood preparations will be placed in 300 ml volume plastic bags.
Three different formulations of plastics will be used for the bags. The
dimension of the filled blood bag will vary with the component place in
it due to differing volumes being inserted into the bags. The configur-
ation of the chambers must ensure that the bags do not come in contact
with one another, are held in position to avoid any shifting, and are
spaced in uniform distances. The chambers must provide a constant flow
of air to maintain the exchange of oxygen and carbon dioxide across the
wall of the blood bags containing the formed elements of the blood.
12.3 The power and air supply must have capability of maintaining the res-
trictions stated in the Table I for a total of I0 days. The temperature
must remain within stated ranges. Should there be an interruption of
power, the temperature within the chambers containing red cells and
leukocytes should not rise above TBD for more than TBD at any one time.
The temperature of the chamber containing platelets should not rise at
above TBD for more than TBD at any one time.
12.4 In addition to the design of the environmental chambers, ADL is
responsible for the following:
12.5 Proper placement of the insert holding the blood bags in the dewars,
activation of the environmental system and closure of the lockers.
12.6 Packaging and delivery of the lockers to KSC personnel.
12.7 Assuring that the proper environmental conditions are maintained pre and
post flight.
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12.8 Placement of the lockers on and off the orbiter
The lockers will be loaded and delivered to ILSC personnel a minimum of
12 hours prior to launch. During this period, specified environmental
conditions must be maintained within the lockers.
13.0
13.1
13.2
# of
Tubes
POSTFLIGHT ALIQUOTING OF SAMPLES FOR TESTING
Labeling of plastic tubes for aliquoted samples
All blood will be aliquoted into prelabeled prearranged plastic cen-
trifuge tubes, test tubes or syringes. All labeling of tubes will be
completed prior to the landing of the orbiter. All labeling and all-
quoting will be performed in a secluded area by authorized personnel.
Whole Blood
For each of the 18 whole blood units label with corresponding code
numbers the following tubes:
Tube Volume Investigator
Volume Needed
3 50 ml 50 ml
1 50 ml 30 ml
2 15 ml i0 ml
2 I0 ml i0 ml
1 15 ml 5 ml
1 15 ml 5 ml
M. Jacobson (A.B.[I])
I. Szymanski
M. Jacobson
D. Ausprunk
M. Jacobson (A.S.)
M. Jacobson (S.K.)
W. Curby
13.3
# of
Tubes
Leukocytes
For each of the 18 leukocyte units label with corresponding code numbers
the following tubes:
Tube Volume Investigator
Volume Needed
50 ml 30 ml F. Lionetti
15 ml 5 ml D. Ausprunk
15 ml 5 ml W. Curby
13.4
# of
Tubes
i
1
1
1
1
1
i
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Platelets
For each of the 20 platelet units label with corresponding code numbers
the following tubes:
Tube Volume Investigator
Volume Needed
3 ml syringe 1.5 ml M. Jacobson
50 ml 30 ml F. Chao
50 ml 15 ml F. Chao
15 ml 5 ml I. Szymanski
15 ml 4 ml D. Ausprunk
15 ml 3 ml M. Jacobson
15 ml 1 ml W. Curby
13.5
13.6
13.7
Removal of bags from the dewars
TBD
ADL will unload the lockers (separate procedure TBD).
CBR personnel will unload the dewars (separate procedure TBD).
The platelet dewar will be unloaded and platelets place on a rotator for
approximately 30 minutes prior to aliquoting.
13.9
13. i0
13.11
13.8.2
Aliquoting
For each component a specified volume will be aliquoted into pre
labeled tubes according to the charts in 13.2-13.4
Using a coupler with a spike on each end, enter a bag. Be sure the
roller clamp is closed. Rang the bag above the rack of pre-
labeled tubes. Open the clamp and allow the required volume of
sample to flow into premarked tubes.
Once the earth stored dewars are unloaded and samples aliquoted the
same procedure will be repeated for the orbiter stored dewars.
Aliquoted samples will be stored at the following temperatures until
received by the investigator:
Whole blood and leukocytes i-6°C
Platelets 20-24°C
Only when all aliquoting operations are complete, will each investi-
gator will receive a rack of coded samples. All assays will be per-
formed as described in 14.0 Detailed Experimental Procedures
14.0 DETAILED EXPERIMENTAL PROCEDURES
?_::_2CEDING PAGE E;..A,t'_K NOT Flt.MED
14.1
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Erythrocyte Studies (Technical Proposal 3.2.2)
Sample Aliquoting and Designated Responsibility for the Erythrocyte Study
Personnel:
D. Ausprunk (D.A.); A. Byrnes (A.B.); W. Curby (W.C.); M. Jacobson
(M.J.); S. Kevy (S.K.); A. Scanlan (A.S.); I. Szymanski (I.S.); L. Wolfe
(L._.).
whole Blood Responsible Performance
TESTS Volume (ml) Person Site
Physical Measurements
Nears Critical Hemol. vol
Osmotic Fragility
Morphology and
Shape Change (E.M.)
pH, PO=, PC02
Membrane Properties
Intact Cells- Lipids
Ghosts
Spectrin Extraction
Spectrin-Actin-4.1 Binding
Changes in Membrane Proteins
Membrane Glycoproteins
Metabolites
ATP, DPG, Glucose
Electrolytes
WB K+, Na+, plasma K+, Na+
plasma Hgb, WB, Hgb
Plasma
Lipids
plasticizer quant.
coagulation factors
membrane dust
Immunology
5 W.C. on site
5 S.K., AmS. on site
on site and Boston
10 D.A.
A.S. on site
10 M.J. on site and Boston
10 A.B., L.W. on site
50 A.B. on site and Boston
A.B. Boston
A.B. Boston
SO M.J. on site and Boston
(red top
i0 tube) A.S.
(autoclear
I0 tube) A.S.
A.S.
50 M.J.
M.J.
M.J.
M.J.
M.J. , A.B.
30 I.S.
on site and Boston
on site and Boston
on site and Boston
on site
on site and Boston
on site and Boston
on site and Boston
on site and Boston
ON-SITESTUDIES
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A. MEMBRANE PROPERTIES
I. Intact Cells
a) I0 cc of each whole blood sample will be washed by centri-
fugation 3X with cold buffered saline and the buffy coat removed
by passing through a cellulose column. The cells will be resus-
pended in 3 cc of PBS.
b) 0.5 cc will be saved for electronic Hematology parameters by
Coulter analysis.
(I) Lipid Analysis: I ml cells will be extracted with
chloroform-isopropanol and back extracted with O.OS M KCI.
The extracts will be stored frozen (-20°C) and will be
transported back to the laboratory at CHMC in Boston for
completion of analysis (see below for methodology).
•" o Red Cell Ghosts
a) 50 cc of whole blood will be prepared into ghosts by a modi-
fication of the method of Dodge (see below). The ghosts will be
counted electronically by Coulter analysis.
(I) Protein Structure will be analyzed by two-dimensional
SDS geJ electFophoresis. Ghosts will be so]ubilized in 0.5_
SDS plus O.S mM EDTA and with and without 0.02 M dithio-
thFeitol, incubated I hF (37°C), frozen and brought back to
Boston (-40°C). The ghosts will be analyzed in Boston by 5%
polyacrylamide gel electrophoresis, as desc_'ibed by
Fairbanks et al. The resulting gels will be stained for
protein with Coomassie Blue and for gIycoproteins with PAS
(see below).
(2) Spectrin Extraction: SpectFin dimet will be isolated
from 10 cc of ghosts by low ionic strength extraction at
37°C and purified by gel chromatography at 4-b°C (see
below). Samples will be stored at 4-6°C and transported
back to CHHC laboratory in Boston. See protocol below for
Spectrin-Actin Protein-4.! assay.
(3) GIycoprotein Labeling: See section under platelets.
B. RED CELL METABOLISM
I. 10 ml of whole blood will be used to determine the metabolic state
of the Fed cell.
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a) 2,3 Diphosphoglyceric Acid: I ml of whole blood will be
immediately deproteinized by pipetting into 3.0 ml Trichloroacetic
Acid in a IS ml polypropylene centrifuge tube.
(I) Vortex immediately and sit in ice for 5 min.
Centrifuge at 2500 x g for lO mir, and take off clear
supernatant. Freeze (-20°C) and transport back to CHMC
laboratory in Boston for completion. See protocol.
b) ATP: Adenosine-S-triphosphate
(I) Pipet into a 15 ml centrifuge tube 4.0 ml of 0.6 N
perchloric acid (ice cold) and 1.0 ml whole blood. Mix well
(Vortex).
(2) Allow to stand in ice for 10 min then centrifuge for I0
min at 2500 x g at 4°C.
(3) Take off supernatant and freeze at -40°8 for transport
back to CHMC lab in Boston for completion. See protocol.
c) Glucose
(I) Pipet 0.4 ml whole blood into 15 ml centrifuge tube
into 3.6 ml 3% trichloroacetic acid. Centrifuge for I0 min
at 2500 x g. Take off supernatant and freeze for trans-
portation back to CHMC lab in Boston for completion.
d) Plasma Hemogloblin
(I) 3 ml of whole blood will be placed into a plastic 7 ml
centrifuge tube and centrifuged in a Sorvall at 4oC for 30'
at 5000 rpm. The supernatant is taken off and respun. The
supernatant will be stored at 4-6°C for transport back to
the CHMC lab in Boston. See protocol.
e) The remaining whole blood will be transported at 4-6°C back
to.the CHMC lab for K+, HgB, Na+ determinations.
2. Plasma: 25 ml of whole blood in a 50 ml plastic centrifuge tube
will be centrifuged at 4200 x g for 5 min. The plasma will be
separated.
a) 3 ml aliquot will be frozen at -20°C for factor analysis and
transported back to the CHM8 laboratory.
b) 3 ml aliquot will be extracted for lipid analysis in
chloroform-methanol and back extracted with 0.2 M KCI. Extracts
will be stored frozen (-20°C) for return to the CHMC laboratory.
See protocol for analysis.
c) The remaining aliquot will be frozen at -20°C and transported
back to the CHHC lab for plasticizer quantitation. See protocol
for analysis.
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C. Physical Properties
I. Osmotic Fragility: I ml of whole blood will be used for this test.
A unopette osmotic fragility kit will be used for these determinations.
Fragilities will be determined with and without incubation for I hour at
22°C in buffered saline. See protocl for" analysis.
2. pH: 0.5 ml of whole blood will be placed into a I ml plastic vial
and stored frozen at -20°C until pH is read.
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PREPARATIONOF RBCGHOSTS
Modification of method of Dodge, J.T., Mitchell, C., and Hanahan, D.J.:
Arch. Biochem. Biophys. 100:119-130 (1963).
Media
5mMIsotonic phosphate buffered saline, pH 8.0.
0.1 mmEGTA
Procedure
I .
.
°
4.
.
.
.
.
Approximately 4 cc anticoagualted blood washed 3x with cold buffered
saline. Resuspended in ~3 cc of B.S. Send ".S cc or less to lab for
Hgb and RBC. WBC must be removed when cells hemolyzed.
2.5 cc of resuspended RBC's diluted to 35 cc in a graduated cylinder
with cold 30 mosm buffer and inverted several times to ensure complete
mixing and hemolysis of the red cells. (Ghosts should be kept at _4°C
at all times during the procedure). Approximately 9 cc apportioned to
each of 4 centrifuge tubes. Graduate rinsed once with "S cc 30 mosm
buffer, which is added to tubes.
Centrifuge tubes balanced, centrifuged at 9000 x g for I0 min in cold.
Hemolysate aspirated and button of ghosts resuspended with stream of
cold 30 mosm buffer from a wash bottle.
Ghosts in each centrifuge tube are resuspended with "I0 ml of 30 mosm
buffer. Tubes are inverted several times to ensure complete suspension.
Centrifugation, aspiration of supernatant and reusspension is repeated,
using cold 30 mosm buffer, until supernatant is completely clear and
ghost button is white. At this point all ghosts are combined in one
centrifuge tube, resuspended in 10 cc, 30 mosm buffer and collected a
final time (usually a total of 4-5 centrifugations will be required).
If a small button of debris and/or unhemoIyzed BRC'S remains below the
ghost button, this is left behind when ghosts are combined in the last
step (b above).
Ghosts are resuspended at the desired volume (usually 5 ml) with 30 mosm
media. They may be washed and stoerd in other media as desired.
Recovery : usually 90-951
Yield : S ml of ghosts with a concentration of "3xI0 _ ghosts/m1.
Ghosts may be counted in Coulter counter or in RBC counting chamber (phase
microscopy) after standing 30 min.
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SDS GEL ELECTROPHORESIS
REFERENCE: Fairbanks, G., Steck, T.L., and Wallach, D.F.H. E1ectrophoretic
analysis of the major poIypeptides of the human erythrocyte
membraned. Biochemistry 10:2606-2617 (1971).
as modified by -- Steck, T.L. Cross-linking of the major proteins
of the isolated erythrocyte membrane. J. Mol. Biol. 6_:295-305
(1972).
as modified by -- Laemmlle, U.K. Cleavage of structural problems
during the assemblyof the head of bacteriophage T4. Nature
227:680 (1970).
STOCK SOLUTIONS:
i. Conc A+B: Acrylamide (20 g) (USE GLOVES)
Bis (0.75 g)
Water to I00 ml. Freeze iF, 150 ml lots (-20°C)
2. Gel Buffet', pH 7.4 (xlO):
Tris 24.25 g Final cor,c : 0.4 M
NaoH 4.0 g .... : 0.2 M as NaAc
Na2EDTA 3.7 g .... : 0.02 M
HAc to pH 7.4
Water to 500 m1. Freeze in 10 ml lots.
, Solubilizing Solution (x5):
TFis 1.21 g Final conc: 0.i M
Na2EDTA 0.37 g .... : 0.01M
Sucrose 50.0 g .... : 50%
Titrate to pH 7.4 with IM HCf
Water to 100 ml. Freeze irm 5 ml lots.
4. 20X 5DS: SD3 I00 g
Water to 500 ml. Freeze in I00 ml lots.
. 1.5% Ammonium Persulfate:
Amm. Per. 0.15 g
Water to I0 ml.
(USE GLASS TO PIPET) (make up fresh_
o 0.5 TEMED: TEMED 0.05 mJ
Water to 10 ml. Freeze in 5 ml lots.
(USE GLASS TO PIPET) (make up fresh)
,
Coomassie Blue Stain:
MeOH 454 ml
H20 454 ml
Glacial Acetic Acid 92 ml
Coomassie Brilliant Blue 1.25 g
Filter with Whatman No. I filter paper.
B °
8. Fixative: MeOH 500 ml
H_O 450 ml
HAc SO cc
.
Making Gel
Destain: HAc 10%
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i. Set up plates (use medium spacers and 20 well comb).
2. Make the following solution:
Stock solution Amount
A + B 12.0 cc
XIO 6.0 cc
20% SDS .6 cc
Water 32.4 cc
1.5% AP 6.0 cc
.05% TEMED 3.0 cc
3. Pour solution between plates, place comb, and wait for
polymerization.
4. Remove comb and place gel into chamber.
5. Fill chamber top an,Jbottom with electrophoresis buffer.
X10 200 ml
I0% SDS 20 ml
Water to 2 I
, Place 30 ug of protein in each well
a. Solubilizing Solution
XS Sol. soln. : .8 ml
20 % SDS : .4 ml
Dithiothreitol : " 25 mg
Pyronin Y : dash
b , To solubilize protein add:
33 ul Sol. solr,, to I00 ul of sample
Boil 3 minutes.
7. Run gel at " 75 volts until tracking dye reaches the bottom of the
gels (takes about 2 hrs).
8. Put gel in fixative overnight shaking.
9. Stain with Coomassie Blue, shaking, I hr.
I0. Destain with 10% HAc, shaking.
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ATP: ADENOSINE -5'-TRIPHOSPHATE ASSAY
REF: Method Bucher, Th., Biochim.
Biophys. Acta (Amst) i, 129,
(1947 a Denneman, H.A., ges.
exp. Med. 134, 335) (1961
REAGENTS:
Solutions I:
I . 0.151 gms Glycerat-3-phosphate (BM#127116) dissolved in 100 ml of
Triethanolamine buffer (Sigma #665-5).
Solution stable for four months at 4°C.
Solution II:
. 0.018 gms -Nicotinamid-adenin-dinucleotide NADH (BM#127345) in i0 ml
of distilled water.
Solution stable for four weeks at 4°C.
. a) Giycerin-3Phosphat-dehydrogenase/Triosephosphat Isomerase
(BM#127787).
b) 3-Phosphoglycerat-Kinase/Glycerir, aldehyd-3-phosphate-Dehydroger, ase
(BM#I08456).
. O._N Perchloric Acid:
8_.I ml of 70% Perchloric Acid diluted to lO00ml with distilled water In
a volumetric flask.
. ATP standard (Sigma #A-3127) i00 um/ml
.0623 gms/ml of distilled water
Aliquots stored in freezer for daily use.
Dilute 25 ul of standard in 2.5 ml distilled water just prior to use.
SPECIMEN:
Since ATP is rapidly decomposed, specimen should be deproteinized as
soon as possible.
DEPROTEINIZATION:
I. Pipet into a 15 ml centrifuge tube:
4.0mi O.bN Perchloric Acid (ice cold)
1.0 ml blood and mix well
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Allow to stand at room temperature for lO min. then centrifuge for 10
min at approximately 3000 rpm (Sorvall). Use supernatant for assay.
Store clear supernatant at -80oC.
SPECTROPHOTOMETRIC MEASUREMENTS:
Wavelength: 340 nm
Glass cuvette: I cm light path
Temperature: 20-25oC
PROCEDURE:
Pipette into cuvette:
2.0 ml Solution I
0.2 ml Solution II
0.2 ml supernatant fluid, unknowns, diluted standards, etc.
Mix by inverting with parafilm cover. Read optical density E_.
Ad 10 ul of BM suspension #127787 and 10 ul of BM suspension
#I0:345_.
Mix by inverting with parafilm cover, wait until reaction stops
(approx. lO min> and read optical density E2.
El - E2 : E
CALCULATIONS:
239 x E 340 nm= ATP/IO0 ml
mg ATP/IO0 ml -- gmsl of hgb : uMoles ATP/gm hgb.
507 (MW of ATP)
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2,3 - DIPHOSPHOCYLCERIC ACID ASSAY
REF: Sigma Technical Bulletin
No. 35-UV
REAGENTS:
A.
-DPHN, Preweighted Vial, Stock No. 340-101
Each vial contains 1.0 mg -DPNH
Stable for over one year at room temperature whiJe kept dark and
dessJcated.
B ° Triethanolamine Buffer Solution, Stock No. 665-5
Triethanolamine Buffer containing Magnesium ions and EDTA.
Stable 6 months or longer when stored at 0-5°0.
C. Adenosine - 5' - Triphosphate (ATP)
Vial containing 500 mg of Product No. A-5394
Sigma Grade ATP, Disodium Salt
Store below O°C. Stabel one year or longer.
c' Reconstitute vial with 5 ml Triethanolamine Buffer, Stock No.
655-5 (reagent B). Stable several months when stored frozen.
D. GAPD/PGK Enzymes, Stock No. 366-2
Glyceraldhyde Phosphate Dehydrogenase and PhosphogIyceric Phosphokinase
suspension in Ammonium Sulfate.
Mix by inverting before each use (DO NOT SHAKE).
Stable at least 6 months when stored at 0-5°C.
E. Phosphoglycerate Mutase (PGH), Stock No. 665-3
PhosphogIycerate Hutase Enzyme suspension in Ammonium Sulfate.
Mix by inverting before each use (DO NOT SHAKE).
Stable at least 0 months when stored at O-S°C.
F . Phosphoglycolic Acid, Stock No. 6_5-2
50 mg preweighted vial. Stable when stored below O°C.
f' Reconstitute vial with 5.0 ml water. Stable for several
months when stored frozen.
Go Trichloroacetic Acid 8X, Stock No. 665-8
Approximately :3% Trichloroacetic Acid (w/v).
Stable for at least 6 months when stored at 0-5°C.
H, DPG Standard (BH#I05821) I um/ml
0.0083 gms/lO ml of distilled water
0.0083 gms/100 ml of distilled water
A1iquots stored in freezer for daily use.
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2,3 DIPHOSPHOCYLCERIC ACID ASSAY
SPECIMEN:
2,3-DPG appears to be stable in whole blood for at least 2 hours when stored
in an ice bath. Trichloroacetic filtrates are stable up to 2 weeks when stored
at 0-5°C.
DEPROTEINIZATION:
Pipett 1.0 ml of freshly drawn blood (heparin, ACD or CPD) into 3.0 ml of cold
8% Trichloroacetic Acid, Stock No. 655-8.
Shake vigorously for several seconds. Keep the mixture cold for an additional
5 minutes to assure complete protein precipitation.
Centrifuge 5 to I0 minutes at approximately 3000 rpm (Sorvall) to obtain a
clear supernatant.
SPECTROPHOTOMETRIC MEASUREMENTS:
Wavelength:
GJass cuvette:
Temperature:
340 mu
I cm light path
20-25oC
PROCEDURE:
I . Into a I mg DPNG vial, Stock No. 340-101 pipette:
8.0 ml Triethanolamine Buffer Solution (Stock No. 6_5-5).
Cap and invert several times to dissolve the DPNH.
Stable up to one week when stored at 0-5°C. (DO NOT FREEZE).
. Into two cuvettes marked BLANK and TEST, pipette the following:
(NOTE: ONLY ONE BLANK IS NEEDED FOR EACH SERIES OF TESTS)
Mixture from Step I
ATP Solution (Reagent C)
Water
Protein Free Filtrate
(From Step B under Preparation
of Protein Free Filtrate)
BLANK
2.5 ml
0.1 ml
0.25 ml
Mix by inversion and add:
GAPD/PGK Enzymes
(Reagent D) 0.02 ml
PGM Enzyme (Reagent E) 0.02 ml
Mix by inversion
Wait approximately 5 minutes
TEST
o 5 ml
0.1 ml
0.25 ml
0.02 ml
0.02 ml
5.
.
.
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Read and record 0D34o mu of both the BLANK and TEST.
Cuvette using water as reference.
To each cuvette add: 0.1 ml phosphoglycolic acid (Reagent F).
Mix by inversion. Let stand for 25-30 minutes (to allow reaction to go
to completion).
Read and record 0D34o mu of BLANK and TEST usirlg water as reference.
CALCULATIONS:
a)
b)
c)
d)
OD BLANK : OD of BLANK (step 3) - OD of BLANK (step 5).
OD TEST : OD of TEST (step 3) - OD of TEST (step 5).
Calculate OD by subtracting a) from b);
OD : ( OD TEST) - ( OD BLANK)
uMoles of 2,3-DPG : ( OD) X (3.0)
per ml of blood (6.22) X (0.0625)
: ( uD) X (7.7)_
The factors are explained as follows:
a) 3.0 represents the volume of liquid in the cuvette.
b) 6.22 is the millimolar extinction coefficient for -DPNH at 340 mu.
c) 0.0625 represents the volume of original samplein ml Jr, the reaction
mixture.
NOTE
You can also use above answer to calculate 2,3-DPG levels on the basis of
Packed Cells, or Hemoglobin as follows:
i) uMoles of 2,3-DPG
per ml Packed Cells
(u_oles of 2,3-DPG
per ml Whole Blood X (I00)
Hematocrit in percent
Ex: If 2,3-DPG level is 2.2 uMoles per ml Whole
blood and Hematocrit is 451, then:
uMoles of 2,3-DPG : (2.2) (100)
per ml of Cells : 4.9
(45)
2) uMoles of 2,3-DPG
per grams Hemoglobin :
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(uMoles of 2,3-DPG
per ml Whole Blood X (I00)
grams Hemoglobin pet" I00 ml
Ex: If 2,3-DPG level is 2.2 uMoles per ml Whole
blood and Hemoglobin level is 15 grams, then:
uHoles of 2,3-DPG =
per grams Hemoglobin
(2.2) (100)
(15)
: 14.7
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Tetramethylbenzidine (TMB) Method for
Measuring Supernatant Hemoglobin
Reagents:
I. TMB Reagent, II (Aldrich Chemical Co.)
Dissolve I gram of TMB in 90 ml of glacial acetic acid and dilute up to
100 ml in a volumetric flask with distilled water. The reagent's
reaction with hemoglobin will remain stable for at least 5 weeks despite
some darkening of color if stored at 4°C.
2. Hydrogen Peroxide, I% (3OX, Fisher #H-325)
Dilute 3.3 ml of 30% hydrogen peroxide to I00 ml in a volumetric flask
with distilled water. Prepare daily.
3. Acid Diluent Solution, i0% Glacial Acetic Acid
A IOX by volume acid diluent solution is prepared by adding 100 ml of
glacial acetic acid to $00 ml distilled water. Stability of reagent is
at least one month at R.T.
. Platelet-Poor Hemologlobin "Free" Plasma (PPHFPI, Diluent for standards
and samples
Prepare from fresh citrated whole blood clarified by centrifugation and
frozen in aliquots at -20°C. Prior to use, thaw and centrifuge. In
order to compensate for the hemoglobin in this plasma diluent, a plasma
blank is included with every run. The absorbance reading of this blank
is then subtracted from the standards and the diluted samples.
Preparation of Hemoglobin Standards:
I ° Packed red cells (hematocrit 70-80_) prepared from a unit of citrated
whole blood should be Iysed with distilled water (3 ml H_O per ml red
cells). Stroma and other debris should be removed by centrifugation and
the hemaglobin concentration of the lysate should be determined by the
cyanmethemoglobin method (Protocol #9). Aliquots should be frozen at -
20oC.
2. Prepare a 200 mgs X standard from lysed cells:
Example:
W.B. Hgb of lysed cells : 11.1 gmsX
1i,oo.__9_o
200 _ x
or .181 I0 ml distilled water
1.81 I00 ml distilled water " 200 mg % solution
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Prepare a working standard of 100 mg% with equal amounts of PPHFP and
the 200 mgX standard solution.
Conc. of Standard Amt. of 100 m9% Soln.
5 mgZ ! ul
25 mgZ 5 ul
50 mgX 10 ul
75 mgX 15 ul
100 mgX 20 ul
Plot O.D. versus concentration.
Preparation of Samples for Assay:
Supernatant or plasma samples will be prepared by filling a sufficient number
of 12 mm polypropylene tubes to provide enough plasma or supernatant for
assay. The amount of blood required wi11, of course, be dependent upon the
hematocrit of the blood.
Centrifuge the tubes in the Sorval at 5000 RPM for 20' at a temperature of
IOoC.
Pipet the supernatant/plasma into another 12 mm polypropylene tube using a
plastic pipette. Clear any entrained red cells from the sample by repeating
the centrifugation, and pipetting the supernatant/plasma into a separate glass
tube.
Spectrophotometric Measurements:
Instrument : Unicam spectrophotometer
Wavelength : 515 nm
Glass cuvette : I cm light path
Temperature : 20-25°C
Assay Procedure:
i . For each unknown, blank, plasma bank, and standards, measure i ml of IX
TMB into a test tube and add 20 ul of plasma or standard to each rude.
° Add I ml of I% HzO; solution to each tube. Mix and let stand at room
temperature for 20 minutes.
5. Following incubation add I0 ml of lOX CH3COOH, mix _ell and wait I0
minutes before measuring absorbancy at 515 rim.
4. Calculate concentration of hemoglobin from standard curve.
pH Determination
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Instrument:
Radiometer pH meter 4
Micro Electrode Unit
Circulation Thermostat
Operation:
l ° Be sure the electrode water jacket is full of circulating water and the
thermometer is set for the desired temperature.
. Remove the glass electrode off its holder and press the suction cap
against the plastic tip, with your thumb and suck distilled water
through the capillary electrode until a few drops have passed the
suction cap.
. Fill the polyethylene tip and the capillary electrode with the buffer
solution (7.381 pH).
° _ Stop the suction and lift the polyethylene capillary out of the buffer
solution.
. Put the glass electrode back in its holder with the polyethyler, e tip
immersed in the KCI pool of the calomet electrode (this is the measuring
position).
b. Set the pH meter at READING.
. Rotate the BUFFER ADJUSTMENT knob of the pH meter until the meter reads
the pH of the buffer solution.
8. Set the pH meter to STAND BY.
. Flush the electrode with distilled water, by sucking it through the
capillary.
10. Suck air through the electrode for 3-5 seconds to dry its capillary.
11. Place the glass electrode in its resting position but with the
polyethylene tip outside the beaker.
12. Mix the blood and insert the polyethylene tip into the tube or segment.
13. Press the suction cap against the plastic tip and suck blood into the
capillary electrode until one drop is visible in the suction cap. Air
bubbles must r_ot be present in the polyethylene tip and in the glass
capillary electrode.
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14. Place the glass electrode in its measuring position, and read the pH
when the meter has come to rest. Take down the result (the actual pH).
15. Immerse the polyethylene tip in a buffer solution for rinsing purposes.
(Buffer solution is used for the rinsing because it prevents poisoning
of the capillary electrode. The pH of the rinsing buffer should be
between 7.3 and 7.4). Now create the suction and the rinsing buffer
wi11 clear the capillary electrode of the blood.
16. Rir,se the glass capillary electrode with distilled water, refill with
buffer of pH 7.38 and place the electrode in its resting position.
Instrument:
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DETERMINATION OF RED CELL HEMOGLOBIN CONTENT
Coleman Jr. Spectrophotometer or Unicam Spectrophotometer
The standard curve is set up by increasing dilutions of the Hycel
Cyanmethemoglobin Standard. For the 5.0 ml volume employed in the unknown
samples the undiluted standard corresponds to 20.0 Gm/dl hemoglobin. Dilutions
are made to correspond to 15 Gmldl, I0 Gm/dl, 5 Gm/dl and zero. Dilutions
must be made with the Hycel Cyanmethemoglobin Reagent -- never with water.
Place five test tubes in a rack. Mark the tubes 20, 15, I0, 5 and B.
Dilutions must correspond to the following table:
Gm/dl Hemoglobin 20 15 I0 5 Blank
Volume of Standard 6.0 ml 4.5 ml 3.0 ml 1.5 ml none
Volume of Reagent none 1.5 ml 3.0 ml 4.5 ml 6.0 ml
Transfer the dilutions to well matched cuvettes. Set the instrument to
the proper wave length, 540 mu or filter. Adjust the instrument so the Blank
tube has zero Optical Density or lOOX Transmission. Take the readings for the
standard and plot Optical Density on straight graph paper and Z Transmission
on semi-log graph paper.
Determining Unknown Sample:
Place 5.0 ml of Reagent in 19 x 150 mm cuvette test tube. Add exactly
0.02 ml of blood and mix contents. Read against Reagent Blank. Transfer
reading to standard curve and obtain hemoglobin concentration in Gm/dl.
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REF: Sigma Techr, ical Bulletin
No. 635
THE COLORIMETRIC DETERMINATION OF GLUCOSE
REAGENTS:
A. O. Toluidine Reagent, Stock No. 635-6
Store in dark at room temperature.
Caution: Do not pipet by mouth. Avoid contact with skin.
Do not inhale fumes.
Bo Trichloroacetic Acid Solution, 3% (W/V), Stock No. 635-3
Store in refrigerator at 0-5°C.
C° Glucose Standard Solution, Stock No. 635-I00
Standardized at 1.0 mg/ml (100 mg/lO0 ml or 5.5 m moi/I) with
Benzoic Acid added as preservative
Store in refrigerator at 0-5°C.
D, Hyland Q-Pak--Chemistry Control Serum I
List No. 045-050
Store between 2° and B°C before and after reconstitution.
SPECIMEN:
Glucose can be determined on whole blood, plasma, or serum. At room
temperature, glucose in blood undergoes glycolysis at a rate of
approximately 5X per hour.
DEPROTEINIZATION:
Into a centrifuge tube, pipet:
0.4 ml sample
3.6 ml of 3X TrjchloroacetJc Acid, Stock No. 635-3
Mix well by shaking. A11ow to stand approximately S minutes to
precipitate proteins.
Centrifuge (5-10 minutes) until clear supernatant is obtained in the RC-
3 at 3000 rpm. Store clear supernatant at O-Sot, if determination is to
be within a few hours. Otherwise freeze clear supernatant.
INSTRUMENT:
Practically any photoelectric colorimeter that transmits light in the
range of 620-6S0 nm can be used.
Instrument: Coleman Jr.
Wavelength: 63S nm
Cuvette: 19 x IS0 mm
NOTE: Instrument readings should be made in terms of
Absorbance (A) for use in calculations and for
preparation of calibration curves.
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PROCEDURE WITH DEPROTEINIZATION
For whole blood and markedly icteric or hemoIyzed samples.
CAUTION: Avoid inhaling fumes resulting from the O-Toluidine Reagent. It is
suggested that the procedure be carried out in a well ventilated
area or hood. DO NOT pipet this reagent by mouth:--
.
.
_°
S.
I. Label test tubes or cuvets BLANK, STANDARD, CONTROL, TEST I, TEST 2, etc.
TO BLANK ADD:
0.1 ml water
0.9 ml 3_ TCA Solution
Stock No. 635-3
TO STANDARD ADD:
0.1 ml Glucose Standard
Solution
Stock No. 635-100
0.9 ml 3Z TCA Solution
Stock No. 635-3
TO CONTROL & TESTS ADD:
1.0 ml supernatant
To each tube add:
CAUTION: DO NOT PIPET BY MOUTH
5.0 ml O-Toluidine Reagent, Stock No. 635-6
Mix by lateral shaking.
Place all tubes in a vigorously boiling water bath for exactly I0
minutes.
NOTE: If results are calculated from a standard that is assayed with the
Test, the boiling period can be 10 + I minute.
Quickly remove all tubes and cool to room temperature by placing in tap
water for approximately 3 minutes.
Transfer contents of tubes to cuvets and read Absorbance of STANDARD and
Tests at 635 + 15 nm, using BLANK as reference. Complete readings
within 30 minutes.
CALCULATIONS:
Use of Standard:
Glucose (mg/lO0 ml) : ^Test
^Standard x l 0 0 0 *
*:Represer, ts the concentration of the Glucose Standard (mg/lO0 ml).
NOTE: If the reading of Test indicates a Glucose concentra-
tion greater than 250 mg/lO0 ml, dilute the test with
an equal volume of O-Toluidine Reagent, Stock No.
635-6. Read Absorbance of the diluted Test and
multiply result by 2.
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FLAME PHOTOMETRY
SODIUM AND POTASSIUM DETERMINATIONS
EQUIPMENT:
REF: Instrumentation
Laboratory Manual 143
IL Model 143 Flame Photometer
Compressed Air - Supply with a minimum pressure of 25#/in _
site gauge showing clean oii and with a flow of
moisture-free air of 0.5 ft_/min.
Fuel: Propane, (instrument grade)
Dade Dilutor Model 200
REAGENTS:
#35000
#53203
#35050
#35100
#97517-50
#97518-50
#97519-50
(Instrumentation Laboratory, Inc.)
Stock Lithium Concentrate 1500 mEq Li/liter
dilute 20 ml stock to 2,000 ml with distilled water
150 mEq K/1
50 mEq Na/liter/lO0 mEq K/liter
100 mEq Na/liter/5 mEq K/liter
140 mEq/Na/liter/2 mEq K/liter
120 mEq/Na/liter/2 mEq K/liter
160 mEq/Na/liter/8 mEq K/liter
OPERATION:
I . Turn the front panel toggle switch to the ON position.
This allows ignition to take place.
a. Open the propane Shut-off valve located at the top of the fuel
cylinder, one-half counter clockwise turn.
b. Open laboratory air manifold fully.
. Turn ON/_>FF switch to its upper position. The Flame On indicator light
should come on and the faint sparkling sound cease within a matter of a
few seconds.
. Place a lithium blank solution or distilled water on the sample stand,
raise the stand and aspirate for at least five minute before
calibrating.
SAMPLE AND STANDARD PREPARATION:
I . Lithium Diluent - It is imperative that the lithium concentration in all
calibrating standards and unknown samples be kept constant. Dilute (20
ml) #3500 Stock Lithium Concentrate 1500 mEq Li/liter to 2,000 ml with
distilled water.
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a.. Calibrating Standards - Once the lithium diluent is prepared, dilute
working standard can be made. Dilute a11 calibrating standards and also
all biological unknown TWO HUNDRED TIMES with the lithium diluent. This
is done via the Dade Dilutor with 50 ul of sample and 9.95 ml of
diluent.
NOTE: It is recommended that approximately one ounce disposable plastic
cups be used to hold standards and samples for analysis.
ANALYSIS OF DILUTED SAMPLES:
I° As recommended aspirate lithium diluent through the atomizer for several
minutes before calibration. Doing this allows the diluent to thoroughly
circulate around and wet the walls of the atomizing chamber, thus
preventing the collection of droplets on the atomizer wails and
instability in the readout.
2. Change the lithium solution and aspirate a fresh lithium diluent.
. Set the needle on the Lithium Response Meter at the center of the
reference triagle with the Lithium Set Control.
, Set both the Sodium and Potassium Digital Concentration Displays to 0000
with their respective Zero Controls.
. Aspirate an appropriate working standard 140 Na/5 K and switch the
Potassium Range Selector Switch to the required position (20 for Serum).
. Set both the Sodium and Potassium Digital Concentration Displays to the
corresponding values of this standard with the respective Balance
Controls. For example, the 140 Na/5 K working standard would be
calibrated at 1400 and OSO0, respectively.
. Replace the standard with arm unknown sample correctly diluted with
lithium diluent and aspirate. Read and record the concentration of the
unknown from the Sodium and Potassium Digital Concentration Display.
NOTE: Initially, it is advisable to recheck the calibration of the
instrument after every five to ten unknowns. After term to fifteen
minutes of use, the calibration, typically, need be check less
frequently.
INSTRUMENT SHUT DOWN:
I . After completing your determinations, aspirate lithium diluent through
the unit for several minutes. This serves to thoroughly wash the
atomizer and burner system.
. Turn the propane Shut-Off Valve at the top of the fuel cylinder,
clockwise (closed). Do not overtighten this valve, finger" tight is
adequte.
3. Close the air manifold fu11y.
4. Place the ON/OFF Switch in its lower position.
I .
3.
4.
5.
6.
1
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MAKING GHOSTS IN RC 2B OR 5B SS34 ROTOR
(All done at 4°C)
Solutions for making ghosts:
a. 0.15 M NAP04 Stock
titrate .015 M NazHP04 7H_O with .15 M NaH_P04 H20 until pH :
7.4
b. PBS
50 mI 0.15 M NAP04 stock
8.77 g NaCl
c. 5P8
33.3 ml of 0.15 M P04
can also make it 0.5 mM EGTA : 2.5 cc of 200 mff stock
i I : total volume
pH to 8 with NauH
Spin down whole blood (go up to 12 K Fpm, then cut out rotor).
Remove plasma.
Suspend and mix RBC's with PBS, spin down RBC (go up to 12 K rmp, then
cut out rotor), aspirate off supernatant.
Repeat #4 2 more times.
Suspend and mix cells with SPS, spin down ghosts at 20 K rpm for 10-15
min. Aspirate supernatant and any white cells at the bottom of the
tube.
Repeat #5 until ghosts are pure white (4-8 times depending on the amount
of blood in the tube).
IBSE Protocol
Page 44
MAKING SPECTRIN EXTRACT
Unless otherwise indicated, done at 4°C in SS34 rotor in RC2B or RCSB
centrifuge.
I °
2.
3.
4.
5.
6.
o
8.
Make ghosts.
Suspend and mix ghosts in ice cold 0.1 mM P04 (20 cc of 5P8/I).
Spin at 20 K rpm : 50 kg for 20 min, aspirate off supernatant.
Repeat #2 and 3.
Incubate ghosts, shaking at 37°C for .5 hr.
Place ghosts into 60 TI rotor and spin for I hr at 39 K rpm : II0 kg in
Sorva11 or Beckman ultracentrifuge.
Aspirate and save supernatant = Spectrin extract.
Read OD28P against HzO = Spectrin concentrate.
I °
2.
3.
4.
.
MAKING SPECTRIN DINER
(All done at 4°C)
Make spectrin from 50 cc of whole blood.
Concentrate spectrin to about 5 mg/ml.
Make extract I0_ sucrose.
Load extract on 12 x 1000 me column
(column gel : Biorad A-15).
A-15 Buffer
150 mm NaCI
10 em TFiS
.I me EDTA
.02% Na Azide
Run at 3 cc/hr, collect 20 ein fractions.
Chromatograph.
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SPECTRINACTIN4.1 BINDINGASSAY
_:_lutior_
Actin Buffer : Buffer A
2 mM TFis-HCI pH 8
0.2 mM ATP
0.5 aM DTT
0.2 mM CaCl2
2 ml of I M stock
40.111 g (variable M.W.)
77 mg
0.2 ml of I M stock
total vol : i liter
High Salt Buffer : HS Buffer
I M NaCI
59 M TFiS
(pH 7.4)
2.7 mM DTT
0.9 aM ATP
[store at -20°C]
5.84 g
0.7139 g
0.0416 g
0.536 g
total vol : I00 al
4.1 Buffer
I0 mM P04
.5 mM DTT
[pH : 7.4]
B °
I.
2.
3.
XIO Sucrose Buffer
1.5 M NaCI
40 mM P04
2 aM MgCI_
5 aM DTT
I00 aM Tris
l.O aM ATP
50 aM KCI
[store at -20°C]
PolymerizeActin
Take Actin frozen at -20°C in glycerol and dialyze X3 in Buffet A.
Make Actin 50 mM KCI, 2 aM MgCtz.
Let sit 2 hrs at room temperature.
C° Mixes a la Wolfe
S-A-4. l Mix
F Actin
4.1
BSA
HS Buffer
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240 \ of OD2eo : 2.0 in Buffer A
600 \ of OD=e,) = 0.2 in 4.1 Buffer
20 \ of 35X Sterile
160 \
1020 \
S.-A. Mix
F Actin
4.1 Buffer
BSA
HS Buffer
240 \ of ODz,o : 2.0 ir, Buffer A
20 \ of 35% Sterile
16o \
1o2o \
P °
I .
2.
,3.
4.
5.
b.
7.
S Nix
F Actin Buffer
4.1 Buffer
BSA
HS Buffer
20 \ of 35% Sterile
160 \
1o2o \
The Ass;By
SA 4.1
50 \ of SA 4.1 mix
SA
50 \ of SA mix
S
p
50 \ of S mix
2-40 ug _2Sl spectrin
dimer up to 30 \ in
A-15 Buffer
2-40 ug 2251 spectrin
dimer up to 30 \ in
A-15 Buffer
2-40 ug ]ZSl spectrin
dimer up to 30 \ in
A-15 Buffer
A-15 Buffer
total vol : 80 \
A-15 Buffer
total vol = 80 \
A-15 Buffer
total vol = 80 \
Incubate at 23°C 60-90 min.
Layer bO \ of each sample above 5% sucrose in sucrose buffer leaving an
air space in polyethylene tubes.
Centrifuge 2 hrs at 20 K rpm in SS34.
Freeze tubes and clip 7 mm from bottom. Count supernatant and pellet.
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PROTEIN 4.1 PREPARATION BY TWEEN 20
A11 done at 4°C in SS34 rotor in RC-2B or RC-5B unless otherwise indicated.
A.
B.
Make ghosts.
Band 6 extraction (GIyceFaldehyde-3-phosphate dehydrogenase)
I. Stir membranes in:
0.155 N NaCI : 9 g/1
0.5 mM EGTA : 2.5 ml/l of 200 mM stock
5 mM Na phosphate, pH 8
for 30 min on ice, i.e. add salt and EGTA to ghosts.
2. Centrifuge at 20 K rpm for 10 min.
3. Wash with PBS and recentrifuge.
4. Wash with giycine buffer (part C) and recentrifuge.
C. Spectrin and actin (Band 5) extraction
I . Suspend membranes in 6 vols of: (for unit bring vol to I I)
5 mM glycine = 1.13 g/3 1
0.5 mM EGTA = 7.5 ml of 200 mm stock/3 1
5 mM beta-mercaptoethanol = 1.07 ml/3 1
3 mM azide = .585 g/3 l
pH to 9.5
2. Stir on ice 6-12 hrs and spin at 20 K rpm for 20 min.
3. Repeat extraction 2 more times.
. Susper, d membranes in b vols of: (for unit bring to 1 i)
O.E mM Na Azide : 0.78 g/2 1
O.E mM EGTA : 5 mls of 200 mm stock/2 1
pH to 8
5. Stir on ice 6-12 hrs and spin at 20 K rpm for 20 min.
6. Repeat Azide extraction once more and recentrifuge.
D. Tween 20 4.1 Extraction
I . Dilute membrane with an equal volume of:
0.2 M gIycine 7.5 g
2% Tween 20 10 cc
2 mM Na tetrathionate .30b g
I mM EGTA 2.5 ml of 200 mm stock
pH 9.8 500 ml
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2. Stir on ice 10-15 hrs.
3. Spin at 39 K rpm for I hr in 60 Ti rotor in SorvaI or Beckman
ultracentrifuge.
E. Purification at 4.1
I ° Layer sample on DE52 column
(.15 ml DE52/mg protein) equilibrated in:
0.05 M gIycine 3.75 g
0.5 mM EGTA 2.5 cc of 200 mm stock
0.5 mM dithiothreitol
pH 9.8 I liter
2. Wash with equilibration buffer until OD2eo falls to 0.05 or lower
using white-white tubing (36 cc/hr).
3. Apply gradient
4. Collect using black-black tubing (19cc/hr).
5. Collect 10 min fractions.
6. Run on SDS-PAGE gels to check put'ity.
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METHODFORRBCLIPID EXTRACTION
[_.l _ IN _CAllZ
I . Wash anticoagulated RBC three times in saline, remove WBC with cellulose
acetate columns. Final WBC should be less than 400/mm :.
. Extract approximately 0.2 cc of packed RBC and determine RBC count on
Coulter.
3. Use disposable 16 x 150 mm glass tubes to do the extract.
° Add 0.5 cc distilled water to hemolyse samples. Vortex. After Iysis is
completed, place samples in ice bath and let cool for 5-I0 minutes.
, Add 5.5 cc of cold isopropanol to Iysate and vortex. The isopropanol
must be cold or the lipids will not be completely extracted from the
RBC. After approximately 15 minutes in ice, let samples remain at room
temperature with frequent vortexing for approximately I hour. The RBC
membranes should look fluffy and will settle by this time.
bo Place the samples back in the cold ice bucket and add 3.5 cc COLD
chloroform. Again vortex, remove from the cold in 15 minutes, _FiiJkeep
at room temperature for I hour. Frequent vortexing is necessary.
. After 1 hour, centrifuge at "1,5000 x g, filter supernatant with glass
wool pipets into 16 x 150 mm tube, and wash pellet.
. Remove inorganic phosphorus by adding 2 cc .5M KCI/IO cc extract.
Vortex and spin down. Remove aqueous layer (top). Repeat 2 more times.
If doing just cholesterol assay skip this step.
9. Dry down extract with nitrogen in 40-45°8 bath.
10. Bring up to known volume (9.25 cc) with chloroform/methanol 2/I and
aliquot for assay.
NOTE: A11 glassware must be phosphorus free for phosphorus assay. No
rubber stoppers should be used for cholesterol assay. They are
not recommended for phosphorus either.
May stop at 2 points:
i) after addition of isopropanol
2) after addition of chloroform and store at -20°C overnight.
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METHOD FOR PHOSPHORUS DETERHINATION
I. Reagents: Perchloric Acid 69-72X as purchased from J.T. Baker.
Ammonium Holybdate 2.5X. Dissolve 2.5 g per 100 ml water._
Ascorbic Acid I0% (Purchased from Fisher). Dissolve i0.0 g
per lO0 m[ water.
*Keep at 4°C irl dark bottle, make 500 cc, storage okay for I
month.
2. Tubes used: 16 x 150 mm disposable borosilicate glass culture tubes.
Specimen:
Plasma: Make lipid extract from 0.2 ml plasma or serum.
Use 1.0 ml extract for phosphorous determination.
RBC: After washing in isotonic saline 3X and removing WBC's,
use icc at 20I Hcf, spin and discard supernatant or use 0.3
cc red cells from 80% Hct to make lipid extract.
Use 1.0 of the extract for phosphorous determination.
4. Procedure:
I. Evaporate all aliquoted extracts to dryness with N2 in 40-45°C HzO
bath.
2. Add 0.5 ml perchloric acid to each.
3. Heat in J60°C heating block for 30 min; if samples are not clear',
heat longer.
4. Let cool "5 min.
5. Add 3.3 ml H20 to each.
6. Add 0.5 ml ammonium molybdate and vortex.
7. Add 0.5 ml ascorbic acid and vortex.
8. Boil in lO0°C water" bath for 10 rain; put marbtes on top of tubes.
9. After coolir,g "10 rain read at 797 rim.
5. Standard Curve:
Hake .8650 g Na2HP04 7HzO stock solution = I00 ug P/cc.
Hake working stocks of I ug/ml, 2 ug/ml, 3 ug/ml from above stock.
For daily standard curve, use Iug, 2 ug, 3 ug by drying I ml from each
of the above working stocks in oven.
These may be dried in a batch and stored at room temp indefinitely.
Alt: Pre-ashed phosphor,Js STD may be purchased.
NOTE: A11 g]assware must be new or acid washed.
TOTALCHOLESTEROL
Methodof 21atkis
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REAGENTS
I. Standard Cholesterol solution (I mg/ml).
a. Dissolve 100 mg pure, dry, ash-free cholesterol in 100 ml glacial
acetic acid.
b. Alternative: Purchase Sigma's Cho1. Standard Solution in Glacial
Acetic Acid (I mg/ml).
c. Daily set up fresh standard curve with standards of 50 ug, 75 ug,
I00 ug.
FeC13 6H20 Solution: 10 g/t00 ml HAc (W2).
Make fresh daily.
Color Reagent (#3): Slowly dilute I ml of #2 to 100 ml with conc. H2S04.
o
.
PROCEDURE
. Use either 0.2 ml plasma or 0.2 cc packed RBC. Perform isop/(hlor lipid
extract as indicated.
Use 3.0 ml of the extract for cholesterol determination. Use 16 x 150 mm
borosilicate glass tubes. Evaporate extract to dryness with N_ in HzO
bath at 40-45°C.
2. Add 3 ml HAc to sample tubes. Vortex 30 sec.
. Add 2.0 ml Color Reagent (#3), slowly down the side of the tube.
This will form two layer's.
Vortex I min to mix very well.
4. Let tubes come to RT (30 min).
5. Read at 5_0 nm in same order as added Color Reagent.
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14.2 Platelet Studies
Sample Aliquoting and Designated Responsibility for the Platelet Study.
Persons Involved:
D. Ausprunk (D.A.); W. Curby (W.C.); M. Jacobson (M.J.); I. Szymanski (I.S.); A.
England (A.E.); Lisa Rice (L.R.); B. Kim (B.K.); D. Kenney(D.K.); F. Chao (F.C.).
Reference Section
Responsible Blood Performance in Original
Tests Person Volume(ml) Site Proposal
pH viscosity M.J. I on site 4.2.2.1
platelet count
volume W.C. I on site 4.2.2.1
size 4.2.2.2
shape
morphology & D.A. 7 on site 4.2.2.2
shape change 4.2.2.3
platelet aggregation
& ATP release
4.2.2.4
B.K. & A.E. 4 on site 4.2.2.7
Thromboxane
generation L.R
uptake & release
of 5 HT F.C
on site &
2 in Boston 4.2.2.5
on site &
2 in Boston 4.2.2.6
_-thromboglobulJn
release A.E
on site &
2 in Boston 4.2.2.7
PF-3
measuremer,t F.C & L.R. 3 or, site 4.2.2.8
Y
H,_15otonic
Stress B.K 3 on site 4.2.2.9
X
membrane
glycoproteins
cytoskeleton
Immunology
on site &
D.K & F.C. 15 in Boston 4.2.2.10
D.K. & F.C. 15 on site & in Boston 4.2.2.11
I.S. 3 on site
Assays of Platelet Aggregations and Release Reaction
A. Working Space
50" x 25" bench space
4 plugs of the power line with 115 V AC, 60 Hz
B. Equipment and Accessories:
I. Lumi-Aggregometer (Model 1020, Payton Scientific, Inc., Buffalo, NY)
2. TwoDual Channel Strip Chart Recorders (Model 500, Payton Sci., Inc.,
Buffalo, NY).
3. Chart Paper (#0100-025, Payton Sci., Inc., Buffalo, NY); one roll
4. Cuvettes, disposable (CU312, Payton Sci., Inc., Buffalo, NY); two boxes
S. Stirring Bar, (SB312, Payton Sci., Buffalo, NY); 100 bars
6. Pipettes, I ml, 200 ul, I0 ul capacities; two each
7. Pipette tips, blue and yellow
C. Reagents:
D°
I. ADP stock solution, I0-3 H in 0.87X NaCI, 10 ml in total
2. Collagen stock solution, 20 mg X, S ml in total
3. ATP standard solution, 10-_ H, 3 ml in total
4. Luciferase-Luciferin Reagent (Part #395, Chrono-Log Co.); four vials
Assay Procedures:
I ° Preparation of samples:
Platelet concentrate of 3 ml aliquot sampled from each storage unit will be
adjusted to platelet count 300,000 per ul by diluting with pooled citrate
plasma. For this, 60 ml of pooled plasma wiii be obtained of which 10 ml
will be used for control samples (before storage; to) and 50 ml for stored
samples. The plasma for stored samples will be kept at 4°C until used.
° Simultaneous assays for aggregation and release reaction:
Platelet samples of 0.4 ml plus the luciferase-luciferin reagent of 0.05 ml
will be prewarmed to 37°C in the incubator of lumiaggregometer. The record-
ing chart will be adjusted to a full scale with the sample and plasma as O:
and i00_ light transmittance, respectively. The assay will be started by
adding aggregating agent of 0.05 ml into stirring sample. Aggregating
pattern and the intensity of luciferin light produced by the released ATP
wi11 be recorded in a dual channel recorder. At the end of reaction
(usually 4-5 mins), 2 ul of ATP standard solution containing 2 nmol will be
injected and light intensity will be recorded and used as an internal stan-
dard for calculation. Two different concentrations of both aggregating
agents, ADP (10 uM and 100 uM) and collagen (6.25 ug and 12.5 ug per assay)
will be tested for each sample. Maximal degress of aggregation will be
recorded and the value of release reaction will be expressed in umol ATP
released from the aggregating platelets, e.g. per I011 cells.
PRECED;NG PAGE _LANK NOT FILMED
UPTAKE _ RElEASE OF 5EROTOI_N
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Equipment:
Microfuge
Vortex
Water Bath 37° C
Pipettes
Materials:
Distilled H20
NaC1
EDTA
Horm collagen
Protozol
plastic tubes for incubation
plastic vials for counting
pH meter
Scintillation Counter
Cell counters
Heater
pooled plasma; platelet cor,centrates
TES
HCl
14C - 5HT
NaOH
Scintillation fluid
microfuge tube, polycarbonate outer tubes
Plasma preparation:
Dilute platelet concentrates with pooled plasma to 300,000 cells/ul.
Solutions:
1.2% paraformaldehyde solution (PFA)
I. Dissolve 6 gm of PFA in 100 ml of distilled H_O; heat to 60-70°C; add 5N NaOH
until solution becomes clear.
2. Dilute (I part) 6% formalin solution with 5 parts of TES-saIine-EDTA (0.01 M
TES, 0.14 M NaCl, 5 mH EDTA; pH 7.4).
3. Adjust pH to 7.4 if necessary by adding HCf.
Collagen solution (Horm Collagen)
Dilute collagen stock (IO0 ul) with 400 ul buffer (conc. 200 ug/ml).
Procedure:
I. Mix PRP (2 ml, 300,000 cells/ul) with 14C-5HT (final conc. 5 uM) and incur,ate
at 37°C.
2. At I, 3, 5, 10 and 30 min. after incubation, remove 150 ul of the reaction
mixture and put in microfuge tubes (hard tube); centrifuge at 12000 rpm for
2 min. in a microfuge.
3. Remove 50 ul (x2) of supernatant plasma and add 0.2 ml of protozol. Incubate
overnight. Add scintillation fluid and count.
.J
°.
_o
o
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Remove 50 ul of PRP in duplicates and mix with 0.2 ml of protozol to
determine total radioactivity.
To the remainder of PRP, add 10 ul of diluted collagen (final conc. 2 uglml),
mixed by vortex.
At I, 3, 5, I0 and 15 min after addition of collager_, I00 ul of the reactive
mixture will be removed and added to 400 ul of 1.2% paraformaldehyde
solution.
Centrifuge at 12000 rmp for 2 min. in a microfuge, remove 50 ul of
supernatant, mix with 0.2 ml of protozol overnight and 5 ml of Liquiscint
solution (National Diagnostics; Liquiscint will be acidified by mixing 10 ul
of glacial acetic acid with 1.5 ml of Liquiscint prior to use). The samples
will be counted for radioactivity in a liquid scintillation counter using an
established counting program.
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Sw_MFLEPF_ZPAP._WI'IC_ISFOR _ -TG _ TxB _ BY RIA
i ° Gently add 2.5 ml of platelet concentrates to the blood collection tubes
(which contain anticoagulent and antiplatelet agents) provided with the
radioimmunoassay kit. The tubes are pre-marked at 2.5 ml.
2. Stopper the tubes and mix the content by gentle inversion two or three times.
. Cool the sample by placing the blood collecting tubes in cooling bath for 15
min.
4. Centrifuge the sample at 1500-2000 g at 2-4°C for 30 min.
, Remove the top 0.5 ml of plasma using a pipette with a disposable plastic
tip.
6. Transfer the sample to a separate labeled specimen tube.
7. Store the sample at -20°C and transport the sample back to Boston for assay.
Storage conditions: 24 hrs at room temperature
7 days at 2-4°C
4 weeks at -200C
8. See attached package inserts.
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INITIAL BLOODSTORAGEEXPERIMENT- PLATELETS PF3-1
PF--3 l__=__qurements
Equipment:
Microfuge
Congulatron assay water bath
Stop watches
Materials:
PIatelet concentrates
glass clotting tubes
Russell's vipor venom
Microfuge tube (hard tubes)
Wire loop
Ice buckets
Cell counter
Distilled water
CaC]2, TES, NaCl
Pipette
Ice
PPP prepared from platelet concentrates
Solutions:
I. Russe11's vipor venom, working stock 10 ug/mI iF, TES-saline.
_. CaCl_. 0.05 M CaClz in H20
Platelet and plasma preparations:
i. Centrifuge 2 ml of platelet concentrate at 12,000 rmp at room temperature for
2 min to obtain PPP.
2. Save 0.5 ml of PPP for PF-3 measurement.
3. Dilute platelet concentrate with PPP to obtain PRP at cell cour,t of
300,000/ui.
4. During preparation of PPP and PRP, the tubes will be capped.
Procedures:
1. Prewarm CaC12 solution at 37° C.
Store PRP and PPP at room temperature.
Keep RVV on ice.
2. Add 0.1 ml of PRP or PPP into a glass clotting tube.
Add 0.1 ml of CaCI_, incubate at 37° C for I min.
Add 0.1 ml of RVV. Start the stop watch.
Mix the reactior_ mixture constant]y with a wire loop until a film clot forms
over the loop; stop the watch; record the time.
.
4.
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Assay of Platelet Response to Hypotonic Stress (PRHS)
A° Working Space:
65" x 25" bench space
2 plugs of the power with 115 V AC, 60 Hz
B° Equipment and Accessories
I. Spectrophotometer (Beckman DU, Model #2400)
2. Strip Chart Recorder (Omni-Scribe, Model #B-S000)
3. Chart Paper (Cat. #13-939-35, Fisher Sci. Co.); one roll
4. Cuvettes, semi-micro uv cell, I ml capacity; one set of four
5. Pipettes; two I ml and one 0.2 ml capacity
6. Pipette tips; blue and yellow
7. Other facilities for platelet countings (Coulter count, sample diluting
vials and Isotonic diluent, etc.)
C. Reagents: NONE
D°
I .
Assay Procedures:
°
Preparation of samples:
Platelet concentrate of 2 ml aliquot sampled from each storage unit wi11 be
adjusted to platelet count 400,000 per ul by diluting with pooled donor
plasma. The pooled plasma of 50 ml will be needed, 5 ml for the to sample
and 45 ml for the stored samples.
Assay:
P1atelet sample of 0.5 ml will be admixed rapidly _ith an equal volume of
disti1_ed water in the cuvette and the change of optical density of the
platelets will be recorded in a spectrophotometer at the light wave length
of 420 nM. A sudden drop in optical density occurs by exposing the plate-
lets to a hypotonic condition which is followed by a gradual return to the
orginal density. The latter phase, an increase in optical density units
during the first 2 minutes, wi11 be the value of the PRHS test.
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Introduction of 12sI into Tyrosines on Platelet Membrane Proteins and
Glycoproteins by Lactoperoxidase Catalyzed Radioiodination
Literature: Modified from Phillips, D.R., Biochem. 11:a582-4588, 1972;
Phillips, D.R. & Agin, P.P., J. Biol. Chem. 252:2121-20, 1977;
Holihan, J.R. & White, G.C., Blood 57:174-181, 1981.
REAGENTS:
I. H20_ -Fisher Cat. #H-325; 30% stock (8.8 M) diluted 1:1000 into cold (4°C)
PBS immediately before use. Stock is kept refrigerated and discarded
approximately I month after opening.
2. Lactoperoxidase - Cal. Biochem Cat. #427488; dissolve in PBS pH 7.a at 200
ug or .2 U/ml store frozen at -20°C in 600 ul aliquots. Molecular weight
80,000.
3. Na_Sl - Amersham Cat. #1MS-J0; purchased in I mCi quantities - takes i-2
days for delivery after order; store at room temp. in radioactive area.
4. 10 mM KI - prepared as a stock, kept frozen in aliquots.
5. Solution of TES/Tyrode's with 5 mM EDTA + glucose and 200 uM KI.
6. Solution of TES/Tyrode's with 5 mM EDTA + glucose and 100 uM KI.
7. Solution of TES/Tyrode's with 5 mM EDTA, no glucose, no KI.
8. Solution of I% Nonidet P40 in TES/Tyrode's with 5 mM EDTA (no glucose), 5 mM
lodoacetamide, .2 mM PMSF.
EQUIPMENT:
Hood equipped for radioiodination
Intermediate Speed Centrifuge
Facilities for disposal of iZSl waste
Vortex
pH Meter
Cell Counter
PROCEDURE FOR 5 ml LABELING-REACTIUN MIXTURE:
I .
.
3.
4.
5.
Count washed platelets and adjust concentration to 0.5 x 10_/ml (range 3-7 x
I08/mi) in 5 ml.
Bring solution to 10 uM KI (5 ul of I0 mM/5 ml).
2.5 ul of Nal _ (or 250 uCi).
Add 1.25 nMoles LPO (500 ul of frozen stock).
H20_ diluted in ice-cold PBS just before use.
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.
.
8.
9.
I0.
Ii.
12.
13.
Add H20_ at 30 sec. intervals in 5,6 ul aliquots. Platelet suspension is
stirred constantly on a magnetic stirrer with Fisher microbar (Cat. No.
14511-69) magnet.
Dilute to 35 ml with TES/Tyrodes, 5 mM EDTA, + 20D uM KI.
Pellet in IEC centrifuge at 2,000 rpm for 10 min at room temp.
Resuspend pellet in 15 ml TES/Tyrodes with S mM EDTA + 100 uM KI.
Pellet in IEC at 2,000 rpm for 10 min at room temp.
Resuspend in TES/Tyrodes/EDTA (no glucose) at a final concentration of 1.0 x
10_/ml (cells must be counted).
Extract platelets for 5 min at room temp. with O.SZ NP40 by adding an equal
volume of TES/Tyrodes + 5 mM EGTA containing S mM iodoacetamide and IZ NP40.
Freeze at -20°C for electrophoretic analysis.
Analysis of _Z_l-labeled Membrane Proteins (Boston)
A. One dimensional SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) wi11 allow
detection of gross changes (i.e., cleavage, loss from membrane) in major
platelet surface glycoproteins, particularly gpIlb and gpIIIa. Samples will
be analyzed under both reducing and non-reducing conditions to detect
changes in S-S bonding and SH-groups (and effect of microgravity) of
membrane proteins that occur during storage. SDS-PAGE will be carried out
using the discontinuous Laemmli System (Laemmli, Nature 227:680-85, 1970).
° Solubilize extracts (prepared in #12 above containing I mg platelet
protein/ml) with 1/10 volume 10X SDS, boil for 2 min at I00°C, mix
with Laemmli Sample Buffer containing 1.8% SDS, 12S M TFiS-HCI pH 6.8,
20I glycerol, bromophenol blue, and for analysis of proteins under
reducing conditions, 5_ beta-mercaptoethanol.
. Apply aliquots of solubilized samples containing 50-120 ug of protein
to precast SDS-slab gels consisting of a 4X stacking gel and 7.5:
resolving gel.
Electrophorese at 24 mAmps/slab until bromophenol blue tracking dye
reaches the leading edge of the gel. Run off for 4S min additional
minutes at 24 mAmps to improve resolution of components in the 100-
200,000 molecular weight range.
*4. Stain gels in 0.025% Coomassie Brilliant Blue for 2 hrs.
S. Destain in 2-3 changes of 30% methar,ol/lO= acetic acid overnight.
. Photograph wet gel using ar, orange filter to record profile of total
platelet polypeptides.
.8.
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Dry down gel on vaccum slab gel dryer.
Detect radiolabeled proteins by autoradiography using X-OMAT (Kodak)
film and intensifying screens. 3-5 days exposure at -80°C will give
bands of sufficient intensity.
Quantitation of radiolabeled proteins will be performed by
densitometric scanning of autoradiograms using a Hoeffer gel scanner.
*Duplicate gels will be stained by the Alcian Blue method which selectively stains
glycoproteins (Wardi and Mechow, Anal. Biochem 49:m07-09, 1972).
I .
2.
.
4.
S.
6.
7.
8.
9.
Fix gels in 12.5% Trichloroacetic acid for 30 min.
Rinse gels 5X with distilled water then oxidize glycoproteins with I:
periodic acid.
Rinse 2X, with changes 30 min each distilled water.
Soak gels in 0.5% potassium metabisulfite for 30 min.
Rinse gels in distilled water.
Stain overnight in I% Alcian Blue in 5% acetic acid.
Destain with 7% acetic acid.
Photograph wet gels.
Dry down and subject to autoradiography as described above.
B. Two-Dimensional ElectrophoFetic Analysis of _ZSl-labeled surface proteins
involving separation of pFoteins first on the basis of charge by Isoeiectric
Focusing then on the basis of molecular weight by SDS-PAGE. The method used is
that of O'Farrell (J. Biol. Chem 250:4007, I775) as modified by Linck et al. (Ceil
Motility 1:127, 1982). The analyses will permit detection of subtle changes in
charge distributLon of membt'ane proteins.
I ° NP-40 extracts of _SI-labeled platelets are prepared for isoelectFic
focusing by adding solid urea (ultrapure), Triton-X-lO0, dithiothreitol to
final concentrations of 9.5 M, 3.2% and 100 mM respectively.
,) Isoelectric focusing gels, cast in 200 ul glass capillary pipettes,
consisting of 3.5% polyacryJamide, 3.2% Triton-X-t00, 4% ampholines (pH
range 5-_), 0.4% ampholines (pH range 4-o), 0.6% ampholines (pH range 3.5-
I0), are prefocused at 200 V for 15 min, 300 V and 400 V each for 30 min.
Electrode solutions are 0.02 M NaOH at the cathode and 0.01M H=PO, at the
anode.
. Samples containing 30-bO ug total platelet proteins are applied to the basic
end of the isoelectric focusing gels and focused for I_ hrs at 400 V and 2
hFs at 1000 volts (8400 vo|t hours).
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°
.
.
.
The isoelectric points of relevant polypeptides are determined from
duplicate IEF gels electrophoFesed in parallel without protein. Ihe blank
gradient gel is cut into 5 mm length and eluted with 0.5 ml deionized water;
the pH of the eluted ampholines is measured with a pH meter. The pH values
of eluted ampholines are plotted with respect to gel length. The
isoelectric points are then correlated with the stained bands on another
duplicate gel after correction for expansion of the stained/destained gel.
For $DS-PAGE, the IEF gel containing fractionated proteins is equilibrated
for 20 min at room temperature in Laemmli sample buffer containing 5Z beta-
mercaptoethanol and placed across a precast slab gel consisting of a 4_
stacking gel and a 7.51 resolving gel.
Electrophoresis of the 2nd dimension SDS-PAGE is as described above for one
dimensional SDS-PAGE.
Gels are stained with Coomassie Blue, destained and labeled proteins
detected by autoradiography as described above.
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3H-Labeling of Sialic Acid Residues of Platelet Membrane GIycoproteins
It is necessary to examine possible storage-induced changes in platelet
surface membrane proteins (and the effects of microgravity on these changes) by
both the 12_I and 3H methods since different membrane proteins become radiolabeled
by these techniques. For example, platelet membrane gIycoprotein Ib, the vWF
receptor, which is lost from the platelet membrane during storage, labels well
with _H-NaBH4 technique, but does not incorporate significant _2sI or stain with
Coomassie Blue.
Literature:
Steiner et a1., Thrombo. Res. 29: 43, 1983.
Reagents:
Modified Tyrode's Buffer containing
5 mM EDTA buffered with Hepes at pH 6.8 and 7.6
[ _H] NaBH4 (5 mCi in 50 ul cold 0.01 M NaOH)
iodoacetamide - .5 M frozen stock
sodium metaperiodate - prepared fresh as 4 mM
Solution in Hepes/Tyrodes EDTA at pH 6.3
Equipment:
Intermediate Speed Centrifuge
Cell counter
Fume hood
Barrel for disposal of SH contaminated waste
EDTA: .25 M stock
HEPES: 1M stock
NP-40: I0: stock sol. (w/w)
NaoH: .1 N stock
Ice Machine
pH Meter
Vortex
Procedure:
Wash platelets twice by differential centrifugation in a modified Tyrodes'
buffer containing 5 mM EDTA and buffered at pH 6.8 with I0 mM HEPES.
Resuspend washed platelets in i-2 ml of the same buffer.
. Adjust platelet count to 0.5 x I09/mi. Equilibrate at 4°C in the dark for
20 mins.
° Add freshly prepared 4 mM sodium metaperiodate to the cooled platelet
suspension to a final concentration of 2 mM and allow the reaction mixture
to stand in the dark for lO mins:
. Dilute platelet suspension to 15 ml with HEPES/Tyrode's/EDTA at pH 6.8 and
pellet.
o Wash platelets twice with HEPES/Tyrode's/EDTA at pH 7.6 and resuspend it, I-3
ml of the same buffer; adjust platelet count to 0.5 x lO_/ml.
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. Add [_H] NaBH4 (final concentration SO0 uCi/O.5 x I0_ platelets) to the
washed platelet suspension and incubate with periodic agitation, for 30 mins
at room temperature.
. Wash radio-labeled platelets twice with HEPES/Tyrode's/EDTA pH 6.8 and
resuspend in the same buffer.
. Extract platelets with 0.5% NP-40 in the presence of 5 mM iodacetamide for S
mins at room temperature.
i0. Store extracts of radio-labeled platelets frozen at -20°C.
Analysis of 3H-labeled platelet membrane proteins will be performed in Boston
using:
i) SDS-PAGE and
2) Two dimensional isoelectric focusing and SDS-PAGE, essentia11y as
described in the previous section for IzSI-labeled membrane proteins. In
the case of the _H-labeled samples, radiolabeled giycoproteins will be
detected by fluorography using diphenyloxazole as described by Bonner and
Laskey (Eur. J. Biochem. 46:83, 1974}.
C'vt_kelet_ Studies
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These experiments will analyze both qualitative and quantitative changes in the
composition and assembly state of platelet cytoskeletal components.
Approach:
That percentage of the total platelet I) actin and 2) tubulin present in the cyto-
skeletal fraction of platelet lysates after extraction with Triton-X-t00 will be
quantitated. The cytoskeletal fraction which is detergent insoluble will be
harvested by selective centrifugation. Actin filament content will be determined
by quantitative densitometry of Coomassie blue stained SDS-gels of electrophore-
ticalIy fractionated cytoskeletons. Microtubule content will be determined as
_sedimentable tubulin" also by densitometry of Coomassie blue stained SDS-gels of
electrophoretically fractionated cytoskeletons but from platelets that were pre-
treated with Taxol to stabilize assembled microtubules prior to extraction with
Triton-X-100.
Literature:
Fox et al., J. Cell Biol. 98: 1985, I_84.
Kenney and Linck, submitted for publication, IgS5.
Equipment:
Low speed centrifuge
Ultracentrifuge and/or Air fuge (Beckman Instruments)
Cell counter
37oC waterbath
60°C waterbath
boiling waterbath
Platelet Preparation for Assays Described Below:
I. Wash platelets twice in TES/Tyrode's buffer, pH 7.4 containing i0 ng/ml
prostaglandir, E2, and 5.5 mM glucose maintained at 22-35°C.
Resuspend platelets at a final concentration of 0.5 x IO_/ml in TES/Tyro,Je's
pH 7.2 with 5.5 mM glucose.
Equilibrate for I-1.5 hours at 37°C.
.
.
Assembled Microtubules:
I ,
.
3.
4.
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Reagents:
Ml'_bz_-i_elei_ E.xtr_iztionBuffer: TES/Tyrode's pH 6.8; 12 mM EGTA;
Leupeptin 10 ug/ml; I% Triton-X-t00 at 22°C.
T_ol: 20 mg/ml in dimethylsulfoxide stored at -20°C.
23_ SL_rc_se: in TES/Tyrode's pH 6.B with 6 mM EGTA.
_iLd_ilizatic_ BuffE: I% SDS in 0.125 H TFis-HCI pH 6.8; 6 mM EGTA;
I0 m MDTT; 0.5% Na azide.
Procedure:
I .
.
.
Treat 10 ml aliquot of washed, 37oC equilibrated platelets with Taxol
(4 ug/10 a platelets) for 2 mins at 22 + 2°C.
Extract platelets by mixing with 10 ml MT-cytoskeleton Extraction Buffet for
5 mins at 22 + 2°C.
Layer 20 ml extract on top of 271 Sucrose.
4. Pellet assembled microtubules at 100,000 x g for" 30 min at 25°C.
5. Discard supernatant and sucrose layer.
. Solubilize pellet (prepared from S.O x I0_ platelets) in 400 ul
Solubilization Buffer, heat at 60°C for 30 min and then boil for 2 min.
Store samples frozen at -20°C for analysis in Boston.
. To determine total platelet tubulin (microtubule protein), extract a parallel
10 ml aliquot of each platelet suspension, with 10 ml extraction buffer'.
Add Taxol to a final concentration of 50 ug/ml of extract (assuming that
each ml contains protein from .25 x 109 platelets), and incubate for 30 mins
at 37°C; Pellet and solubilize microtubules as described above in #4 and _o.
Actin Filament:
I.
.
3.
RL_gent3:
A-Cytoskeleton Extraction Buffer: 2_ Triton-X-lO0; I0 mMM EGTA; .I M Tris-
HCf, pH 7.4 at 22°C.
Solubilizatior, Buffer: (see Microtubules).
4X Solubilization Buffer: 0.4:3 M Tris-HCl, pH 6.:3; 9.67, SDS; 40 mM MDTT.
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Procedure:
I.
_°
Treat 5 m] washed, 37°C equilibrated platelets with 5 ml A-Cytoskeleton
Extraction Buffer at 22 + 2°C.
Pellet insoluble cytoskeletons at 150,000 x g at O°C for 45 sins.
. Wash sedimented material with I:I mixture of TES/TyFode's pH 7.4 and A-
Cytoskeleton Extraction Buffer.
. Solubilize actin cytoskeletons from 2 x 109 platelets in 200 ul
solubilization buffer, boil for 2 min, then freeze at -20°C for analysis in
Boston.
, Extract 1.5 ml aliquot of each platelet suspension directly with 500 ul 4X
Solublilization Buffer for determination of the total actin in platelet
extract. Boil the extract for 2 min, therl freeze at -20°C for analysis in
Boston.
Analysis of Cytoskeleton Poiypeptides
Analysis of cytoskeleton polypeptides will be carried out on poiypeptides
which are electrophoretically fractionated using the SDS system of Laemmli (Nature
227:_80, 1970) with 4Z stacking gel and 8Z resolving gels.
I ° Cytoskeleton pellets (and platelet extracts used for determination of total
platelet tubulin and actin) are solubilized with i: SDS, brought to a final
concentration of 0.0625 M Tris HCf, pH b.8, and the disulfide bonds reduced
with 5% beta-mercaptoethanol.
2. Electrophoresis is carried out at 24 mAmps per gel for 4-5 hrs.
. Gels are stained with 0.025% Coomassie Brilliant Blue and destained with 30%
methanol/lO% acetic acid and photographed.
4. Molecular weights of cytoskeletal polypeptides are determined based on
migration of the standard polypeptides: spectrin heterodimer 240,000 and
220,000; beta galactosidase, 130,000; phosphorylase a, 94,000; Bovine serum
albumin, 684000; glutamate dehydrogenase,'56,000; creatine kinase, 40,000
and carbonic anhydi'ase, 29,000.
. Major polypeptides of the platelet cytoskeleton to be examined for
qualitative and quantitative changes are: Actin binding protein, 260,000;
Myosin, 200,000; alpha actinin, 90,000; Tubulin alpha, 58,000; Tubulin beta,
53,000 and actin, 43,000.
. Amounts of individual polypeptides in cytoskeletons and supernatant
fractions will be quantitated by densitometry of Coomassie Blue Stained gels
using a Helena Quick Scan Densitometer with a 570 nm filter. Mean values
will be determined from three scans of each sample.
. Percent of the total cytoskeletal protein which is assembled in organized
cytoskeletal structures will be determined by quantitating that particular
polypeptide in the insoluble cytoskeJetal fraction relative to the total
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quantity of that platelet protein. It is anticipated that during storage l)
the content of cytoskeleton associated microtubule protein will decrease and
2) the content of cytoskeleton associated actin will increase.
viscosity
Viscosity determinations will be made on a modified cone plate Wells-
Brookfield microviscometer. The modifications facilitate measuring shear stress
at low shear rates. The cone and plate contain radial etchings 60 microns deep to
reduce the plasma layer effect at the containing surfaces. All determinations are
made at 37°C. Viscosity will be measured at shear rates from 45-2.2 sec -I. Each
determination requires 0.5 cc sample and is done in duplicate. The instrument is
standardized with samples of known viscosity obtained from Wells-Brookfield.
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THE COLORIMETRIC DETERMINATION OF GLUCOSE
REF: Sigma Technical Bulletin No. 635
REAGENTS:
A° O. Toluidine Reagent, Stock No. 635-6
Store in dark at room temperature.
Caution: Do not pipet by mouth. Avoid contact with skin.
Do not inhale fumes.
B. Trichloroacetic Acid Solution, 3% (W/V), Stock No. 635-3
Store in refrigerator at 0-5°C.
C. Glucose Standard Solution, Stock No. 635-100
Standardized at 1.0 mg/ml (100 mg/100 ml or 5.5 m mol/1) with
Benzoic Acid added as preservative
Store in refrigerator at 0-5°C.
D. Hyland Q-Pak--Chemistry Corttrol Serum I
List No. 045-030
Store between 2° and 8°C before and after reconstitution.
DEPRO!EINIZATION OF PLATELET CONCENTRATE:
Into a centrifuge tube, pipet:
0.4 ml sample
3._ ml of 3% Trichloroacetic Acid, Stock No. 635-3
Mix well by shaking. Allow to stand approximately S minutes to precipitate
proteins.
Centrifuge (5-10 minutes) until clear supernatant is obtained in the RC-3 at
3000 rpm. Store clear supernatant at 0-5°C, if determination is to be
within a few hours. Otherwise freeze clear supernatant.
INSTRUMENT:
Practically any photoelectric colorimeter that transmits light in the range
of _20-650 rlm can be used.
Instrument: Coleman Jr.
Wavelength: 635 nm
Cuvette: 19 x 150 mm
NOTE: Instrument readings should be made in terms of Absorbarmce
(A) for use in calculations and for preparation of
calibration curves.
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ASSAY PROCEDURE:
I. Label test tubes or cuvets BLANK, STANDARD, CONTROL, TEST I, TEST 2, etc.
TO BLANK ADD:
0.1 ml water
0.9 ml 31 TCA Solution
Stock No. 635-3
TO STANDARD ADD:
0.I ml Glucose Standard
Solution
Stock No. 63S-I00
0.9 ml 3X TCA Solution
Stock No. 635-3
TO CONTROL & TESTS ADD:
1.0 ml supernatant
.
To each tube add:
CAUTION: DO NOT PIPET BY MOUTH
5.0 ml O-Toluidine Reagent, Stock No. 635-6
Mix by lateral shaking.
.
.
Place all tubes in a vigorously boiling water bath for exactly I0 minutes.
NOTE: If results are calculated from a stan,Jard that is assayed with the
Test, the boiling period can be 10 + I minute.
Quickly remove all tubes and cool to room temperature by placing in tap water
for approximately 3 minutes.
. Transfer contents of tubes to cuvets and read Absorbance of STANDARD and
Tests at 635 + 15 rim, using BLANK as reference. Complete readings within 30
minutes.
CALCULATIONS:
Use of Standard:
Glucose (mg/lO0 ml) : ^Test
^Standard _ looo,
_Represents the concentration of the Glucose Standard (mg/iO0 ml).
NOTE : If the reading of Test indicates a Glucose concentration
greater than 250 mg/lO0 ml, dilute the test with an equal
volume of O-Toluidine Reagent, Stock No. _35-_. Read
Absorbance of the diluted Test and multiply result by 2.
A. REAGENTS:
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DETERMINATION OF LACTIC ACID
REF: Sigma Technical Bulletin No. 826-UV
I. Lactic dehydrogenase (Sigma stock #826-6).
2. Glycine Buffer (Sigma stock #826-3).
3. NAD preweighed vial (Sigma stock #260-110).
4. Lactic acid standard solution (Sigma stock #826-10).
B ° EQUIPMENT:
I. Spectrophotometer
C. DEPROTEI_JIZATION OF PLATELET SAMPLE:
Trichloroacetic acid extract of sample prepared for glucose assay will be
used.
D. ASSAY PROCEDURE:
I. Pipet into each of the NAD vials
2 ml Giycine Buffet
4 ml water
0.1 ml LDH
The number of vials has to be determined based on each vial per 2
assays.
2. Combine the reaction mixture prepared above in a flask.
3. Label an appropriate number of tubes and pipet into each tube; 2.8 ml.
4. To blank add 0.2 ml of 3% TCA. To sample tube add 0.2 ml of Fespetive
extract, and mix gently.
5. Incubate at 37°C for 30 rain or at 25°C for 45 rain.
_. Read absorbance of sample tubes at 340 nm vs. blank as reference. At
this point the reading should be stable (less than 0.001 per min incremerJt).
If it is changing more than 0.002 per min, an additional incubation for 15
min should be done.
I0
A_4o x 7.23 x 3 : mmol L A/L
7. Calculation:
10
or A_4_, x 65.I x : L A mg/100 ml
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4.3 LEUKOCYTES
OUTLINE OF ISOLATION AND TESTING
4/17/8s
1:3 Bags of Sedimented Buffv Coat (150.0 ml each, 9 in space, 9 on ground)
6 each in PVC-DEHP, PVC-TOTM, and Polyolefine Plastic
;ount.
Fix.
1.5 ml
:.W.L.
;.J.L.
"lectron
11croscopy
).A.
PMN.
25.0 ml
F.W.L.
F.J.L.
r
_ize
)ist.
[.0 ml
;urby
&
Microfluor-
escence.
2.0 ml
J.K.
F.J.L.
LEUKOCYTE CONCENTRATES
Ficoll!Isopaque
Centriluga.
tion
Mononuclear--
Ceils
15.0 ml
JoK.
F.J.L.
Glucose
Oxidation
F._.L.
F.J.L.
Phago-
cytosis.
F.W.L.
F.J.L.
Fix.
Electron
Microscopy
0.1 ml
D.A.
Size
1.0 ml
Curby
/
Microfluorescer, ce
2.0 ml
J.K.
F.J.L.
B & T Lymphocytes
H.C.
J.C.
Abstract
LEUKOCYTES
Buffy coat white cells will be isolated from whole blood and sedimented with
Dextran. Leukocyte concentrates will be centrifuged, and the supernatants
containing Dextran and platelets discarded. Nine bags of leukocytes will be
reconstituted to IS0 ml with buffered plasma and sent into space. An additional
nine bags will be maintained on the ground for an equivalent storage period. All
bags will be coded and randomized post-flight.
Polymorphonuclear cells without further purification will be examined by
electron and fluorescence microscopy, and electronically for volume distribution.
Phagocytic and respiratory burst activity also will be assayed.
Hononuclear cells will be separated from leukocyte concentrates with Fico11-
Hypaque. They wi11 be examined without further purification by electron and
fluorescence microscopy, electronically for size distributions and by flow
cytometry for differential counts and cell stimulation responses.
A°
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POLYMORPHONUCLEAR CELLS
I. Preparation of Leukocyte Concentrates.
Using the standard procedures for obtaining platelets, 75.0 ml of buffy coats
will be harvested into a 300 ml transfer pack. Via a sterile connector 15.0 ml of
sterile 21 Dextran will be added from a stock previously filtered through 0.44 u
membrane filter. The bag contents are mixed briefly manually and the bag
suspended upside down. Sedimentation of red cells is allowed to proceed for 45
minutes at room temperature. The red cells are carefully drained via the original
sterile connector and discarded. The bag containing the leukocyte concentrate is
centrifuged in a RC-3 Sorval centrifuge in a blood bank head HG at 4°C and 300 x g
for 8-10 minutes. The supernatant fluid containing Dextran and platelets is
expressed and discarded. The white cell pellet is resuspended to 150 ml in the
bag with PB$ buffered plasma (1:1).
2. Microfluorescence of Cytoplasm and Nuclei of Granulocytes.
The reaction of gFanulocytes with fluoFescein diacetate (FDA) and ethidium
bromide (EB) in Hank's balanced salt solution (HBS$) without calcium and magnesium
is performed. About I x 106 granulocytes are mixed in proPortions of 0.05 to 0.25
ml with O.SO ml of a mixture of fluorescein diacetate and ethidium bromide. Wet
mounts are made at room temperature and the cells are viewed within one minute
with an Olympus Vanox transmission microsc:ope. A green exciter filter (G533) is
used for identification of the granulocytes and fluorescence is viewed after
s_itching to a UV exciter filter (Schott BG-12) and a blue barrier filter (Schott
OG-SJO). Esterase activity in the cytoplasm of granulocytes is measured as the
percent of cells showing green fluorescence of the fluorescein liberated from
fluorescein diacetate. The percentage of cells with red fluorescence nuclei due
to uptake of ethidium bromide is also recorded. Two hundred cells are counted.
IBSE Protocol
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The percentage of viable ceils is obtained from the fraction of green ceils to the
total of green plus Fed fluorescent cells.
3. Determination of Size Distributions
Cell suspensions containing I00,000 to 150,000 granulocytes per ml are sized
in a Coulter Model ZH with a 8-1000 Channelyzer and an X-Y recorder. Prior to
testing the granulocyte samples, the Coulter aperture is flushed with the buffere4
solution that is used to dilute the granulocytes. The sample volume is 0.1 ml.
All solutions are rendered particle-free by filtration through both the 0.45 and
the 0.20 micron filters in a Coulter filtration system or with 0.22 micron Falcon
filters. A 7084 aperture is used. This is set at an amplification of i, an
aperature current of 4, an exclusion of 4, a lower threshold of 5, and an upper
threshold of ')9. The settings for the Channelyzer are: count control on External,
count range I K, base channel threshold I, and window width 100. Calibration is
with 2.0 micron and 9.8 micron polystyrene particles. Granulocyte counts are made
by integration of the number of cells within the granulocyte distribution.
Granulocyte counts in whole blood and other samples are also made with a Coulter
Counter Model F blood cell counter after iysis of red blood cells with Zap-lsoton.
Red blood cell contamination of isolated granulocytes is counted as the difference
in counts between the nontreated and Zap-lsoton treated aliquots at a 500 fold
dilution.
4. Phagocytosis Assay.
a. Preparation of _2Sl labeled Staph aureus.
Staphy1occus aureus (IgGsorb) is reconstituted with 10 ml cold distilled H=O
yielding a 10% (v/v) cell suspension in phosphate buffered saline (PBS) (150 mM
NaCl, 40 mM phosphate pH 7.2 containing 0.05% azide). A 0.5 ml aliquot of the
stock suspension is washed three times with 3 ml of PBS pH 7.0 at 2200 rpm for i0
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minutes at 4°C and resuspended to 0.3 ml. Three hundred ul of washed IgGsorb is
then added to a I0 x 100 glass tube which contains 50 ug of Iodogen evaporated on
the vessel bottom and the original tube is washedwith 100 ul buffered saline (pH
7.0) and combined. Five hundred uCi of l_sI in 100 ul of buffered saline is ther,
added, gently rotated to initiate contact with the Iodogen pellet and allowed to
incubate with occasional rotation on ice bucket under constant rocking. Orlehalf
milliliter of 150 mHKI is added to stop the reaction. The labeled cell
suspension is washed four times with 3 ml volumes of buffered saline (pH 7.0) and
the cpm/ul of Staph aureas and the _Sl incorporated is determined.
b. Phagocytosis of lodinated Staphy1occus aureus by Human Neutrophils.
In each sample to be tested I00 ul of a 20-fold diluted 12sI-Staph aureus
susper!sion is added to 12 x 75 polypropy1ene tubes containing (in duplicate) 0.5
ml of fresh normal autologous, heterologous, or heat-inactivated serum. Controls
will contain buffered saline plus Mg++ and Ca++. The suspensions are incubated at
37°C for 30 minutes with constant shaking to keep cells suspended. The opsonized
particles are then washed 2X in ice cold buffered saline at 2200 rpm for 10 min at
4°C. After the final centrifugation, the cell pellets are resuspended to 0.4 ml
in KRP pH 7.4 plus 5 mH glucose. Neutrophils (5 x 106 ) are added to each tube and
the final volume adjusted to 0.5 ml. The suspensions are mixed continuously for
20 minutes at 37°C. Ice cold buffered saline is added to stop ingestion and the
ceils are washed to remove free uningested particles (150 x g for I0 minutes at
4°C). The cells are then counted in a gamma counter. The phagocytes indices are
determined as counts of radioactivity ingested per 106 ceils (cpm in normal sera -
cpm in PBS : cpm ingested by Staph aureus).
.91ycose.
Glucose Oxidation by Human Leukocytes.
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C140z from _4C-1 labeled
Human leukocytes from control and 5 day old test samples in a concentration
of I-1.5 x IOT cells/ml will be suspended in 3 mls of Kreb's Ringer Phosphate pH
7.4 containing 1 mM glucose and 0.5 uCi of [l-_4C]glucose (approx. 50 mCi/mM}.
Then I-2 ug of PMA or f-MLP (106 M), both soluble stimuli for neutrophils wilt be
added. The suspension will be incubated in a 25 ml side-arm erlenmeyer flask
stoppered by a cap fitted with a cup containing 0.2 ml of hyamine hydroxide.
After a 30 min incubation at 37°C in a shaking water bath, the mixture will be
acidified by injection of I ml of 5 N H=S04. The cell suspension will be
equilibrated for an additional 30 min and then the cup removed and the contents
assayed for radioactivity by liquid scintillation counting using a Beta Counter.
The amount of 14C02 released from [1-_4C]glucose will be expressed as the
percent of (control) unstimulated leukocytes. Fresh preparations of purified
human neutrophils and leukocyte rich plasma will also be included as contro]s for
each test grOUp.
6. Electron Microscopy - Diana Ausprunk.
Granulocytes and mononuclear cells will be studied by transmission an,J
scanning electron microscopy following fixation in 2.5I glutaraldehyde buffered to
pH 7.4 with sodium cacodylate. The samples will be transported to Boston at a°C
following post fixation in IZ osmium tetroxide in sodium cacodylate buffer.
a , Scanning: An aliquot of fixed leukocytes will be passed through a
nucleopore filter. The filters with attached cells will be dehydrated in
ethanol. Following deposition of gold-palladium the cells will be examined
and photographed in a JSM-35 scanning microscope. This will provide a
three-dimensional view of the shape and surface structure of the cells.
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b°
C°
Transmission: An aliquot of fixed ceils will be dehydrated in increasing
i
concentration of ethanol. The dehydrated cells are infiltrated with plastic
resin, cut on an ultra microtome, placed on grids and stained. The stained
sections are studied and photographed in a JEff 100 B electron microscope.
This will provide a high resolution view of the structure of the cell cyto-
plasm.
Whole Mount Preparation: A suspension of cells is spread on a Formvar-
coated electron microscope grid and processed by critical point drying.
entire complement of organelles and cytoskeleton within each cell can be
observed simultaneously. Any defects in cell spreading or cytoplasmic
organization can be readily detected.
Th e
7. Cell shape analysis of granulocytes and mononuclear cells - W.M. Curby.
a.
b °
Electronic Analysis: The shape of stored white ceils will be analyzed
using the Curby Biodetector (CBD). The ability of each cell type to
maintain size and shape against known osmotic gradients over fixed
time intervals will be monitored.
Photomicrographs of wet slide preparations wiT1 be made of cells from
each formed element population before and after the application of
gradients.
Stop action photomicrographs of each cell population will be done using
Xenon strobe, point source light illumination. The cells will be
photographed in hanging drop slide preparations to obviate distortion
associated with the adherence of a blood cell to a glass microscope
slide.
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B. MONONUCLEAR CELLS*
i. Isolation of Mononuclear Cells
Ten ml of leukocyte concentrate are overlaid onto 3 ml of Lymphoprep in a
15 ml conical tube and centrifuged at 1500 rpm (400 x g) for 30 min at 20oC. The
top 5 ml is removed and discarded. The mononuclear ceils are removed from the
interface between Lymphoprep and saline and placed ir, a 15 ml test tube. The
remaining fluid above the pellet is discarded. All cells are kept on ice (2°C).
2. Tests on Mononuclear Cells
Monocytes and Iymphocytes in Lymphoprep isolates will be tested for size and
membrane integrity by microfluorescence as described in A (Polymorphonuclear
Cells). Lymphocyte differential counts will be made with an EPICS cell sorter
using monoclonal antibodies to specific cell types. Helper-suppressor T cell
ratios wi11 be determined as well as the T ce!1 stimulation response.
*Note: Protocols for mononuclear cell studies from collaborators, Carter, Taylor
and Yur,is are in discussion.
_Protocols for mononuclear cell testing are being developed collaboratively with
Drs. Carter and Taylor.
Leukocyte-_O
WHITE CELL EXPERIMENT
MATERIALS AND EQUIPMENT
Processing Buffy Coat to isolate PMS and MNES
Quantity per unit processed
MATERIALS:
2 Sampling site coupler (Fenwal 4C2405)
50 ml syringes (BD 5663)
I box 18 g needles 1.5" x 18 g (lO0/box) (BD 5196)
2 Styrofoam rack for 15 ml and 50 ml T.T.
DEXTRAN Hi M.W. Sigma D-52SI 200,000-300,000 M.W.
MaC1
10 ml pipettes 25/unit
2 pipette bulbs
15 and 50 ml polyproplene test tubes/conival tubes
Lymphoprep 1.077 gr/ml I case (100 ml bottles)
PBS pH 7.4 + glucose 3 liter's
glass microscope slides 75mm x 25 I box
glass microscope slips 22mm x 22m 1.5 thickness 1 box
Fluorescein Diacetate po_der
Ethidium Bromide powder
Pooled Plasma 3.0 liters
12 x 75 mm test tubes polyproplene with caps 2 cases
Coulter accuvettes For cell counting&ZAP-oglobin II (Azide free) 2 boxes
Coulter chart paper" for" C-I000 xy plotter
Glass Pasteur pipette 5.75" disposable glass
Plasma expressor and 3 hemostats & I paiF scissors
Isoton, Coulter, I cube
EQUIPMEf_T
Sorvall RC 3B refrigerated centrifuge with head (_ place)
IEC CRU 5000 centrifuge with head #253
Refrigerator for blood storage 4-6°C range & reagents
Fluorescence microscope w/Schott 0G-530 barrier and Schott BG-12 filters
Water bath, shaking, 37°C
Coulter ZH counter, CI000 channeIyzer and X-Y plotter
vortex mixer
Magnetic stirrer and magnetic stir bars
Balance - triplebeam
Vacuum and vacuum trap set up with small air pump
Double beam spectrophotmeter, Cuvettes
J isotope counter (gamma)
Leukocyte-_1
SPACE, PLUMBING AND ELECTRICAL REQUIREMENTS FOR
WHITE CELLS' STORAGE EXPERIMENT
Fabian Lionetti
F. Wm. Luscinskas
James Cohn
For" Microscopy:
Water bath, 37°C, 20" x 15" x 6" approximately
Olympic Vanox fluorescence microscope
Illuminator
Bench space 2' x 6' x 2.5' = 14 sq'
2 Electrical outlets II0 V
I sink, stainless, 20" x 10" x I0"
For Cell Counting and Volume Studies:
Coulter Model ZH
Coulter Channelyzer
Coulter X-Y Recorder
Dade Diluter
Vortex Mixer
Coulter Filtration System
Bench Space 2' x 10' x 3' = 20 sq'
6 Electrical outlets IIOV
Coulter S+4 Diff. Counter 10 sq'
Leukocy t e-_-_2
LEUKOCYTES
SUMMARY OF BENCH SPACE, PLUMBING AND ELECTRICAL REOUIREMENTS
Bench Space: 70 sq'
40 sq' Work
30 sq' For Equipment
Desks: (2) 2' x 5' : 20 sq'
Sinks: (2) 2' x 2' x 1.5'
Outlets: (16) 110 V
Special power requirements for Coulter S+4 Diff. Counter:
An independent, protected circuit three wire outlet, 105-125 Vac.
single phase input power, 20 A. 1500 W power consumPtion.
14.4
Part I.
A.
Electron Microscopy Protocol
To be completed at on-site facility
Fixation of RBC
i) 10 41 whole blood
2) ghosts
B. Fixation of P1atelets
I) 5 ml platelet concentrate
2) ADP-stJmulated pJatelets
3) serotonin-stimulated platelets
C. Fixation of Leukocytes
D. Preparation of Platelet Whole Mounts
E. Preparation of Leukocyte Nhole Mounts
Part II.
A.
B °
C.
D.
To be completed at Children's Hospital, Boston
Transmission Electron Hicroscopy of RBC, Platelets and Leukocytes
i) postfixation, dehydration, embedding
2) sectioning and microscopy
Scanning Electron Microscopy of RBC, Platelets and Leukocytes
Freeze-fracture of RBC
TEM & SEM of Nhole Mounts of Platelets and Leukocytes
IBSE Protocol
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EQUIPMENTANDSUPPLIESFORELECTRONMICROSCOPY
Equipment:
Tabletop centrifuge
Top loading balance
Refrigerator
C02 incubator
Phase contract microscope
Tank of 51 C02: 95% air mixture
Supplies:
Pipettes (I, 5 & I0 ml)
Pasteur pipettes (6", plastic)
Conical test tubes (plastic w/caps) I00 ml + 50 ml
Parafilm (ro11)
Scissors
Timer (i hr)
Racks for test tubes
Gold grids (formvar coated)
Petri dishes (35 mm, sterile, tissue culture plastic)
Forceps
Hemacytometer
Pocket calculator
Graduated cylinders (SO ÷ I00 ml)
Reagent bottles
Reagents:
Distilled H20
G1utera]dehyde (10%, nitrogen sealed vials)
Sodium cacody1ate
tact2
Sucrose
Dulbecco's PBS
Eagle's medium
30 mOsm buffer
IBSE Protocol
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DETAILEDEMPROTOCOL
Part I. To be completed at on-site facility
k. Fixation of RBC (9 samples of 5 ml each)
100 ml of I% gluteraldehyde in Eagle's medium (pH 7.0) will be added
to each S ml sample of RBC. After 30 min at room temperature, RBCs are
centrifuged at room temperature and I00 rpm for 10 min. After removing the
supernatant, the cells are washed in Eagle's medium, recentrifuged and
resuspended in I00 ml of Eagle's medium containing 6I sucrose. The cells are
stored at 4°C and transported to CHMC. Red cell ghosts (obtained from Dr.
Jacobson) will be similarly prepared except that 30 m Osm buffer replaces
Eagle's medium.
B. Fixation of P1atelets (9 samples of 2 ml each)
40 ml of 2.5I gluteraldehyde in 0.1 M sodium cacodylate buffer (pH
7.4) will be added to each 2 ml sample of platelets. After 30 min at rOOm
temperature, platelets are centrifuged at room temperature and 5000 g for 7
min. After removing the supernatant, the platelets are washed in 0.i M sodium
cacodylate buffer, recentrifuged and resuspended in 40 ml of cacodylate buffer
containing 6% sucrose. The cells are stored at 4°C and transported to CHMC.
Platelets stimJlated by ADP and serotonin will be similarly prepared.
C. Fixation of Leukocytes (9 samples 3 ml each)
60 ml of 2.5Z gluteraldehyde in 0.1M sodium cacody1ate buffer (pH
7.4) will be added to each 3 ml of leukocytes. After 30 min at room temper-
ature, cells are centrifuged at room temperature, 100 rpm for 10 min. After
removing the supernatant, the cells are washed in cacodylate buffer, recentri-
fuged and resuspended in 60 ml of cacodylate buffer containing bZ sucrose.
The cells are stored at 4°C and transported to CHMC.
IBSE Protocol
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D. Preparation of Platelet Whole Mounts (9 samples of i ml each)
Gold electron microscopy grids will be prepared at CHMCin advance
of arriving at Cape Kennedyby cleaning them in dilute nitric acid, coating
the grids with a thin film of 0.7%. Formvar plastic and evaporating a thin
layer of carbon onto the Formvar film. P1atelets are washed free of plasma
proteins and resuspended at a concentration of 50,000/mi in 0.9% NaCi. One
drop of platelet suspension from each sample is placed onto each of four grids
laying on a piece of Parafilm contained in a 35 mmPetri culture dish. The
dishes are covered and placed in a himidified CO_incubator (51 C02: 95% air)
at 37aC for 10-20 min. Each grid is removed from the incubator, rinsed in
Dulbecco's phosphate buffered saline and placed in a vial containing ! ml of
2.51 gluteraldehyde in 0.I M sodium cacodylate buffer (pH 7.4). After
fixation for 30 min at room temperature, the grids are rinsed in cacodylate
buffer and then stored at 4°C in I ml of cacodylate buffer containing 6I
sucrose.
E. Preparation of Leukocyte Whole Mounts (9 samples of I ml each)
Gold electron microscopy grids are prepared as described for plate-
let whole mounts. Leukocytes are diluted to a concentration of 200,000
cells/ml in 0.9I saline. A drop of cell suspension is placed onto each of
four grids contained in a Petri dish as described for platelets. The covered
dishes are placed in the 37°C incubator for 2 hr and then fixed and processed
using identical methods described for the platelet whole mounts.
Part II. To be completed at Children's Hospital, Boston
A. Transmission Electron Microscopy of RBC, P1atelets and Leukocytes
(27 samples)
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One ml of each sample of fixed RBCs, RBC ghosts, platelets and
leukocytes will be centrifuged into a pellet and postfixed in buffered I _
osmium tetroxide (in Eagle's medium for RBC, 30 mOsm buffer for ghosts, 0.1M
sodium cacodylate buffer for platelets and leukocytes) for 60 min at 4°C.
After washing 3X in distilled water, cells aFe dehydrated in increasing
concentrations of ethanol (70%, 80%, 95%, 100%) for 5 min in each alcohol.
The dehydrated cells are placed in 2 changes of propyline oxide (20 min each)
and embedded in plastic resin (Poiybed). Sections I mm thick are stained in
methylene blue-azure II examined by light microscopy and photographed using
Kodak P1us-X film. Thin sections are cut with diamond knives on a Reichert
ultramicrotome, doubly stained with uranyl acetate and lead citrate and
examined and photographed in a JEM 100 B electFon microscope.
B. Scanning Electron MiCFOSCOpy of RBC, Ghosts, Platelets and
Leukocvtes (27 samples)
0.25 ml of each sample of fixed RBCs, ghosts, platelet and leuko-
cytes will be passed through a Nucleapore filteF (0.45 um poFe size) by
pressure filtration. Filters with attached cells are dehydrated in ethanol
and critical point dried from liquid C02. A thin layer gold-polledium is
deposited on the cells in a sputter coater. After attaching the filteFs to
specimen stubs, the cells will be examined and photographed in a JEOL JSM-35
scoFning electron microscope.
C. Transmission and Scanning Electron Microscopy of Whole Mounts of
Platelets and Leukocytes
Whole mounts of fixed platelets and leukocytes are postfixed for S
min at 4°C 0.S% osmium tetroxide buffered to pH 7.4 with 0.1M sodium caco-
dylate. The cells are dehydrated in ethanol and cFitical point dFied ft'om
liquid COz. A thin layer of carbon is evaporated over the cells. The pre-
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parations will be studied, by transmission electron microscopy and photo-
graphed in a JEM I00 B electron microscope. The microscope is equipped with a
goneiometer stage so that pairs of stereophotographs will be obtained by
tilting the stage ÷6°-7 ° from the horizontal. After transmission electron
microscopy, the same specimen will be coated with gold-palledium in a sputter
coater and examined in the scanning electron microscope.
D. Freeze Fracture of RBCs and Ghosts
One m] aliquots of fixed RBCs and ghosts are centrifuged into a
pellet, washed with Dulbecco's PBS and the pellet resuspended in 20% glycerol
in PBS for 15 min. GIycerinated cells will be fractured in a Bolzers
apparatus at -115°C and the fracXure face will be replicated by evaporating
platinum and carbon onto its surface. Replicas are cleaned by floating OVer
methanol and chlorine bleach to digest away the cells. The replicas are
transferred to copper grids and examined in the transmission electron
microscope.
Part I.
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Time Frame for Completion of Electror, Microscopy
Work to be completed on-site
I. Fixation of all ceils
2. Centrifugation and washing of cells
3. Resuspension of cells in storage buffer
4. Packing of specimens for transport to Boston
2 hours
3 hours
o hours
3 hours
TOTAL i0 hours
Part II. Work to be completed at Children's Hospital, Boston
Im_unoloq_-I
The Initial Blood Storage Experiment
NASA-IBSE
Protocols to be Performed at the Launching Site
lannmanolo_
Introduction
The following protocol describes the tests to be done by UMMC staff at
the Kennedy Space Center in the context of the NASA-IBSE (Initial Blood
Storage Experiment). The protocol is divided into two sections, I Materials
and II Methods. Section I will describe the essential laboratory space
required including the m_aior equipment. Some of the equipment already exists
at KSC laboratories and is available for our use. Other equipment is provided
by the manufacturer for the period of the experiment. The remainder is to be
either brought in by UMMC staff or ordered to be sent to KSC directly. These
items are indicated by ". In the Materials section there will be a ]ist of
the laboratory supplies and the reagents and buffers required for processing
the RBO and platelet specimens for the immunological assays. Special reagents
needed for individual tests will be given in the Methods section, under the
heading of each special test. The II section will describe the following
procedures to b-e conducted at KSC:
1.0 GIycerolization and Freezing of RBC
2.0 Processing Platelet Concentrate Samples
3.0 Quantitative Antiglobulin Consumption (QAC) for Platelet-kssociated
C3c and C3d
4.0 QAC for Piatelet-Associated IgG
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I. MATERIALS
LABORATORY SPACE AND HA30R EOUIPHENT:
A -80°C freezer must be available in the laboratory at the site.
A 4°C cold room with sufficient space and accessible electrical outlet
to accommodate a 0.5 amp, 110 V powered test tube agitator"
(12'xg'x24').
A sink with 2 faucets for the attachment of two aspirator pumps.
An RC-5 centrifuge (Sorval) with SS-34 rotor.
Bench space (approx. 15'x2.5') to accommodate the following:
2 IEC centr-7 centrifuges equipped with #210 rotors and
carriers for 13 mm, 16 mm, and 30 mm diameter test tubes.
"2 vortex mixers.
An electronic cell counter (capable of counting platelets) and
associated reagents and supplies.
Crushed ice supply.
Dry ice SUpply.
LABORATORY SUPPLIES:
"Adjustable Finnpipettes TM and tips.
"Test tu_e agitator.
'20 and 5 ml graduated syringes.
"4" and 250' roll of parafilm.
"250 ml beakers.
"2000 ml and 500 ml graduated cylinders.
"Plastic and glass transfer pipets.
"Insulated containers for sample transport.
"Electronic 3-channel timer.
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*Test Tubes.
"12 x 75 mm glass tubes.
*16 x IDo mm siliconized glass tubes (vacutainer red tops).
"30 x 100 mm plastic centrifuge tubes.
"2 ml and 13 _1 capped plastic freezing tubes.
*Assorted reagent containers.
*Tape, markers, etc. for labeling.
*Racks for test tubes.
"SO0 ml volumetric flasks.
REAGENTS, BUFFERS:
100 1 reagent HzO
"Dry chemicals, pre-weighed, for making the following:
0.9 g/dl NaCI with 10 mH phosphate, 0.I g/dl NAN,, pH 7.2 (PBS).
PBS containing 0.5 g/dl bovine serum albumin (PBSA).
PBSA containing 0.15 g/dl NazEDTA (PBSA-EDTA).
GIycerolyte TM 57 solution.
II.
1.0 PROCESSING WHOLE BLOOD SAMPLES FOR SHIPMENT TO UMMC
Reference: I.O. Szymanski, J.M. Harper, P.R. Odgren, C.R. Valeria.
Freezing red blood cells prepared for quality control of antiglobulin
sera. Transfusion 21:498-501, 1981.
1.1 Sample required: 30 ml whole blood
1.2 Procedure
1.2.1 The sample(s) is divided into two 50 ml centrifuge tubes
and washed 3 times with PBS and the RBC packed after final wash.
1.2.2 After the final wash add to the packed cells a volume of
glycerolyte equal to 0.4 times the volume of the packed cells. The
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glycerolyte is added slowly and with constant gentle mixing on
vortex mixer.
1.2.3 The RBC and glycerolyte are al]owed to equilibrate at room
temperature for lO min.
1.2.4 Slowly and with constant gentle mixing on vortex mixer, a
volume of glyceroIyte equal to 1.6 times the original volume of
the packed RBC is added.
1.2.5 The contents of both tubes are then pooled, mixed and
aIiquoted as follows:
Two aliquots of at least 1.5 mI each (for detection of IgG
and complement by direct agglutination tests)
Four aliquots of at least 6 ml each (for quantitation of C3
and IgG on RBC membrane)
1.2.6 10 min. after the final addition of glycerolyte, the
samples are frozen at -80°C.
1.2.7 Samples are stored in -80°C freezer until they are trans-
ported to UHMC, at which time they are packed in an insulated
container with dry ice, and shipped.
Man hours for the processing of whole blood sample: one person can handle 18
samples in approximately 6 hours.
2.0 PROCESSING PLATELET CONCENTRATE SAMPLES
2.1 Sample required: A 10 ml sample is obtained on the day of launch,
and 18 5 ml samples of platelet concentrate are obtained on the day of
return of the satellite. A larger sample is required initially since
platelet-bound complement is low in that sample.
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2.2 Platelets are pelleted by centrifugation at 2000 RCF for 7 minutes,
the supernatant plasma decanted, and they are then washed 6 times with
S ml PBSA-EDTA.
2.3 After the final wash, platelets are suspended with a volume of
PBSA-EDTA sufficient to yield a concentration of approximately 1 x I0_/
microliter in day 0 sample and approximately S x lOS/microliter in day S
samples. The exact platelet count in the washed platelet suspension is
determined using the cell counter.
3.0 QUANTITATIVE ANTIGLOBULIN COMSUMPTION TEST (QAS) FOR PLATELET-ASSOCIATED
C3c AND C3d
Reference: 1.0. Szymanski, R.E. Swanton, and P.R. Odgren.
of the third component of complement on stored red cells.
24:194-197, 1984.
3.1
Ouantitation
Transfusion
Additional reagents required:
3.1.1 Anti-C3 (C3c-specificf): Goat anti-human C3, IgG fraction,
obtained from Atlantic Antibodies (Scarborough, ME). For this
assay, it is diluted 1:100,000 in PBSA, and has been given lot
#C3(G).
3.1.2 Anti-C3d: Goat anti-human C3d, obtained from Netherlands
Red Cross (Amsterdam). Heteroagglutinins have been removed from
this serum by absorption with bromelin-treated RBC. For this
assay, it is diluted 1:5,000 in PBSA and has been given lot #17.
3.1.3 Zymosan Standards (ZyC3) consist of zymosan A particles
which have been coated with 03, washed, and diluted in PBSA. This
ZyC3 has been analyzed for C3 quantity as described before and
sets of aliquots have been prepared for both C3c and C3d assays.
Each set consists of ten 1.0 ml aliquots, each containing a dif-
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ferent concentration of ZyC3. For C3d standardization, the C3
content in aliquots range from 1.81 x 101° molecules/ml through
7.24 x I0 _ mol/ml. For C3c standardization, the C3 range is from
8.06 x 109 mol/ml through 1.6 x I011 mol/ml.
3.2 Procedure
3.2.1 Sample dilution:
3.2.1.1 Day 0 suspension is tested both undiluted and
diluted I/2 in PBSA-EDTA.
3.2.1.2 Day 5 suspensions are tested undiluted and diluted
I/2 and I/5 in PBSA-EDTA.
3.2.2 Sample pipetting: I ml of each platelet suspension and
required dilution(s) of ZyC3 is dispensed into a 2 ml tube in
triplicate. One set is pipetted for C3c, another one for C3d.
3.2.3 OZ neutralization controls: I ml PBSA is dispensed into 20
2 ml tubes.
3.2.4 Antibody pipetting: To each tube of the C3 set (i.e.,
including dilutions of various platelets, three sets of ZyC3 stan-
dards, and 10 PBSA controls) exactly I ml of anti-C3c will be
added; to each tube of the C3d set exactly I ml of anti-CSd will
be added.
3.2.5 The tubes are all tightly capped, placed on test tube agi-
tator, and allowed to incubate overnight (18-24 hrs.) at 4°C.
3.2.6 The incubated samples are centrifuged for 30 minutes at
12,000 RCF and the supernates transferred to appropriately labeled
2 ml freezing tubes.
3.2.7 The supernates are frozen at -80oc and stored until shipped
to UMMC in insulated containers with dry ice.
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4.0 QACT FOR PLATELET-ASSOCIATED IgG
Reference: N. Levitan, R. Tano, I. Szymanski. An autoanalyzer test for
the quantitation of pJateJet-associated IgG. Submitted for pubJication.
4.1 Additional reagents required:
"4.1.1 Anti-IgG (Fc specific), obtained from Atlantic Antibodies
(Scarborough, ME) was absorbed with bromelin-treated RBC to
remove heteroaggJutinins and given BBR Lot #2. For this assay it
is diluted 1:1,000,000 with PBSA.
"4.1.2 I_G Standards consist of Beckman ICS CaJJbrator I serum
(Beckman Instruments) which has been calibrated against a World
Health Organization IgG Standard. It is diluted with PBSA (in
two-fold fashion) to a minimum of 8 dilutions, each 1.0 ml in vol-
ume. The concentration of IgG in these 8 standards is to range
from 31.B ng/ml to 0.24 ng/ml. Four "O"X neutralization targets
are prepared also by dispensing 1.0 ml of PBSA into each of four
tubes.
"4.1.3 19G Control consists of Beckman ICS CaJibrator serum which
is diluted in PBSA (in two-fold fashion) to 4 dilutions, each 1.0
ml in volume. The concentration of IgG in these controls is to
range from 14.2 to 1.77 ng/ml.
4.1.4 PlateIet Dilution: P1atelet suspension (from 5.3 above) is
diluted to contain approximately 200,000 platelets/ml in PBSA-
EDTA.
4.2 Procedure
4.2.1 Anti-lgG neutralization by the IgG Standards: To each of
the 1.0 ml standards (from 7.1.2 above), add 1.0 ml of the
1:1,000,000 dilution of anti-lgG (from 7.1.1 above).
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4.2.2 Anti-lgG neutralization by P1atelets: Set up the consump-
tion of anti-IgG by testing four concentrations of the platelet
suspension (7.J.4 from above) as follows:
Dispense l.O ml of PBSA into each of four 12 x 75 mm tubes.
To one of each of the tubes add 10, 20, 30 and 40 ul of the
platelet suspension. Next add 1.0 ml of the diluted anti-
IgG reagent (4.1.1 from above) and mix thoroughly. (Since
these are set up in duplicate, the final number of tubes per
test is eight.) (It has been found that with such small vol-
umes of the platelet suspensions it is not necessary to take
into account the platelet volume when making these
dilutions.)
4.2.3 Anti-lgG neutralization by the IgG controls: To each of the
1.0 ml controls (from 4.1.3 above), add 1.0 ml of the diluted
anti-lgG reagent (4.1.1 from above).
4.2.4 After the above have been set up, all tubes are stoppered
and incubated at 4°0 for at least 18 hr with constant, gentle agi-
tation on the tube shaker (2.1). It is important that the un-
knowns be incubated simultaneously with the standards. After
incubation, the tubes are centrifuged at 2000 x g for 10 min and
the supernates transferred to the 2.0 ml plastic freezing tubes,
capped tightly, and placed in the -80°C freezer. These are even-
tually transported in the frozen state to UMMC where the assay
will be completed.
PRE'CEDtHG PA"3_ '_ _ _"r
'-:'-_:!';_, _OT FILMED
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TEST TO BE I:_ZRFOR'IEI) FOR_AT
THE_ITYOF_It_S_-/d6ETTSMEDIC_L_C_WTER
INTRODUCTION:
The purpose of these studies will be to measure red blood cell (RBC) arld
platelet associated immunoglobulin and complement on samples of human blood
which have been stored in a micro-gravity environment and on the Earth's sur-
face. This is done with the intent of establishing if deposition of these
plasma proteins increases (or decreases) upon the storage of human blood in
space. A sensitive, automated direct agglutination assay will be used to
determine relative amounts of immunoglobulin (Ig)G and the complement frag-
ments, C3a, C3c and C3d on intact RBC. Precise quantitation of IgG, C3c and
C3d on intact RBC and plateIets will be made with the quantitative antiglobu-
tin consumption test (QACT). In addition, the QACT for IgG will be performed
on isolated RBC stroma and Iysates. Both of these assays use the Autoanalyzer
(Technicon Corp., Tarrytown, NY) and are described in detail below.
1.0 The automated direct agglutination assay: This assay detects the pres-
ence of specific protein(s) on the surface of RBC and is based on the
phenomenon of agglutination of said RBC by specific antibody. The results,
expressed in percent agglutination, are proportional to the amount of protein
of the RBC. Therefore, it is possible to express relative concentrations of
cell-bound protein among different RBC populations. This assay will be per-
formed as described in detail elsewhere (I). Briefly, washed RBC, suspended
to a fOX hematocrit in Ficoll and 0.91 NaCl are introduced continuously into
an Autoanalyzer manifold together with 1.0X polyvinylpyrrolidone K-g0 (PVP) in
0.9% NaCl while appropriately diluted antibodies (to each of the four pro-
teins) are sampled discontinuously. RBC bearing the specific protein agluti-
hate in the presence of corresponding antibody. The agglutinated RBC are
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removed by gravity and the remaining unagglutinated RBC hemolyzed with Triton
X-IOO and water. The ODsso of the lysate Js recorded and the percent aggluti-
nation which reflects directly the amount of protein on the RBC membrane is
then calculated.
I.I Materials.
I.I.I Phosphate buffered saline (PBS):
to pH 7.2 w/O.Ol H sodium phosphate.
0.gZ NaCl, O.II NAN,, buffered
1.1.2
1.1.3
1.1.4
1.1.5
Manifold cleaning solution: 2.51 urea in 0.05I NaOH in H20.
0.5I Ficoll (Pharmacia) in PBS.
0.5% bovine serum albumin (BSA) in PBS.
1.0Z polyvinylpyrrolidone K-90 (PVP) in PBS containing 2 drops of
Tween-20 (Technicon) per 50 ml of solution.
I.I.6 Antisera to:
IgG (Fc specific) (Atlantic Antibodies, Scarborough, ME) (diluted
1:5000)
C3a (Cappel) (diluted 1:200)
C3c (Atlantic Antibodies) (diluted 1:2000)
C3d (Neatherlands Red Cross) (diluted 1:200)
1.1.7 Lysing solution: I.OZ Triton X-lO0 (Sigma Chemical Co.,
St. Louis, MO) in H=O with 0.1% NAN3.
1.1.8 The glassware, instruments and facilities for performing the as-
say are available at the UMMC Blood Bank Research Laboratories.
1.2 Samples: Samples of glycerolyzed RBC will be thawed and deglycerolyzed
(Appendix). The recovered RBC will be washed in PBS and suspended to a I0.0%
hematocrit in 0.5% Ficoll solution.
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1.3 Procedure:
1.3.1 An Autoanalyzer (Technicon, Tarrytown, NY) is outfitted with a
sampler, tubing, manifold, reservoirs, pump, and colorimeter as shown in
Figure I.
1.3.2 The reservoirs for PBS and Triton are filled.
1.3.3 The platen on the proportionating pump is engaged and the sam-
piing probes placed in the cleaning solution.
1.3.4 The pump, colorimeter and recorder are turned on.
1.3.5 After 20-30 min the probes are placed in PBS containing 2 drops
of Taeen-20 per liter of solution for 20-30 additional min.
The electronic scale is adjusted to read between Oo and 10011.3.6
T(T).
1.3.7 The antibody probe is placed in the BSA solution. The Analyzer
is allowed to run for 10-20 min. The appropriate sampling probes are
placed in the RBC suspension (which is agitated continuously with a mag-
netic stirrer and always maintained in an ice bath) and PVP solution.
The antibody probe is engaged to the sampler and sampling is begun. The
reaction products will reach the photo cell of the colorimeter in
approximately 25 min.
1.3.8 After the fluids have reached the colorimeter, the baseline is
adjusted with the "baseline" knob to 80-90%T.
1.3.9 After the baseline is established, sampling of the antibody solu-
tions follows.
1.3.10 The change in optica] density from the baseline for each sample
is determined from the chart paper and the % agglutination calculated
from the following formula:
IT of baseline-IT of the sample X 100 =
%T of the baseline I agglutination
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The percent agglutination is proportional to the number of molecules of
antigen on the surface of the RBC and provides a measure of the relative
quantities of membrane bound protein among different cell populations.
2.0 The quantitative antiglobulin consumption test (OACT): This assay
quantitates the molecules of a specific protein (IgG, 03c ro C3d) that accumu-
late on or within RBC and platelets. In this test varying amounts of test
sample or known standards are incubated with a known amount of specific anti-
body. Thereafter, the antibody remaining in the supernate is measured by
direct agglutination of indicator RBC coated with the specific protein. The
percent neutralization is calculated and dose response curves constructed.
The total number of molecules of protein per cell is then determined by using
the dose response curves, Avogadro's number and the known molecular weight of
the protein.
2.1 Materials:
2.1.1 All of the material described in section I.I.
2.1.2 RBC products to be tested:
2.1.2.1 Intact RBC: RBC samples received will be deglycerolyzed
(Appendix), washed three times with PB$, resuspended to about 50%
hematrocrit and the total cell count determined electronically
with a Coulter Counter (Coulter Electronics, Hialeah, FL).
2.1.2.2 Lysates for internal IgG determinations: For each 1.0 ml
of the 501 RBC suspension, 0.5 ml of a 0.51 solution of digitonin
in PBS is added while gently mixing on a Vortex mixter. 1.5 ml of
PBS is added and after 2 min the mixture is centrifuged at 2000 x
g for 7 min and about 1.0 ml of the supernatant hemolysate is
transferred to dialysis tubing (12,000 to 14,DOO molecular weight
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sieve) and dialysed against 250 volumes of PBS for I hr. (The
pellet is saved for the preparation of the stroma as outlined
below). The hemoglobin concentration of the Iysate is determined
on a Coulter Counter and kept at 4oC until tested for IgG.
2.1.2.3 RBC stroma: The pellet from step 2.1.2.1 is washed with
PBS five times or until there is no visible hemoglobin and resus-
pended in an equal volume of PB$. A 100 ul aliquot is mixed with
2.0 ml of 1.0% sodium dodecylsulfate in HzO for I0 min. The OD of
the solution at 260 and 280m nm is obtained and the total stromal
protein determined from the following formula:
(21(I.55(OD2go)-D.77(OD2=o) = mg protein/ml stromal suspension
((8.1 mg/ml = 10 _° RBCm stroma))
2.1.3 Indicator, IgG coated RBC: Approximately 250 ml of packed group
0 Rho positive RBC are combined with GO ml of anti-Rho (Ortho Diag-
nostics, Raritan, N3). After 30 min at 37°C the RBC are glyceroIyzed
(2), aliquoted and sotred at -80°C.
2.1.4 Indicator, C3-coated RBC: These indicator RBC are prepared as
previously described (3). These are also glycerolyzed and stored at
-80°C.
2.1.5 TgG soluble standard: Beckman ICS Calibrator serum (Beckman
Instruments, Irvine, CA) with known concentration of IgG is diluted with
PBS to a concentration of approximately 30 ng/ml. This stock solution
is aliquoted and stored at -80°C. Working standards (to range in con-
centration from 30 to 0.025 ng/ml are prepared by serially diluting the
stock solution.
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2.2 Procedure for the QACT:
2.2.1 The first step of this assy consists of combining different
amounts of the antigens (intact RBC, lysates, soluble IgG standards and
ZyC3) with a known amount of antiserum according to the following table:
Volumes of the antisera
Anti-lgG Anti-C3c Anti-C3d
Antigen 4 ml (I:2M) O.S ml (I:SOK) O.S ml (1:4.5K)
50% RBC 20* - -
40 - -
151 RBC 598 Sg8
7.SI RBC - 541 54!
Stroma 200 - -
100 - -
Lysate 20
40
IgG standards 20
ZyC3 standards - 5000 5OO
*Volume of antigen in ul.
These mixtures are incubated ovenight at 4°C with gentle agitation
whereafter they are centrifuged and the supernatants tested for remain-
ing antibody activity against the appropriate indicator RBC by the
direct agglutination test described in 1.0.
NOTE ON PLATELET QACT: The incubation of the platelets with the
antibodies will have been done on NASA site and the frozen super-
natants containing the remaining antibody will be tested at UMMC.
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2.2.2 Calculation of results: The percent agglutination is calculated
and a dose-response curve depicting the percent neutralization of anti-
body by known standard is constructed. Molecules per cell are deter-
mined by using the dose response curves, Avogadro's number and the
mo]ecular weight of the given antigen (IgG, C3c, or C3d).
Appendix:
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Deglycerolization of frozen RBC:
I*
2.
.
o
5.
6.
7.
.
9.
lO.
II.
Frozen RBC are thawed at 37°0.
12X NaCl is added* in a volume equal to 2SX of the glyceroIyzed sample
and allowed to equilibrate at room temperature for 5-10 min.
1.6X NaCI is added in a volume equal to the g]ycerolyzed sample and
allowed to equilibrate for at least 2 min.
The sample is centrifuged and the supernatant decanted.
1.6I NaCI is added as in step 3.
Step 4 is repeated.
PBS is added in a vo|ume equal to the original glyceroIyzed sample
volume and a11owed to equilibrate for at least 2 min.
Step 4 is repeated.
Step 7 is repeated.
Step 4 is repeated.
The RBC are resuspended in the desired diluent.
*A11 solutiorms are added slowly and with constant stirring with Vortex
stirrer.
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Figure I.
INITIAL BLOODSTORAGEEXPERIMENT
Biophysics Protocol
All data taking to be completed at on-site facility.
A. Total Cellular Count
i ° From each red blood cell sample, a lO-X ml aliquot will be added to
a lO.O ml of 0.9% w/v particle free saline and mixed by capping
and inversion ten times. From this stock solution, 1.0 ml will be
taken and added to ? ml of the 0.91 particle free saline solution.
This final concentration will be read directly on the Curby Bio-
detecter (CBD) using a short tunnel S x 10.2 an diameter aperture.
Cell counts and cell shape analysis will be made on 5 x lO-_ ml
volumes of the final concentration fluid.
° White blood cell counts will be made on a final solution concentra-
tion containing I0-z ml of each white blood cell sample in lO.O ml
of 0.9% particle free saline. Cell counts and cell shape analysis
will be made on S x lO-2 ml volumes of the Final concentration
fluid.
. Platelet counts concentration will be arrived at by first making a
stock solution containing i0-z ml of the piatelet preparation in
I0 ml of O.9Z particle free saline. 2 ml of the stock solution is
then added to 8 ml of the O.9Z saline to make the final counting
solution. All pipetting will be done using automatic microliter
adjustable pipets and certified pipet tips.
° For all cell counts, the CBD will be set to count one peak per
generated pulse. The size will be determined by placing the add
one count in the memory storage channel equal to the maximum pulse
height within the pulse. All pulse height measurements will be
made when a negative pressure equivalent of 7.0 inches of mercury
exists across the aperture tunnel of the 5 x 10-2 am aperture.
B . Cell Shape Analysis
i . Pulse shape analysis will be done using I inch of mercury pressure
differential across the aperture. Aliquots of each sample will be
drawn through the aperture, and in sequence, reading first the
peak height and then the pulse height generated by each cell at 4,
8, 16 and 32 microseconds after the initial rise Of the voltage
pulse. All samples will be normalized by allowing the cell fre-
quency distribution to be accumulated in the computer memory until
the highest peak in the storage channel vs. frequency distribution
reaches lO0 counts full scale.
2. Distributions will be plotted by the CBD plotter and filed for
analysis.
C° Red Blood Cell Action to Applied Unit Stress
I ° Pulse height data will be collected as in Section AI. Immediately
after the initial reading I ml of particle free, pyrogen free dis-
tilled water will be added to the sample and peak readings will be
repeated once every 2 minutes until a peak shift of more than 10
channels is observed between subsequent readings.
. The cell counts and size frequency data wi11 be recorded and printed
out by the CBD.
D_ Photomicrographs
I ° Photomicrographs of each sample will be taken.
light and Xenon source light will be used.
Tungsten source
. Two photomicrographs of each sample of red blood cells will be made
using a Nikon Model S-re Hicroscope, an anachromatic dark contrast
optical combination, viz., a IOOX DLL achromatic objective and a
matching I00 annular diaphragm in the focal plane of the conden-
ser. Dark-low-low phase _ontrast images will be recorded on 35 mm,
I000 ASA speed print film. The field coverage film frame indexing
will be done using a I0-z mm etched spacing stage micrometer. Red
blood cells will also be photographed using a IOOX plan apochromat
lens and direct lighting under similar tungsten light source con-
ditions.
. A slide for each sample wi11 be prepared by dropping exactly I0-2 ml
of samp!e onto a cleaned microscope slide and tipping a I cm x
I cm cover slip onto the sample so that the center of the cover
slip lands on the center of the drop. k drop of immersion oil
having a refractive index of 1.515 will be centered on top of the
cover slip. No oii wi11 be used to fi11 in below the microscope
slide and the microscope condenser.
4 . Samples of platelets and white blood cells will be applied to make
up 6icroscope slide preparations in the manner described in D3.
DLL phase contract pictures will be made from these samples.
. Red blood cell samples will also be prepared for hanging drop stop-
action photomicrographs by placing a I0-_ ml of a one in ten di-
luted drop of each sample on a I cm x i cm cover slip and care-
fully inverting the cover slip and placing it over the center of a
depression slide. The cover slip will be waxed in place.
. Stop action (IOOX objective) photomicrographs will be made using E.
Leitz Microscope Equipment and a Leica "Microibso" unit with a I/3
lens to reform the image on the camera film plane. The light
source will be a Xenon Strobe Unit which is centered along the op-
tical axis of the microscope IS centimeters below the objective
focal plane of the microscope. Five centimeters above the strobe
light bulb a diaphragm having a 4 mm openir,g is placed centered on
°the optical axis parallel to the film plane. (This diaphragm ef-
fectively forms the point for formation of a new wave front.) No
condenser is needed. A columnated tungsten light source and 45°
removable mirror is placed above the diaphragm when a focusing
light is needed. The microscope is focused onto the center of the
hanging drop of sample, the mirror is removed and a flash picture
is made of the cells drifting in the drop.
Color print film (35 mm) will be ASA matched to the optical system.
As before a I0-= mm spacing stage micrometer will be used for fram
identification and size indexing on the films.
15.0
16.0
17.0
17.1
ACQUISITION OF DATA
ANALYSIS OF DATA
SAFETY PROCEDURES
Dr. Fabian Lionetti from The Center for Blood Research, is the Safety
officier.

I_IITIAL BLOOD STORAGE EXPERIFIENT
Schedules for Blood Collection, Component Preparations and Distribution
° •
1.0 The purpose of this document is to define the timelines and responsibility
for IBSE personnel to collect, prepare, pool and distribute whole blood and its
components in preparation for loading into flight hardware and shuttle launch.
The activity described in this document is detailed in Annex 8 of the Payload
Integration Plan.
2.0 Manpower Requirements
M.S. Jacobson CHMC
D. Van Pelt CBR
S. Kevy CHMC
F. Lionetti CBR
T. Curran CBR
0
C. Smith CFBB
A. Scanlon CHMC
3.0 Schedule
The activity of blood collectlon, component preparation and sample
distribution is scheduled in relation to the shuttle launch. The schedule is
developed on the basis of a launch on December 18, 1985 at 7:00 a.m. The
activity begins at twenty-five hours prior to launch (T-25, 6:00 a.m.,
12/17/85). The schedule of the activity is as follows:
See following page for table
4.0 Activity Record
The activity related to blood collection, platelet and leukocyte
preparation will be entered on the attached record sheets.
|Code
3.1
3.2
3.5
3.6
3.7
3.8
3.9
3.10
3.11
3.12
3.13
3.14
3.15
3.16
3.17
Time
T-25 (6:00 a.m. 12/17)
Activit_
Begin blood collection
Personnel
Responsible
May Jacobson
T-24.5 (6:30 a.m. 12/17) Begin platelet and
leukocyte preparation
T-22.5 (8:30 a.m. 12/17) Begin whole blood pooling
T-22 (9:00 a.m. 12/17) Completion of blood
collection
T-20 (11:00 a.m. 12/17) Completion of whole blood
pool
T-20 (11:00 a.m. 12/17) Completion of individual
leukocyte units
T-20 "(11:00 a.m. 12/17) Begin distribution of whole
blood
T-20 (11:00 a.m. 12/17) Begin leukocyte pooling &
distribution
T-19.5 (11:30 a.m. 12/17) Completion of individual
platelet units
T-19.5 (ii:30 a.m. 12/17) Begin platelet pooling &
distribution
T-19 (12:00 p.m. 12/17) Completion of distribution
of whole blood, leukocytes,
platelets into designated bags
T-19 (12:00 p.m.. 12/17) Begin packing blood bags into
8 boxes for transportation
to KSC
T-18.5 (12:30 p.m. 12/17) Completion of packing blood
bags
T-18
T-17
T-17
(I:00 p.m. 12/17) Departure of blood from CFBB
(2:00 p.m. 12/17) Arrival of blood at KSC
(2:00 p.m. 12/17) Begin loading of dewars
Continuation of pre-launch activity as described in "Prelaunch Closeout
Procedures" (ADL Reference C-532B2-45).
ACTIVITY RECORD - WHOLE BLOOD COLLECTION
UNITS COLLECTION TIME STARTED TIME COMPLETED OPERATOR
IST DONOR
2ND DONOR
3RD DONOR
4TH DONOR
5TH DONOR
6TH DONOR
7TH DONOR
8TH DONOR
91"I{DONOR
IOTH DONOR
IITH DONOR
12TH DONOR
13TH DONOR
14TH DONOR
15TH DONOR
16TH DONOR
17TH DONOR
18TH DONOR
19TH DONOR
20TH DONOR
21ST DONOR
22ND DONOR
23RD DONOR
24TH DONOR
25TH DONOR
ACTIVITY RECORD - WHOLE BLOOD COLLECTION
UNITS COLLECTION TIME STARTED TIME COMPLETED OPERATOR
26TH DONOR
27TH DONOR
28TH DONOR
29TH DONOR
30TH DONOR
31ST DONOR
32ND DONOR
33RD DONOR
34TH DONOR
35TH DONOR
36TH DONOR
3?TH DONOR
38TH DONOR
39THDONOR
40TH DONOR
WHOLEBLOODPOOLINGANDDISTRIBUTION
ACTIVITY '
TIM
STARTED
TM
COMPLETED OPERATOR
POOLING OF FIRST 6 UNITS OF WHOLE
BLOOD (FIRST POOL)
MIXING IST
MIXING 2ND
MIXINd3_
MIXING 4TH
MIXING 5TH
MIXING 6TH
POOLINGOF SECOND6 UNITSOFWHOLE
BL_,D (SECO_ POOL)
MIXING IST
MIXING 2ND
MIXING 3RD
MIXING 4TH
MIXING 5TH
MIXING 6TH
&
POOLING OF FIRST AND SECOND WHOLE
BLOOD POOL
MIXING IST
MIXING 2ND
MIXING 3RD
MIXING 4TH
MIXING 5TH
MIXING 6TH
DISTRIBUTION INTO DESIGNATED BAGS
PLATELET PREPSRATION
ACTIVITY
PREPARATION OF
INDIVIDUAL UNITS
UNIT PRP Preparation
Packed platelets
Resting
Rotation
UNIT PRP Preparation
Packed platelets
Resting
Rotation
UNIT PRP Preparation
Packed platelets
Resting
Rotation
UNIT PRP Preparation
Packed platelets
Resting
Rotation
UNIT FRP Preparation
Packed platelets
Resting
Rotation
UNIT PRP Preparation
Packed platelets
Resting
Rotation •
TIME
STARTED
TIME STATUS OF RESPONBILE
CObfPLETED PREPARATION PERSONNEL
I,EUKOCYTE PREPARATION
ACTIVITY
TIME
STARTED
TIME STATUS OF RESPONBILE
COMPLETED PREPARATION PERSONNEL
PHEPARATION OF
INDIVIDUAL UNITS
UNIT 1
UNIT 2
UNIT 3
UNIT 4
UNIT 5
UNIT 6
UNIT 7
UNIT 8
UNIT 9
UNIT i0
UNIT II
UNIT 12
UNIT 13
UNIT 14
UNIT 15
UNIT 16
UNIT 17
UNIT 18
UNIT 19
UNIT 20
UNIT 21
UNIT 22
UNIT 23
UNIT 24
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1.0 PURPOSE
The purpose of this document is to define the procedures for Arthur D
Little, Inc. (ADL), personnel to "close-out" the flight and
ground-based lockers containing the Initial Blood Storage Experiment
(IBSE) in preparation for the shuttle launch.
20 SCOPE
Che scope of this document is to describe the hardware-rela_ed _r_!" i-
ties and the loading procedures as they interface with the hard_.:_r,_
The scientific aspects of the loading are described in the I_SI
Scientific Protocol and in Annex 8 of the Payload Integration Plan.
Performance checkout of the IBSE hardware is described in the Opera-
ring. Maintenance and Handl$ng Procedures.
3.0 MANPOWER REQUIREMENTS
The following IBSE personnel will be involved in the IBSE closeout:
D. W. Almgren, Arthur D. Little, Inc. Engineering Manager
E. J. Boudreau, Arthur D. Little, Inc. Technician
W. A. Curby, Lahey Clinic Medical Center - Science/Engineering
Interface Manager
J. Young, Jr., Lahey Clinic Medical Center Technician
D. Elwood, Lahey Clinic Medical Center Technician
M. S. Jacobson, Children's Hospital - Scientist in Charge of
Blood Bag Loading
F. Chao or D. Van Pelt, Children's Hospital Observer
In addition to loading and closeout personnel, additional personnel
will be available to:
o observe procedures and schedule,
o authorize proposed changes to the procedures
(e.g., use of spare unit or parts, change of loading
sequence, etc.),
o record any procedure changes,
o interface with NASA,
o interface with Central Florida Blood Bank,
Arthur D. Little, Inc.
ORIGINAL _,_,_E IS
OF POOR QUAL_IT%,
o interface with working press,
o interface with point of contact of closeout
team (W. Curby).
The personnel for these activities include:
E. Michel, NASA JSC
W. Paton, NASA KSC
D. Surgenor, Center for Blood Research
S. Kevy, Children's Hospital
P. Glaser, Arthur D. Little, Inc.
Figure I illustrates the IBSE organization during loading and close-
out.
_.0 SCHEDULE
The activities related to IBSE loading and closeout occur in relation
to the shuttle launch. This schedule assumes a launch of January 6.
1986, at 7 A.M. The schedule of events 3 days prior to launch are
shown on the timeline in Figure 2 and are described below. Figure 3
shows the loading sequence of units.
4.1 Three Days Prior to Launch (1/3/86)
4.1.1 Post access list to closeout room.
4.1.2 D. Almgren and E. Boudreau check inventory of IBSE
Hardware and Equipment in Hangar L.
4.1.3 D. Almgren and E. Boudreau check DC power supplies in
Hangar L.
4.1.4 D. Almgren and E. Boudreau inspect each of four !BSE
module, (2) P/N 4215-1200 and (2) P/N 4215-1400, in its
locker.
4.1.4.1 D. Almgren and E. Boudreau install Kapton air f!:,_
passages in three platelet dewars.
4.1.a.2 Perform airflow check (see paragraph 6.1
of Operating, Maintenance and Handling Proced'._re_
4.1.4.3 Set elapsed time meters and record in log book.
/_ Arthur D. Little, Inc.
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4.2
4.1.4.4 Closeout module without Kapton tape on perimeter of
air passages.
4.1.4.5 Install module in locker.
4.1.4.6 Verify spare fuse in foam.
4.1.4.7 Perform thermal performance test (see paragraph 6.2
of Operating, Maintenance and Handling Procedures_
4.1.5 Repeat airflow and thermal zests with IBSE
P/N 4215-1200 spare C/D module (S/N 0003)
4.1.6 D. Almgren and E. Boudreau store modules in Hanger L,
4.1.6.1 Disconnect DC power supplies from IBSE modules by
unplugging 25 foot cable from pigtail to DC power
supply.
4.1.6.2 Cover middeck lockers containing IBSE modules
(located in Curby Crane) and associated 25-foot
power cable with polyethylene bags.
4.1.6.3 Cover spare IBSE module in cardboard box with
polyethylene bag.
4.1.7 Power each locker for approximately i minute/day
until launch preparations. Record data in logbooks
Twenty-Four Hours Prior to Launch (1/5/86, 07:00 A.M.)
4.2.1 E. Boudreau unplugs IBSE module A/B, P/N 4215-1400
(S/N 0002) from power source.
4.2.2 E. Boudreau removes two electrical subpanel screws.
4.2.3 E. Boudreau opens locker door to 180 ° position and
supports it with Lucas door support.
4.2.4 E. Boudreau removes top foam block.
4.2.5 E. Boudreau removes belly band foam.
4.2.6 E. Boudreau removes screws (approximately 16) from
control box/dewar flange and verifies that the control
box/bag support structure can be lifted from dewar.
4.2.7 E. Boudreau repeats 4.2.1 to 5.2.6 for IBSE module
P/N 4215-1200 (S/N 0004), dewars E/F.
/_i Arthur D. Little, Inc.
4.2.8
4.2.9
E. Boudreau repeats 4.2.1 to 4.2.6 for IBSE module
P/N 4215-1200 (S/N 0001), dewars J/K.
E. Boudreau repeats 4.3.1 to 4.3.7 for IBSE module
P/N 4215-1200 (S/N 0005), dewars G/H.
4.3 Eighteen hours prior to launch (1/5/86 - i:00 P.M.)
4.3.1 D. Almgren and D. Elwood lift the blood storaBe racl:_
out of the locker and suspend them for P/Q: 4215-I-
(S/N 0002), dewars A/B.
4.3.2 D. Almgren removes the two thermal shields and stores
them inside the dewars.
4.3.3 D. Almgren covers the open dewars with polyethylene.
4.3.4 Process repeated for P/N 4215-1200 (S/N 0004), dewars
E/F, one thermal shield.
4.3.5 Process repeated for P/N 4215-1200 (S/N 0001), de,cars
J/K, one thermal shield.
4.3.6 Process repeated for P/N 4215-1400 (S/N 0005), dewars
G/H, two thermal shields.
4.4 Seventeen hours prior to launch (1/5/86 2:00 P.M.)
4.4.1 CBR personnel load blood bags into racks of P/N
4215-1400 (S/N 0002), dewars A/B, according to
protocol.
4.4.2 D. Almgren and D. Elwood install two thermal shields
on P/N 4215-1400 (S/N 0002), dewars A/B, and apply
Kapton tape to exterior of shields.
4.4.3 D. Almgren and D. Elwood close out Kapton box around
platelet grids.
4.4.4 D. Almgren and D. Elwood lower bag support structure
into dewars.
4.4.5 E. Boudreau and J. Young closeout P/N 4215-1400
(S/N 0002), dewars A/B.
4.4.5.1 E. Boudreau installs screws holding control bo_<
to dewars,
4.4.5.2 J. Young raises the IBSE modules.
4.4.5.3 E. Boudreau applies Kapton tape to perimeter cf
air passage.
7
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4.5
4.4.5.4 J. Young lowers the IBSE modules.
4.4.5.5 J. Young removes eyebolt.
4.4.5.6 E. Boudreau puts in belly band foam.
4.4.5.7 E. Boudreau installs foam block while
feeding subpanel through cutout in door.
4.4.5.8 E. Boudreau closes locker door.
4.4.5.9 E. Boudreau puts back subpanel screws.
4.4.5.10 E. Boudreau connects 25 foot cable to electric
subpanel with laboratory dc power supply.
J. Young notes time in log book.
4.4.5.11 E. Boudreau verifies current draw and temperature.
J. Young records in log book.
4.4.5.12 Turnover of loaded fight module P/N 4215-1400
(S/N 0002) to NASA.
4.4.6 Repeat 4.4.3 to 4.4.5.12 for P/N 4215-1200
(S/N 0004), dewars E/F.
4.4.7 Closeout process is repeated for ground based units:
P/N 4215-1200 (S/N 0001), dewars J/K, and P/N 4215-i_60
(S/N 0005), dewars G/q].
Twelve hours prior to launch (1/5/86, 6:30 P.M.)
4.5.1 NASA personnel remove P/N 4215-1400 (S/N 0002) and
P/N 4215-1200 (S/N 0004) for cleaning of exterior,
final weighing, transportation and installation in
Orbiter.
4.5.2 E. Boudreau and J. Young record temperature of units:
o as they set out to Orbiter.
o as they arrive at Orbiter,
Activity record forms for each pre-launch time step (24 hours. !$
hours, 17 hours, and 12 hours) are attached.
/_ Arthur D. Little, Inc.
24 HOUR ACTIVITY RECORD
FUNCTION ,
Unplug P/N 4215-1400
(S/N 0002) from power
source (A/B)
Remove two electrical
subpanel screws
Open locker to 180 °
pos + support w/ Lucas
door support
PERSON(S)
Boudreau
Boudreau
Boudreau
TIME
STARTED/COMPLETED
_. Remove top foam block Boudreau
5. Remove belly band foam Boudreau
5. Remove (16) screws Boudreau
from control box and
dewar flange
Verify control box/bag
support structure can
be lifted from dewar
.
3, Unplug P/N 4215-'1200
(S/N 0004) from power
source (E/F)
?. Remove two electrical
subpanel screws
[0. Open locker to 180 °
pos.+ support w/ Lucas
door support
[i Remove top foam block
[2. Remove belly band foam
L3 Remove (16) screws
from control box
and dewar flange
.-. Verify control box/bag
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
support structure can
be lifted from dewar
NOTES
/1_ Arth,,rF% I ittl_ Int, 9
24 HOUR ACTIVITY RECORD
FUNCTION
15. Unplug P/N 4215-1200
(S/N 0001) from power
source (J/K)
16. Remove two electrical
subpanel screws
i- Open locker to 180 °
pos.+ support w/ Lucas
door support
18. Remove top foam block
19. Remove belly band foam
20. Remove (16) hot plate
screws from control box
and dewar flange
21. Verify control box/bag
support structure can
be lifted from dewar
i'2. Unplug P/N 4215-1400
(S/N 0005) from
power source (G/H)
23. Remove two electrical
subpanel screws
24. Open locker to 180 °
pos.+ support w/ Lucas
door support
25. Remove top foam block
i6. Remove belly band foam
27. Remove (16) screws
from control box
and dewar flange
2%. Verify control box/bag
support structure can
be lifted from dewar
_ERSON($)
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
Boudreau
TIME
STARTED/COMP_ETED NOTES
RECORD COMPLETED BY:
/_ Arthur D. Little, Inc.
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28 HOUR ACTIVITY RECORD
FUNCTION
Lift blood storage
racks and suspend
P/N 4215-1400
(S/N 0002)
PERSON(S)
Almgren/Elwood
TIME
STARTED/COMPLETED NOTES
4 o
.
.
.
.
.
Remove thermal
shields (2) and
store in dewar
Cover dewars with
polyethylene
Lift blood storage
rack and suspend
P/N 4215-1200
(S/N 0004) (E/F)
Remove thermal
shield (i) and
store in dewar
Cover dewars with
polyethylene
Lift blood storage
rack and suspend
P/N 4215-1200
(S/N 0001) (J/K)
Remove thermal
shield (I) and
store in
dewar
Cover dewars with
polyethylene
I0. Lift blood storage
rack and suspend
P/N 4215-1400
(S/N 0005) (G/H)
Almgren
Elwood
Almgren/Elwood
Almgren
Elwood
Almgren/Elwood
Almgren
Elwood
Almgren/Elwood
/1! Arthur D. Little. Inc.
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FUNCTION
ii. Remove thermal
shields (2) and
store in dewars
12. Cover dewars with
polyethylene
18 HOUR ACTIVITY RECORD
TIME
PERSON(S) STARTED/COMPLETED
Almgren
Elwood
NOTES
RECORD COMPLETED BY"
/_k Arthur D. Little, Inc. 12
.FUNCTION
17 HOUR ACTIVITY RECORD
Load blood bags
into
P/N 4215-1400
(S/N 0002) (A/B)
2. Install two
thermal shields
PERSON(S)
Jacobson/Van Pelt
Almgren/Elwood
TIME
STARTED/COMPLETED NOTES
3. Almgren/Elwood
.
°
Apply Kapton tape
to shields'
exterior
Lower bag support
structure into
dewars
Install screws
holding control
box to dewars
Almgren/Elwood
Boudreau
6. Raise the IBSE Young
modules
7. Apply Kapton tape Boudreau
to air passage
perimeter
8. Lower IBSE modules Young
9. Remove eyebolts Young
i0. Put in bellyband Boudreau
foam
BoudreauIi. Install foam block
while feeding sub-
panel through cut-
out in door
12. Close locker door Boudreau
13. Put back subpanel Boudreau
screws
13
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_7 HOUR ACTIVITY RECORD
FUNCTION
15. Connect 25-foot
cable to electric
subpanel w/laboratory
dc power supply
16. Note time of No. 15
in log book
PERSON(S)
Boudreau
Young
TIME
STARTED/COMpLETED NOTES
17. Verify current draw
and temperature
18. Turnover loaded
flight unit
P/N 4215-1400
(S/N 0002) to NASA
19. Load blood bags
into P/N 4215-1200
(S/N 0004) (E/F)
20. Install thermal
shield (one)
21. Apply Kapton tape
to shield exterior
22. Close out Kapton
box around platelet
grid
23. Lower bag support
structure into
dewars
24, Install screws
holding control
box to dewars
Boudreau
Curby
Jacobson/Van Pelt
Almgren/Elwood
Almgren/Elwood
Almgren/Elwood
Almgren/Elwood
Boudreau
25. Raise the IBSE Young
Modules
26 Apply Kapton tape Boudreau
to air passage
perimeter
27 Lower IBSE modules Young
28 Remove eyebolts Young
29 Put in bellyband Boudreau
foam
,,.,.-_._ '+,, r+.":'_' IS
OF POOR QUALITY/_ Arthur D. Little, Inc. 14
FUNCTION
30. Install foam black
while feeding sub-
panel through cut-
out in door
17 HOUR ACTIVITY RECORD
TIME
PERSON(S) STARTED COMPLETED
Boudreau
Boudreau
NOTES
33. Connect 25-foot
cable to electric
subpanel w/labora-
tory dc power supply
31. Close locker door
72. Put back subpanel Boudreau
screws
Boudreau
34. Note time of No. 33
in log book
35. Verify current draw
and temperature
36. Turnover loaded
flight unit
P/N 4215-1200
(S/N 0004) to NASA
37. Load bag into
P/N 4215-1200
(SN 0001) (J/K)
38. Install thermal
shield (one)
39. Apply Kapton tape
to shield exterior
40. Close out Kapton
box around platelet
grid
41. Lower bag support
structure into
dewars
42. Install screws
holding control
box to dewars
Young
Boudreau
Curby
Jacobson/Van Pelt
Almgren/Elwood
Almgren/Elwood
Almgren/Elwood
Almgren/Elwood
Boudreau
Young_3. Raise the IBSE
Modules
15/t_ Ar_h.r D I ittle Ine
17 HOUR 6CTIVITY RECORD
FUNCTION
&4. Apply Kapton tape
to air passage
perimeter
PERSON(S)
Boudreau
TIME
STARTED/COMPLETED NOTES
_5. Lower IBSE modules Young
46 Remove eyebolts Young
_7 Put in bellyband Boudreau
foam
Boudreau&8. Install foam block
while feeding sub-
panel through cut-
out in door
_9. Close locker door Boudreau
50. Put back subpanel Boudreau
screws
Boudreau51. Connect 25-foot
cable to electric
subpanel w/labora-
tory dc power
supply
52. Note time of No. 51
in log book
53. Verify current draw
and amps
Young
Boudreau
54. Load blood bags
into P/N 4215-1400
(SN 0005) (G/H)
55. Install two
thermal shields
56. Apply Kapton tape
to shields'
exterior
57 Lower bag support
structure into
dewars
Jacobson/Van Pelt
Almgren/Elwood
Almgren/Elwood
Almgren/Elwood
58. Install screws
holding control
box to dewars
Boudreau
I
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FUNCTION
59. Raise the IBSE
modules
60 Apply Kapton tape
to air passage
perimeter
_i Lower iBSE modules Young
62 Remove eyebolts Young
63. Put in bellyband Boudreau
foam
Boudreau
17 HOUR ACTIVITY RECORD
TIME
PERSON(S) STARTED/COMPLETED
Young
Boudreau
NOTES
64. Install foam block
while feeding sub-
panel through cut-
out in door
65. Close locker door ! Boudreau
66. Put back subpanel Boudreau
screws
Boudreau67. Connect 25-foot
cable to electric
subpanel w/laboratory
dc power supply
68. Note time of No. 67
in log book
69. Verify current draw
and temperature
Young
Boudreau
RECORD COMPLETED BY:
17
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$2 HOUR ACTIVITy RECORD
FUNCTION
Convert modules
P/N 4215-1400
(S/N 0002) and
P/N 4215-1200
(S/N 0004) from
laboratory dc power
supply to battery
power source
Units P/N 4215-1400
(S/N 0002) and
P/N 4215-1200
(S/N 0004) are
exterior cleaned,
weighed, transported
installed in Orbiter
Temperature of
P/N 4215-1400
(S/N 0002) and
P/N 4215-1200
(S/N 0004) logged as
they set out to, and
arrive at,the Orbiter
_ERSON(S)
NASA
NASA
Boudreau
TIME
STARTED/COMPLETED NOTES
RECORD COMPLETED BY:
Arthur D. Little, Inc.
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1,0 Purpose
The purpose of this procedure is to provide guidance and instruc-
tion to personnel who will be maintaining and operating the IBSE
modules.
2.0 Scope
This procedure covers maintenance and operation of the five,
fligh_ IBSE modules.
3.0 Special Tools Required
No special tools are required.
4.0 Maintenance Schedule
Maintenance of the IBSE modules is not required on a regularly
scheduled basis. It is recommended that a dewar air flow test
and a thermal performance test of a module be conducted at least
60 days prior to any reflight of the module.
5.0 Condition of Environment
The thermoelectric coolers within the IBSE module reject their
heat to the cooling air flowing through the module with more
power dissipation required at higher air temperatures. Satisfac-
tory operation of the modules has been measured with inlet air
temperature up to 80°F. It is recommended, however, that all
testing of the IBSE module be performed at ambient air tempera-
tures between 65 and 75°F to ensure a reduced power dissipation
of the module during testing.
6.0 Maintenance Procedure
Maintenance procedures for the IBSE hardware is based on two
basic concerns: the dewar air flow rate and the thermal perfor-
mance of the thermoelectric devices. In the following descrip-
tion, reference should be made to Figures 6-1 through 6-4 which
are the exploded views of the IBSE hardware.
6.1 _ewar Air FIoM Maintenance Pro_eduTe
The 40-50 ml/mln specified air flow rate through the dewars
is provided by a small, plastic, gear pump powered by a 12 v
dc, brush-type motor. This pump is located in the center
compartment of the control box (see assembly drawing 4215,
sheet 5). The air flow rate being provided to each dewar is
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best measured at the exit of the air tube which terminates
inside each dewar at its closed end. The following proce-
dure is required to measure the air flow rate:
6.1.1 Disassemble control box from flanges of two dewars by
removing eight, allen head screws around the perimeter of
each of the two dewars.
6.1.2 Lift control box assembly and bag support structures from
dewar assembly and lay on its side on a piece of soft
material, e.g., a silicone rubber mat.
6.1.3 Remove the open end of the short horizontal section of TFE
air tubing at the bottom of each dewar from inside the
thermal shield or bag support structure.
6.1.4 Attach a calibrated (air) orifice or similar device to the
exit of each of the two exposed ends of the air tubing.
An air filter identical to the one in the cold plate can
be used.
6.1.5 Install an inclined water manometer, or a similar pressure
differential measuring device, to read the pressure
drop across the orifice or similar device. The air flow
pressure drop characteristics of the orifice should be
approximately 0.i inch of water at I00 ml/min air flow.
6.1.6 Apply 28 v dc power to the module via the connector on the
electrical subpanel and measure the flow rate of air
exiting each air tube.
6.1.7 If adjustments are required to the air flow rate, turn off
the power to the module, and remove the top cover of the
control box.
6.1.8 Adjustment to the air flow to both dewars, simultaneously,
is achieved by changing the setting of the teflon valve
located in the center compartment of the control box.
This valve setting controls the fraction of the air output
from the pump which flows to the two dewars. The remain-
ing fraction of air flows to the electronic compartments
of the control box as cooling air.
6.1.9 If the fraction of the air flow rate to one dewar has to
be changed with respect to the air flow rate to the second
dewar of the same assembly, install a small bore tube
inside the appropriate TFE air tube at the bottom of the
dewar. This additional flow restriction serves to divide
the flow between the two dewars coming from a common
source upstream. Table 6.1.9-1 summarizes the air flow
rates set in all of the IBSE modules at the time of
delivery of hardware to NASA.
*._h,,. _ ! irtlp |nr
TABLE 6.1.9-1 MEASURED AIR FLOW RATEB TO IBSE DEWARS
o OCTOBER 27, 1985
S/N 0001
, s/N 0002
S/N 0003
s/N 0004
S/N 0005
(J/K) COLD: 63 ML/M
(A/B) COLD: I00 ML/M
(C/D) COLD: 50 ML/M
(E/F) COLD: 75 ML/M
(G/H) COLD: 106 ML/M
WARM :
COLD:
WARM:
WARM:
COLD:
250 ML/M
94 ML/M
240 ML/M
263 ML/M
119 ML/M
A
6.2 Thermal Performance Test
6.2.1
6.2.2
6.2.5
6.2.6
The thermal performance of the dewars can be measured from
the exterior of the module without disassembly. There is a
YSI model 44006 thermistor mounted on the cold plate of each
dewar whose resistance can be read from test Jacks on the
front electrical subpanel of each module. The thermal
performance test procedure using these test Jacks is as
follows:
Mount the IBSE module inside a block of foam similar
to the Pyrell foam used in a middeck locker.
Electrically attach a resistance measuring meter to each
of the two, white, test Jacks on the front panel. The
left, white, test jack is connected to the left dewar,
etc. The third, blue, test jack, located below the two,
white, test jacks as viewed from the front of the panel
with the primary power connector to the right, is common
to both thermistors.
Apply 28 v dc power to the module.
Record the transient temperature of each cold plate during
cooldown.
Figure 6.2.5-I is a plot of the transient cooldown
temperature of each of the cold plates in the seven cold
dewars (5_I°C steady state) recorded Just prior to the
time of delivery of the flight hardware to NASA with an
ambient air temperature of approximately 70°F.
If the transient temperatures of a dewar does not approxi-
mately correspond with its previously measured values (see
Figure 6.2.5-1), then initiate a detailed inspection and
testing of all hardware and electronic subassemblies using
engineering and electrical drawings.
7.0 Fault Analysis
The primary parameters to measure for an operating IBSE module
are the temperatures of the cold plates inside the dewar (see
Figure 6.2.5-1) and the current draw of the locker. With an
ambient air temperature of approximately 70°F, the initial
current draw of a cold/cold module (at 28 v de) is approximately
3.5 amperes. The steady state current draw of the same locker
for the same air temperature is approximately 1.5 amperes. The
initial current draw of a cold/warm module is approximately 3.5
amperes and its steady state value is approximately 1 ampere.
The current being drawn by a cold/warm module may show a 5 i0
second cyclical variation of approximately .I ampere due to the
controller for the warm dewar periodically shutting off. If
/_ A.h.r I"1 i iltle lnr
8
OF POOR QUALITY
oO
0
I--
0
c_
--
_,_
0
0
z
_J
0
0
I--
o
o
II
I--
o
o
0
o
o
measured current values are significantly different from the
values plotted in Figure 6.2.5-1, a detailed inspection of the
electrical subsystem should be initiated.
There are three thermostats located inside the control box which
will open if local, internal temperatures exceed l18°F. The
thermostats are in series and will shut off all power to the
module except to the two air cooling fans. There is one addi-
tional thermostat on each cooling fan to turn off power to that
fan if its temperature exceeds l18°F.
There are three fuses inside the control box which, if blown,
will shut off power to one of the two electronic temperature
controllers (3a) or to the entire module (7a).
8.0 Operating Instruction
With the control box bolted to the dewar assembly, and a block of
foam surrounding the assembly, the only remaining action to be
taken by a user to initiate operation of the module is to apply
28 v dc power to the electrical connector on the front of the
electrical subpanel. The application of 28 v dc will cause the
green LED on the front of the locker to light. A blown fuse
inside the locker does not turn the LED off. In a O-g environ-
ment, the air flow flag over the exit air slot or grille will
flutter to show that the cooling air fans are operating and,
therefore, the module is receiving power.
After operating a cold dewar for an extended period of time, the
cold plate/bag support structure should be removed from the dewar
assembly and any condensed water removed. A jet of pressurized
air can be used to blow out any moisture which has accumulated
around the thermoelectric devices which are located in the gap
between the hot and cold plates of the dewar lld assembly.
PRECED:,u",JGPA,_E D_.,.,L_.NOT F_[.MED
/t_ Arthur D. Little, Inc.
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THE CENTER FOR BLOOD RESEARC2-I
800 Huntington Avenue, Boston, Massachusetts 02115 (617) 731-6470
November lg, 1985
Mr. William Paton/LSSM
CS-SED-4
NASA
JFK Space Center
Florida 33899
RE= NAS 9-17222/IBSE
Dear Bill=
Enclosed please find a copy of the DD 1149 form with equipment and
supply llst attached.
For your information we also enclose an Itemlzed bill-of-lading made out
by the transportation company, Daley & Wanzer (form 111g0).
The equipment will be leaving Boston on Friday, November 22nd, and will
be delivered between 8 am and noon on Friday, December 6th.
If there are any changes that are required we are able to reach the
driver in transit on a daily basis.
Please be advised that there are four IEC centrifuges that weigh
approximately 1100 lbs. each and are palletlzed for fork-lift unloading
at KSC.
Very truly yours,
Executive Vice President
RLK=rar
Encl.
cc= E. Michel/EX4
vl:). Surgenor, CBR
F. Llonetti, CBR
C. Kellther, ONR
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NASA IBSE IMMUNOLOGY: UMASS MED CTR.
LIST OF ITEMS TO BE SHIPPED FROM C.B.R.
BOX I: ,Description
Assorted plastic pipet tips. 2000
3 channel.electronic timer 1
20 ml syringe 4 30
Glass pasteur pipets, box of i00 _ 3
Vortex mixer , 2
Glass 500mi vol. glask 1
50 ml grad. centrifuge tube with cap 50
Parafilm, 4" x 250 ft. roll 2
Approximate value:
$500.00
BOX 2:
BOX 3:
BOX 4:
Glycerol'solution, 500 ml BTL
Aspirator pump
i0 ml red top tubes, 100/box
Wire test tube rack
Lab coat
2000 ml plastic beaker
Magnetic silt bars
30 ml plastic vials with cap
Ball point pens
Laboratory larkers, assorted
Scissors
Hemostat
Paper clips, box
Tape, roll
5 ml red top tube, 100/box
Plastic transfer pipets, 500/box
Plastic bottle 2 1
Plastic bottle ill
Plastic bottle 500 ml
Plastic bottle 250 ml
Plastic bottle, wash, 500 ml
Magnetic stirrer
Test tube mixer
Tape dispenser
2
3
3
4
2
2
6
50
6
•.. 10
"" 1
2
1
4
3
3
1
2
4
2
4
1
%
Approximate value:
$3OO.0O
Approximate value:
$350.00
Approximate value:
$290.00
•BOX 5: Description
20 L plastic carboy 1
Plastic grad. cylinder, 2L" I
Plastic grad. cylinder, 500 ml 1
Plastic grad. cylinder, I00 ml 1
Notebook & paper 2
Plastic vol. flask IL .2
5% Bovine albumin P.B.S. 500 ml
3 containers, each with the following:
180g NaCI
22.44g Na2HPO 4
6.712g NaH2PO 4
20 NaN 3
_containers, each with l.Sg Na2EDTA
0
Approximate value:
$160.00
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TABLE I
SUMMARY OF MAIN IBSE ACTIVITY
PLAN K* PLAN KE* PLAN E*
Primary Landing Site KSC Edward
Secondary Landing Site Edward
Location of Lab & Investigators KSC KSC Boston
Flight Hardwares at the time
of launch
KSC KSC KSC
Ground samples (Zero time and
Control)
KSC KSC Boston
Loading of the Dewars KSC KSC KSC
Transportation of ground
control after launch
Within Within
KSC KSC
From KSC to
Boston in
dewars via
air-condi-
tioned van
Transportation of flight
sample after launch
Within From Edward to From Edward
KSC KSC via a jet to Boston
arranged by via a jet
IBSE team arranged by
IBSE team
Plan K:
Plan KE :
Plan E:
KSC landing
Edward landing site with KSC as primary landing site
Edward as the primary landing site
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Acorn Park
Cambridge. Massachusetts 02140-2390
617 864-5770 Telex 921436
t, Arthur D. Little, Inc.
October 15, 1985
McDonnell Douglas Technical
Services, Inc.
16441 Space Center Boulevard
Houston, TX 77058
Attention: Mr. Stephen Gotch
Mail Code D3
Subject: Power Dissipation of the Initial Blood Storage
Experiment
Gentlemen: ADL Reference 53282-51
The following steady-state power dissipation data for the Initial
Blood Storage Experiment (IBSE) is based on test data recorded
during the period of time from October 2, 1985 to October 9,
1985, with a 28V dc power source.
1.0 Air pressure: 14.7 psia _ower
i.I Tai r - 65°F
C/C Module (4215-1400)
C/W Module (4215-1200)
20W
18U
1.2 T
air
- 75°F
C/C Module (4215-1400)
C/W Module (4215-1200)
31W
25_"
1.3 T
air
. 80°F
C/C Module (4215-1400)
C/W Module (4215-1200)
50%"
52W
1.4 T
air - 90°F (max.power dissipation capability of
Modules @ 28 Vdc)
C/C Module (4215-1400)
C/W Module (4215-1200)
81W
70W
OR_G!?_AL PAGE IS
OF POOR QUALITY
Brussels Madrid San Francisco Torunlo
Houston Mexico City S/to Paulo Washington
/]_, Arthur D. Little. Inc.
McDonnell Douglas Technical
Services, Inc.
Attention: Hr. Stephen Gotch
2.0 Air Pressure: 10.2 psia
2.1 Tai r - 65°F
C/C Module (4215-1400)
C/W Module (4215-1200)
2.2 T ,
alr
, .75°F
C/C Module (4215-1400)
C/W Module (4215-1200)
2.3 T
air
. 80°F
C/C Module (4215-1400)
C/W Module (4215-1200)
21W
22W
34W
44W
49W
54W.
If you have any questions, please feel free to call me.
Sincere ly,
David W. Almgren
IBSE Engineering Manager
dwa:In
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Acorn Park
Cambridge. Massachusetts02140-2390
617 86.,I-5770Telex 921436
- ._,v a ' :°-
October i0, 1985
To:
From:
D. MacN. Surgenor
IBSE Principal Investigator
D. Almgren
IBSE Engineering Manager
Subject: Quick Look Report for IBSE Thermal Performance Tests
During the one week period from October 2, 1985 to October 9, 1985, a
cold/cold IBSE module (S/N 0005) and a cold/warm IBSE module (S/N
0001) were tested over a range of temperatures at two pressures: 14.7
and 10.2 psia. This Quick Look Report represents a summary of the
steady state raw data as recorded during the tests.
I. Steady State Condition No. 1 Tai r - 65°F
Date: October 3, 1985 @ 1200
C/C Module: cold plate No. I: _.4°C
cold plate No. 2: A.3°C
T: 1.3°C
Tair: 6,1°C
Power: 20W
C/W Module: cold plate (C): 4.2°C
cold plate (W): 21.0°C
Power: 18W
Pressure - Ih.7 psia
(top to bottom)
(entering at bottom)
OF _._:,OR QUALITY
Brussels Madrid SanFrancisco Toronto
Houston Mexico City Sio Paulo Washington
London Milan Singapore Wiesbaden
Los Angeles Paris Tokyo
/']b, Arthur D. Little. Inc.
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II. Steady State Condition No. 2
Date: October 4, 1985 @ 0840
T o
alr
C/C Module: cold plate No. i:
cold plate No. 2:
T:
T :
air
Power:
C/W Module: cold plate (C):
cold plate (W):
Power:
, 75°F
4.5°C
4.3°C
1.4°C
6.4°C
31W
4.4°C
21.3°C
25W
Pressure - 14.7 psia
(top to bottom)
(entering at bottom)
III: Steady State Condition No. 3 T °
alr
Date: October 5, 1985 @ 1030
C/C Module:
. 90°F
C/W Module:
cold plate No. I: 9.6°C
cold plate No. 2: 8.7°C
T: 2.1°C
Tair: II.7°C
Power: 81W
cold plate (C): I0.2°C
cold plate (W): 24.7°C
Power: 70W
Pressure - 14.7 psia
(top to bottom)
(entering at bottom)
IV. Steady State Condition No. 4 Tai r - 80°F
Date: October 7, 1985 @ 1430
C/C Module: cold plate No. i: 4.6°C
cold plate No. 2: 4.4°C
T: 1.9°C
Tair: 7.2°C
Power: 50W
C/q_ Module: cold plate (C): 5.6°C
cold plate (W): 21.5°C
Power: 52W
Pressure - 14.7 psia
(top to bottom)
(entering at bottom)
/l_k Arthur D. Little, Inc.
October i0, 1985 Page 3
V. Steady State Condition No. 5 T
air
Date: October 8, 1985 @ 0900
C/C Module: cold plate No. i:
cold plate No. 2:
T:
Talr:
Power:
C/W Modulo:
- 80°F Pressure - 10.2 psia
4.6°C
4.4°C
1.7°C (top to bottom)
7°C (entering at bottom)
49W
cold plate (C): 6.4°C
cold plate (W): 21.5°C
Power: 54W
VI. Steady State Condition No. 6 Tai r - 75°F
Date: October 8, 1985 @ 1330
Pressure - 10.2 psla
C/C Module: cold plate No. I: 4.5°C
cold plate No. 2: 4.3°C
T: 1.6°C
T . : 6.6°C
alr
Power: 34W
(top to bottom)
(entering at bottom)
C/W Module: cold plate (C): 4.5°C
cold plate (W): 21.5°C
Power: 44W
VII. Steady State Condition No. 7
Date: October 9, 1985 @ 1300
C/C Module:
T - 65°F
air
C/W Module:
cold plate No. i:
cold plate No. 2:
T:
Tair:
Power:
cold plate (C):
cold plate (W):
Power:
4.4°C
4.2°C
1.4°C
6.3°C
22W
4.4°C
21.5°C
21W
Pressure - 10.2 psia
(top to bottom)
(entering at boczom)
Cc : R. Berthiaume
K. Csigi
W. Curby
P. Glaser
David W. Almgren

]BSE Data Ana]ysis
Donald Blevtns, Ph.D.
Nan Laird, Ph.D.
January 15,1987
RECEIVED
p,,--_,pr-_t--_r_ t_,-;-:.%-
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DATA ANALYSIS
Experimental design;
Each of three different blood components, red cells,
white cells and platelets were subjected to mlcrogravlty aboard
the space shuttle. Each were stored In three different types of
storage bags, PVC DEHP, PVC TOTM and Polyolefin and placed in
labeled Dewar flasks. Controls matched both for type of storage
bag and Dewar position remained on earth.
Upon return to earth, the contents of the bags as well as
the contents of the control bags were distributed In randomly
numbered samples to Individual Investigators. The Investigators
had no knowledge of which were the control samples or of the
different storage conditions of the samples. A total of ?4
different outcome measurements were reported to us for statisti-
cal analysis.
Method of analysis:
The data received from the Investigators was listed only
bycoded sample number. The first step was to match the coded
samples wlth the original bag numbers to determine the informa-
tion on bag type, orbital status, and storage location. The
method of analysis used was analysis of variance, using type of
bag and orbital status as the main factors. Most data sets
Included either I8 or 20 samples, hence allowed Investigation of
a possible Interaction effect as well. The analysis tool used
was SAS (Statfstica] Analysis System, release 82.4, SAS
Institute, Cary, NC). For those data sets wlth fully balanced
factors, the SAS ANOVA procedure was used, while for the others
the GLM (General Linear Models) procedure was used.
One of the bags (bag number 56) was found to have de-
veloped a leak at some time before the samples were taken for
distributlon to Investigators. For experiments Involving that
bag, the statistical analysis was redone wlth It omitted.
Results:
The results of the statistical analysis are summarized tn
the following. The data are listed alphabetically by the name of
the principal Investigator - often In multiple tables If many
measurements were done by the same Investigator. The first
column of each table ts the sample number as given to the Inves-
tigator, the second number ts the number of the bag from which
the sample was taken, the third column ts the label of the Dewar
flask In which the bag was stored. Flasks 8 to d were on the
orbiter while e to h remained on earth. In terms of storage
configuration, 8 and e, b and £, £ and 9, _ and h occupied cor-
responding positions. The fourth column of the table gives the
orbital status; _ Indicates orbit and 0 Indicates a control. The
Page 3
fifth column of the table Indicates the type of bag used, d Is
PVC DEHP, E is Polyolefin, and _ is PVC TOTM. The remaining
column(s) contain the reported measurements. Followlng thls is
an explanatlon of the units of the measurement and a table which
reports the mean of the measurement and the standard error of the
mean (measurement of the accuracy of reported mean) for each
combination of bag type and orbltal and control samples. In
addition, the overall means by bag type and earth/orblt status
are reported In the column and row margins of the table. If the
analysis of variance Indicated statlstical significance for one
or more factors, the corresponding p-value Is reported. If no
such notation occurs, the factor was not significant (at the 5%
level).
For experiments Involvlng samples from bag number 56 as
discussed above, the results of the analysis omitting that sample
are reported In the same format, Immediately followlng the
orlginal results.
Ausprunk - Transmission Electron Microscopy Data - Red Cells
Sample _ Dewar Orbit:l Type V] V2 V3
30I 14 c 1 t 293 7.8 54.3
302 6 a 1 d 290 19.6 54.5
303 19 £ 0 p 468 12.8 57.1
304 17 b 1 p 462 10.0 58.2
305 13 e 0 t 478 13.6 53.8
306 1 g 0 d 432 17.6 58.8
307 3 c l d 444 3.8 63.5
308 8 b 1 t 467 9.4 61.2
309 20 a I p 158 ]0.8 60.7
310 15 e 0 p 433 7.6 58.7
31l 2 £ 0 d 436 8.3 64.7
312 9 g 0 t 457 6.3 60.4
313 16 g 0 p 459 5.7 70.]
314 4 e 0 d 388 4.6 69.1
315 I0 a I t 269 9.7 56.9
316 5 b 1 d 405 5.9 61.5
317 Ii f 0 t 341 5.0 56.0
318 21 c I p 342 3.8 50.3
Vl = Total Number of Cetls Counted
Meen/S.E.M.
Orbit \ Type d p t
37.9
25.9
30.!
31 .8
32.6
23.6
32.7
29.4
28.5
33,7
27.0
33.3
24.2
26.3
33.4
32.6
39.0
45.9
0 418.67/51.65 453.33/51.65 425.33/51.65 432.44/29.8Z
1 379.67/5].65 320.67/51.65 343.00/51.65
399.17/36.52 387.00/36.52 384.17/36.52
V2 = % Normocytes
Mean/5.E.M.
Orbit \,Type d
0 10,17/3.066
l 9.77/3.066
347.78/29.82
p t
8.70/3.066
8.20/3.066
8.30/3.066
8.97/3.066
q.06/!.770
8.9811.7_0
9.97/2.168 8.45/2.16a
v3 = % Echinocytes type I & li
Meen/S.E.M.
Orbit
0
Type d
64.20/2.908
! 59.83/2.908
62.02/2.056
P
61.97/2.908
%6.40/2.908
59.]8/2.056
8.63/2.168
t
56.73/2.908
57.47/2.908
57.10/2.056
60.97/1.679
57.90/].67 Q
V4 = _ Echinocytes type ]]!
Mean/S.E.M.
Orbit \ Tv_e d p
0 25.63/2.956 29.33/2.956
30.40/2.956 35.40/2.956
28.02/2.090 32.37/2.090
Page 4
t
34.97/2.956 29.98/].70E
33.57/2.956
34.27/2.090
33.12/1.706
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Ausprunk - Transmission Electron Microscopy Data - White Ce]ls
Sample 8a_ Dewar Orbit=I _ Vl V2 V3 V4 V5
341 22 a 1 d 0 4 3 2 2.25
342 40 e 0 p 0 2 2 2 1.50
343 24 f 0 d 2 4 2 2 2.50
344 35 b I t I 3 3 2 2.25
345 39 c ! P 2 2 3 2 2.25
346 31 g 0 t I 3 2 I 1.75
347 25 g 0 d 2 2 I 3 2.00
348 4I b l p I 3 ] 2 1.75
349 32 e 0 t I 3 2 2 2.00
350 38 f 0 p 0 I I l 0.75
351 23 c ! d 4 1 l 4 2.50
352 29 a ! t 3 l l 3 2.00
353 37 a l p 2 3 I 3 2.25
354 28 e 0 d ! 3 I 3 2.00
355 36 g 0 P 2 3 l 2 2.00
356 33 f 0 t 2 3 2 2 2.25
357 26 b l d 2 3 2 I 2.00
358 34 c ] t 2 3 2 3 2.50
V] = Degranulated Cells
0 : no cells
l = occasional cells
2 = half o_ cel]s
3 : majority oF cells
4 : all cells
Mean/S.E.M.
Orbit \ Type d t
0 1.67/0.638 0.67/0.638 1.33/0.638 1.22/0.369
I 2.00/0.638 1.67/0.638 2.00/0-638 1.89/0.369
1.83/0.451 1.17/0.451 1.67/0.451
V2 = Swollen Cytoplasm - same scoring as above
Mean/S.E.M.
Orbit \ Type d p t
0 3.00/0.577 2.00/0.577 3.00/0.577
I 2.67/0.577 2.67/0.577 2.33/0.577
2.83/0.408 2.33/0.408 2.67/0.408
2.67/0.333
2.56/0.333
P,3ge 6"
V3 = Swollen Nuclear Envelope - same scorfng as above
Mean/S.E.M.
Drbit \ Type d p t
0 1.33/0.471 1.33/0.471 2.00/0.47!
1 2.00/0.471 1.67/0.471 2.00/0.471
1.67/0.333 1.50/0.333 2.00/0,333
1.56/0. 272
I .89/0.272
V4 = Clumped Chromatin
Mean/S.E.M.
Drbit \ Type d
2.67/0.471
2.33/0.471
p t
1.67/0.471 1.67/0.471
2.33/0.471 2.67/0.47!
2.00/0.2?2
2.4alO.272
2.50/0.333
V5 = Average Ranking
_ean/S.E.M.
3rbit \ Type d
0 2.17/0.204
1 2.25/0.204
2,00/0.333 2.17/0.333
p t
!.42/0.204 2.00/0.204
2.08/0.204
1.86/0.118
2.25/0.204 2. 19/0. 118
2.21/0.144 1.75/0.144 2.13/0.144
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Ausprunk - Transmission Electron Microscopy Data - Pletelets
Samole _ Dewar Orbit=l Type Vl V2 V3 V4 V5
380 45 h 0 d 0 0 4 4 4.0
381 60 h 0 p ] 1 4 3 3.5
382 SO h 0 t l 1 4 3 3.5
383 48 d ! d ] ! 4 3 3.5
384 56 d I t .....
385 6] d ! p 2 0 3 2 2.5
386 62 d 1 p 1 0 4 3 3.5
387 47 h 0 d 0 0 4 4 4.0
388 59 h 0 p t 0 4 3 3.5
389 43 d ! d 0 0 4 4 4.0
390 55 h 0 t 1 0 4 3 3.5
391 54 d I t 2 0 2 I 1.5
392 63 h 0 p 1 0 4 3 3.5
393 53 d ] t ] 0 4 3 3.5
394 44 d l d 0 0 4 4 4.0
395 46 h 0 d 0 0 4 4 4.0
396 58 d 1 p l 0 4 3 3.5
397 5! h 0 t ! 0 4 3 3.5
398 98 h 0 t ! 0 4 3 3.5
399 99 d t t 2 0 4 2 3.0
V! = Pseudopods
0 = no cells
| = occasional cells
2 = half of cells
3 = majority o_ ceils
4 = el I cells
Hean/S.E.M.
Orbit \ Type d p
0 0.00/0.226 ].00/0.22G
..... 1 ,0.3310.226 1.33/0 225
0.17/0.160 1.17/0.]60
orbit p = 0.0400
type p = 0.0003
V2 = Aggregated - same scoring as above
Mean/S.E.M.
t
1.00/0.196
1.67/0 _6
1.29/0.148
Orbit \ Type d p t
0.70/0. 124
1.11 /0.t39
0 0.00/0.231 0.33/0.231
0.33/0.231 0.00/0.231
0.25/0.200 0 _ 2• ,=0/0. I -7
o. oo/o.23 ]
0.]4/0.151
o.1]/0.132
0.17/0.163 0.17/0.163
Page 8
V3 = Degranulated - same scoring as above
Mean/S.E.M.
Orbit \ Type d o t
0 4.00/0.292 4.00/0.292
l 4.00/0.292 . 3.67/0.292
4.00/0.207 3.83/0.207
4.00/0.253
3.33/0.292
3.71/0.191
4.00/0.[60
3.67/0.169
V4 : Swollen or Ruptured Cells - same scoring as above
Mean/S.E.M.
Orbit \ Type d p
0 4.00/0.392 3.02/0.292
! 3.67/0.292 2.67/0.292
3.83/0.207 2.83/0.207
t
3.oo/o.253
2.OOlq.RgR
2.57/0.19l
3.30/0.160
,2.7_/0.169
orbit p : 0.0428
type p : 0.0014
V5 = Average oF V3 and V4
Mean/S.E.M.
Orbit \ Tvme d p t
0 4.00/0.277 3.50/0.277 3.50/0.240
I 3.83/0.277 3.17/0.277 2.67/0.277
3.92/0.!96 3.33/0.196 3.14/0.182
3.65/0.152
3.22/0. 160
type p = 0.0284
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Chao 1
Samole Bag Dewar Orbit=l
580 50 h 0
581 48 d 1
582 56 d 1
583 60 h 0
584 45 h 0
585 61 d 1
586 47 h 0
587 55 h 0
588 62 d I
589 43 d I
590 59 h 0
591 54 d 1
592 53 d 1
593 63 h 0
594 58 d 1
595 46 h 0
596 44 d 1
597 51 h 0
598 99 d 1
599 98 h 0
Vl = Platelet Count x 109/ml
Mean/S.E.M.
OrDit \ Type d
0 1.45/0.018
1 1.47/0.018
1.46/0.013
type p = .0008
Omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d
0 t.45,/0.018
t
d
t
P
d
P
d
t
P
d
P
t
t
P
P
d
d
t
t
t
Vl
1 .45
1 .49
1 .39
1 .42
1 .42
1 .37
1 .43
1 .40
1 .32
I .48
1 .35
! .36
1.35
1 .40
I .41
1.50
1.45
1 .43
1.35
i .41
P
I .39/0.018
1.37/0.018
1.38/0.013
1.42/0.016
1.36/0.016
1.39/0.011
1.42/0.010
1.40/0.010
P
1.39/0.018
t
1.42/0.016 1.42/0.0113
I 1.47/0.018 1.37/0.018 1.35/0.018 1.40/0.010
1.46/0.013 1.38/0.013 1.39/0.012
type p = .0011
Page ]0
Chao 2
Sammle _ Dewar Orbit=! Type Vl
580 50 h 0 t 0.000
58] 48 d ] d 0.000
582 56 d ! t 0.088
583 60 h 0 p 0.000
584 45 h 0 d 0.000
585 6] d ] p 0.000
586 47 h 0 d 0.000
587 55 h 0 t 0.000
588 62 d ! p 0.000
589 43 d ! d 0.000
590 59 h 0 p 0.000
591 54 d 1 t 0.059
592 53 d 1 t 0.000
593 63 h 0 p 0.000
594 58 d l p 0.000
595 46 h 0 d 0.000
596 44 d | d 0.000
597 51 h 0 t 0.000
598 99 d I t 0.007
599 98 h 0 t 0.000
V| = Platelet response to hypotonic Stress (& OD / 2 min)
InsufFicient data to analyse
Paze ll
Chao 3
Samo Ie Bag Dewar Orbit=l
580 50 h 0
581 48 d I
582 56 d I
583 60 h 0
584 45 h 0
585 6] d 1
586 47 h 0
587 55 h 0
588 62 d I
589 43 d I
590 59 h 0
591 54 d l
592 53 d I
593 63 h 0
594 58 d I
595 46 h 0
596 44 d 1
597 51 h 0
598 99 d I
599 98 h 0
Vl : Mean Platelet Volume (urn 3)
t
d
t
P
d
P
d
t
P
d
P
t
t
P
P
d
d
t
t
t
V1
9.1
10.3
7.8
9.5
10.6
9.1
11.3
9.1
9.2
10. I
9.6
8.4
8.6
9.9
9.5
I0.I
10.5
9.2
8.5
9.3
Mean/S.E.M.
Orbit \ Tvoe d P t
0 10.67/0.182
1 10.30/0.182
I0.48/0.129
type p = .0001
orbit p = .0012
Omittfng bag number 56:
MeanlS.E.M.
Orbit \ Tyoe d
0 10.67/0.162
9.67/0.182
9.27/0.182
9.47/0.129
P
9.67/0. 162
1 10.30/0.162 9.27/0.162
10.48/0.115 9.47/0.115
9.1810.158
8.33/0.158
8.75/0.112
9.7710.010
9.18/0.141
8.50/0.162
type p : .0001
orbit p = .0069
8.89/0. I06
9.20/0.010
9.77/0.089
9.36/0.094
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Chao 4
Sample Bao
580 50
581 48
582 56
583 60
58a 45
585 61
586 47
587 55
588 62
589 43
590 59
591 54
592 53
593 63
594 58
595 46
596 44
597 51
598 99
599 98
Vl = Aggregation
@
note "trace"
Dewar Orbit:l Tyme Vl @
h 0 t 6
cl 1 d 0
d I t 75
h 0 p 0
h 0 d 0
d 1 p 20
h 0 d 24
h 0 t 10
d I p 36
d I d 21
h 0 p 0
d 1 t 38
d I t 20
h 0 p 8
d 1 p 0
h 0 d 0
d I cl 0
h 0 t 19
d 1 t 21
h 0 t 0
(by 12.5 ug collagen) _ light
interpreted as 0 For purposes
transmission
o_ analysis
Mean/S.E.M.
Orbit \ Type d p
0 8.00/9.185 2.67/9.185
1 7.00/9.185 18.67/9.185
t
8.75/7.954
38.50/7.954
6.7015.03]
23.1015.03t
7.50/6.495
orbit p = .0370
Omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d
0 8.00/6.731
1 7.00/6.731
10.67/6.495
P
23.63/5.624
t
7.50/4.758
2.67/6.73l
18.67/6.731
10.67/4.758
8.75/5.829
26.33/6.731
16.29/4.406
6.70/3.687
17.33/3.88t4
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:hao 5
;ample Bacj Dewar Orbit=l Type Vl @
580 50 h 0 t 0
581 48 d | d 5
582 56 d 1 t 44
583 60 h 0 p 11
584 45 h 0 d 5
585 61 d 1 p 0
586 47 h 0 d 10
587 55 h 0 t 5
588 62 d 1 p 11
589 43 d 1 d 0
590 59 h 0 p 8
591 54 d l t 45
592 53 d 1 t 9
593 63 h 0 p 0
594 58 d 1 p 0
595 46 h 0 d 0
596 44 d ! d 0
597 5! h 0 t 0
598 99 d ! t 15
599 98 h 0 t ]l
'1 = Aggregation (by 100 uM ADP) % light transmission
@ note "trace" Interpreted as 0 for purposes of analysis
ean/S.E.M.
_rblt \ Type d p
0 5.00/5.709 6.33/5.709
I ].67/5.709 3.67/5.709
3.33/4.037 5.00/4.037
t
4.00/4.944
28.25/4.944
16.13/3.496
5.00/3.127
12.90/3.]27
,mitring bag number 56:
ean/S.E.M.
rbIt \ Type d p
0 5.00/5.159 6.33/5.159
1 1.67/5.|59 3.67/5.159
3.33/3.648 5.00/3.648
t
4.00/4.468
23.00/5.159
12.|4/3.377
5.00/2.826
9.44/2.979
rblt p = 0.0957
ype p = 0.0565
nteractlon p : 0.0299
P._ge 14
Chao 6
Sample B._.__.q Dewar Orbft=l Vl
580 50 h 0 t 0.00
581 48 d i d 0.00
582 56 d I t 2.94
583 60 h 0 p 0.00
584 45 h 0 d 0.00
585 G1 d I p 0.23
586 47 h 0 d 0.00
587 55 h 0 t 0.00
588 62 d 1 p 0.29
589 43 d 1 d 0.00
590 59 h 0 p 0.00
591 54 d 1 t 1.73
592 53 d 1 t 0.17
593 63 h 0 p 0.00
594 58 d 1 p 0.00
595 46 h 0 d 0 . 00
596 44 d 1 d 0.00
597 51 h 0 t 0.00
598 99 d 1 t 0.00
599 98 h 0 t 0.00
Q
_1 = ATP Release (n mol / 10 _ platelets)
ffean/S.E.M.
]rbft \ Type d p
0 0 /0.373 0 /0.373
I 0 /0.373 0.17/0.373
0 /0.264 0.09/0.264
t
O /0.323
1.21/0.323
0.61/0.229
o /o. 2o5
0.54/0.205
3mitting bag number 56:
Mean/S.E.M.
]rbit \ Type d p
0 0 /0.219 0 /0.219 0 /o.189 o /o.12o
! 0 /0.219 0.17/0.219 0.63,/0.219
0 /0.155 0.09/0.155 0.27/0.143
0.27/0.126
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Chao 7
Samole Ba__.q Dewar Orbit:l Type
580 50 h 0 t
58] 48 d ] d
582 56 d I t
583 60 h 0 p
584 45 h 0 d
585 61 d I p
586 47 h 0 d
587 55 h 0 t
588 62 d ! p
589 43 d ] d
590 59 h 0 p
59] 54 d ! t
592 53 d ! t
593 63 h 0 p
594 58 d t p
595 46 h 0 d
596 44 d | d
597 51 h 0 t
598 99 d ! t
599 98 h 0 t
V! = Russell's Viperr Venom Time (sec.)
> 90
> 90
30.62 29.59
> 90
> 90
> 90
> 90
> 90
> 90
> 90
> 90
43.99 43.24
> 9O
> 90
> 90
> 90
> 90
> 90
> 90
> 90
Insufficient data to analyse
Page ]6
Chao 8
Sammle B ae Dewar Orb]t:] T_. V]
580 50 h 0 t 4.7
581 48 d ] d 4.5
582 56 d ] t 57.3
583 60 h 0 p 0.0
584 45 h 0 d 0.0
585 61 d ] p ].9
586 47 h 0 d 0.0
587 55 h 0 t 5.0
588 62 d ] p 0.0
589 43 d l d 6.1
590 59 h 0 P 19.2
591 54 d 1 t 37.9
592 53 d 1 t 0.0
593 63 h 0 p 0.0
594 58 d 1 p |.9
595 46 h 0 d 2.1
596 44 d ! d 3.2
597 5] h 0 t 0.0
598 99 d I t ii.3
599 98 h 0 t 0.0
Vl = Serotonin Uptake % (I0 min. incubation)
Mean/S.E.M.
Orbit \ Type d p
0 0.70/7.385 6.40/7.385
I 4.60/7.385 ].27/7.385
2.65/5.222 3.83/5.222
t
2.43/6.396
26.63/6.396
14.53/4.522
3.10/4.045
12.4[/4.045
Omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d p
0 0.70/5.154 6.a0/5.154
I 4.60/5.]54 1.27/5.15a
2.65/3.645 3.83/3.645
2.43/4.464
]6.40/5_ 154
3.1012.823
7.42/2.976
8.41/3.374
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Chao 9
Sammle _ Dewar Orbit=!. _ V_/1
580 50 h 0 t 0.0
581 48 d l d 0.0
582 56 d 1 t 35.9
583 60 h 0 p 0.0
584 45 h 0 d 0.0
585 61 d ! p 0.0
586 47 h 0 d 0.0
587 55 h 0 t 0.0
588 62 d ! p 0.0
589 43 d 1 d 0.0
590 59 h 0 p 0.0
591 54 d 1 t 29.8
592 53 d ! t 0.0
593 63 h 0 p 0.0
594 58 d 1 p 0.0
595 46 h 0 d 0.0
596 44 d l d 0.0
597 51 h 0 t 0.0
598 99 d l t 0.0
599 98 h 0 t 0.0
Vl = Serotonln Release % (4 min. after stlmulation)
Insufficient data to analyse.
Page 18"
=had |0
5ammle _ Dewar Orbit=l Type
580 50 h 0 t
581 48 d I d
582 56 d I t
583 60 h 0 p
584 45 h 0 d
585 61 d l p
586 47 h 0 d
587 55 h 0 t
588 62 d 1 m
589 43 d ! d
590 59 h 0 p
591 54 d I t
592 53 d I t
593 63 h 0 p
594 58 d 1 p
595 46 h 0 d
596 44 _ I d
597 5! h 0 t
598 99 d I t
599 98 h 0 t
Jl = 8 - Thromboglobulin (Ug / ml)
_ean/S.E.M.
V!
62.32
53.93
36.96
57.87
65.3L
40.78
74.87
59.51
42.98
55.07
43.62
35.04
49.27
52.70
50.46
48.58
82.80
42.65
48.28
49.32
]rbit \ Type d p t
0 62.92/5.894 5].40/5.894
I 63.93/5.894 44.74/5.894
63,43/4.168 48.07/4.168
type p : .0257
3mitting bag number
Mean/S.E.M.
56:
3rbit \ Type d
53.45/5.104
42.39/5.104
47.92/3.609
55.68/3.228
49.56/3.228
t
0 62.92/6.033 51.40/6.033 53.45/5.225 55.68/3.305
1 63.93/6.033 44.74/6.033 44.2016.033 50.9_A/3.483
63.43/4.266
tyDe P : .0434
48.07/4.266 49.48/3.950
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Chao 1!
Sample _ Dewar Orbit=! Type Vl @
580 50 h 0 t 5.2
581 48 d ! d 4.0
582 56 d I t 1.3
583 60 h 0 p 7.4
584 45 h 0 d 16.8
585 61 0 ] p 25.0
586 47 h 0 d 12.0
587 55 h 0 t 5.3
588 62 d I p 1.5
589 43 d I d 2.0
590 59 h 0 p 5.2
59l 54 d l t 1.6
592 53 d I t I.I
593 63 h 0 p 8.0
594 58 d 1 p 1.8
595 46 h 0 d 20.0
596 44 d I d 25.0
597 51 h 0 t 20.0
598 99 d ! t 1.4
599 98 h 0 t 6.8
Vl@: Thromboxane 8
Note "> 20" interpreted as 25 For purposes oF analysis
Mean/S.E.M.
Orbit \ Type d p t
0 16.27/4.574 6.87/4.574 9.33/3.961 I O. 67/2 . 505
! 10.33/4.574 9.43/4.574 ].35/3.96!
13.30/3.234 8.15/3.234 5.34/2.801
Omitting bag number 56:
Mean/S.E.M.
Orbft \ Tvoe d p t
0 16.27/4.746 6.87/4.746 9.33/4.111
l 10.33/4.746 9.43/4.746 1.37/4.746
13.30/3.356 8.15/3.356 5.91/3.107
6.47/2.5 im
10 67/_ 600
. z..
7.04/2.7All
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Chao ]2
Sample Bag Dewar Orbft:l _ Vl
580 50 h 0 t 22.!
581 48 d I d 22.2
582 56 d ! t 16.7
583 60 h 0 p 21.7
584 45 h 0 d 23.9
585 61 d 1 p 21.3
586 47 h 0 d 24.0
587 55 h 0 t 23.1
588 62 d ] p 23.4
589 43 d ] d 24.4
590 59 h 0 p 23.3
591 54 d I t 19.0
592 53 d ! t 20.8
593 63 h 0 p 24.0
594 58 d l p 23.7
595 46 h 0 d 24.8
596 44 d l d 22.3
597 51 h 0 t 24.7
598 99 d 1 t 23.2
599 98 h 0 t 24.4
Vi = Lactate (mM)
Mean/S.E.M.
Orbit \ Type d p t
0 24.23/0.937 23.00/0.937 23.58/0.811
l 22.97/0.£37 22.80/0.937 19.93/0.811
23.60/0.663 22.90/0.663 21.75/0.574
orbit p = 0.0203
Omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d p t
23,60/0.513
2].70/0.513
0 24.23/0.768
I 22.97/0.768
23.60/0.543
23.00/0.768 23.58/0.665 23,60/0.42]
22.80/0.768 21.00/0.7G8 22.26/0.443
22.90/0.543 22.47/0.503
orbit p = 0.0465
Page 21
Chao 13
Samole Ba____o Dewar Orblt=l _ VI
580 50 h 0 t 38
581 48 d I d 23
582 56 d I t 141
583 60 h 0 p 47
584 45 h 0 d 33
585 61 d I p 24
586 47 h 0 d 38
587 55 h 0 t 22
588 62 d I p 26
589 43 d ] d 20
590 59 h 0 p 28
591 54 d } t 86
592 53 d l t 22
593 63 h 0 p 23
594 58 d I p 14
595 46 h 0 d 25
596 44 d I d 21
597 51 h 0 t 20
598 99 d ! t 18
599 98 h 0 t 25
Vl = Glucose (mg / 100 ml)
Mean/S.E.M.
Orbit \ Type d m t
32.00/16.149 32.67/16.149
! , . 21.33/16.149
26.67/II.419
21.33/16.149
27.00/II.419
Omitting bag number 56:
Mean/S.E.M.
26.25/13.986 29.90/8.845
66.75/13.986
46.50/9.889
Orbit \ Tree d p t
39.50/8.845
0 32.00/9.611 32.67/9.611 26.25/8.324 29.90/5.264
1 21.33/9.611 21 .33/9.611 4 _.00/9.611 28.___/5._4°
• • . Q_26 67/6 796 27.00/6.796 33.00/6 2_
Page _°°
Curby l - Red Cells Stress Test
Sample Ba_g Dewar Orbit:i _ Vl V2 V_33
401 17 b 1 p 27.400
402 I g 0 d 133.000
403 13 e 0 t 332.200
404 19 £ 0 p 248.200
405 14 c 1 t ]84.600
406 6 a 1 d 0.000
407 8 b 1 t 149.600
408 2 £ 0 d 140.400
409 20 a ] p 75.600
410 9 g 0 t 148.000
411 3 c l d 268.600
412 15 e 0 p 0.000
413 ll £ 0 t 112.800
414 4 e 0 d 8.199
415 10 a 1 t I41.200
416 16 g 0 p 256.000
417 21 c 1 p 163.200
418 5 b 1 d 65.200
Vl = Loss at 20 min., count/ml x 10 6
14.810 22
58.620 23
204.700 23
123.100 16
104.000 22
0.000 18
91.770 24
92.630 30
42.100 21
108.600 22
173.300 23
0.000 28
60.390 23
5.827 23
90.080 12
26.070 20
58.180 23
45.020 27
Mean/S.E.M.
3rbft \ Tyoe d
0 93.87/60.323
I 111.27/60.323
102.57/42.655
P
168.07/60.323
88.73/60.323
128.40/42.655
V2 = Oversized Particle Loss at 20 min.,
t
197.67/60.323 153.20/34.B2£
158.47/60.323 119.49/34.828
178.07/42.655
4
count/ml x 10
Mean/S.E.M.
Orbit \ Tyme d p
0 52.36/33,452 49.72/33.452
l 72.77/33.452 38.36/33.452
62.57/23.654 44.04/23.654
t
124.56t33.452
95.28/33.452
1o9.92/23.654
75.55,/19.3t4
68.81/19.314
V3 = Peak Chamnel Sh_Ft at 20 min.
'lean/S. E. M.
Drbit \ Type d p
0 25.3312.546 21.33/2.546
1 22.67/2._46 22.00/2.546
24.00/1.800 2].67/].800
t
"_ 67/o 546
19.33/2.546
23.11/1.470
21.3311.470
21.00/1.800
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Curby 2 - White Cell Distribution
Sample Baq Dewa____q Orbit=l Type V! V2 V3 V4
44I 24 f 0 d
442 35 b 1 t
443 31 g 0 t
444 22 a 1 d
445 40 e 0 p
446 39 c 1 p
447 29 a I t
448 25 g 0 d
449 32 e 0 t
450 38 f 0 p
451 41 b 1 p
452 23 c l d
453 33 f 0 t
454 36 g 0 p
455 28 e 0 d
456 26 b I d
457 34 c I t
458 37 a l p
7
V! = 1 - 254 count/ml x 10
3.688 9.588 9(3 0.225
3.802 10.670 94 1.010
2.312 10.100 95 1.041
2.558 9.372 96 0.936
5.807 18.630 II0 0.635
3.964 11.080 lO0 0.712
6.086 15.600 105 1.064
4.080 10.500 89 0.991
7.678 20.800 104 0.779
3.263 9.108 98 0.514
2.877 7.132 90 0.372
2.624 9.736 87 0.806
4.606 II.500 95 0.724
3.421 10.240 94 1.040
7.360 20.440 89 0.785
2.976 10.350 89 1.I07
4.126 10.070 90 1.060
6.831 22.390 99 0.726
Mean/S.E.M.
Orbit \ Type d p t
0 5.04/I.030 4.16/1.030
l 2.72/1.030 4.56/1.030
3.88/0.728 4.36/0.728
6
V2 = > 254 , count m} x 10
4.87/1.030 4.69/0.595
4.67/1.030 3.98/0.595
4.77/0.728
Mean/S.E.M.
Orbit \ Tvoe d p t
0 13.51/3.067 12.6613.067 14.13/3.067 13.43/1.771
1 9.82/3.067 13.53/3.067 12.11/3.067 11.82/1.771
11.66/2.168 13.10/2.168 13.12/2.168
V3 = Peak Channel
Mean/S.E.M.
Orbit \ Type d p
0 89.33/3.413 100.67/3.413
1 90.67,/3.413 96.33/3.4]3
90.00/2.413 98.50/2.4[3
t
q8.00/3.413
96.33/3.413
97.17/2.413
96.0011.970
94.4411.9_0
V4 = Delay Factor - not analysed
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Curby 3 - Platelets Cell Distribution
Sammle Ba_ Dewar Orbit:l _ Vl V2 V__3 V4
481 50 h 0 t 1.249 3.4 12 5.215
482 48 d I d 1.632 4.6 12 7.512
483 61 d 1 p 1.465 6.4 12 6.978
484 60 h 0 p 1.027 5.6 14 7.764
485 45 h 0 d 1.306 6.0 14 7.055
486 43 d 1 d 1.699 6.8 15 7.372
487 55 h 0 t 2.258 6.4 15 1.475
488 47 h 0 d 2.406 3.4 23 1.541
489 62 d 1 p 1.161 2.8 13 6.295
490 59 h 0 p 1.645 7.8 14 6.338
491 54 d I t 1.496 6.8 14 6.663
492 58 d 1 p 1.411 6.2 14 2.588
493 51 h 0 t 1.428 10.2 13 6.590
494 46 h 0 d 1.663 7.2 14 6.700
495 53 d i t 1.279 5.2 14 7.435
496 44 d 1 d 1.483 7.8 12 6.211
497 63 h 0 P 1.280 5.6 12 6.997
498 98 h 0 t 1.654 6.8 12 6.691
499 99 d I t 1.524 9.2 12 5.813
9
VI = I - 254 count/ml x I0
Mean/S.E.M.
Orbit \ Type d p t
0 1.79/0.197 1.32/0.197 1.65/0.171
I 1.60/0.197 1.35/0.197 I 43/0.197
1.70/0.139 1.33/0.139 1.56/0.129
V2 = > 254 , count/ml x I0
1.59/0.1oe
1.46/0.144
Mean/S.E.M.
Orbit \ Type d m t
0 .... 5.53/1.195 6.33/1.195 6.70/1.035
1 6.40/1.195 5.13/1.195 7.07/1.195
5.97/0.845 5.73/0.845 6.86/0.782
V3 = Peak Channel
Mean/S.E.M.
Orbit \ Type d
0 17.00/1.371
1 13.00ZI.371
15.00/0.970
p t
6.24,/0.654
6.20/0.690
13.33/1.371
13..00/1.37l
13.17/0.970
13.00/l.188
13.33/1.371
13.14/0.898
14.3010.751
13. 1 t /'1.792
V4 = Detay Factor - not an,31ysed
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Curby 4 - Red Cel}s Cell Distribution
Samole Ba____a Dewar Orbit=l Type V]
401 17 b I p 3.388
402 1 g 0 d 3.871
403 13 e 0 t 3.446
404 19 f 0 p 4.324
405 14 c 1 t 3.435
406 6 a l d 3.898
407 8 b 1 t 3.534
408 2 f 0 d 3.109
409 20 a 1 p 3.249
410 9 g 0 t 3.295
411 3 c 1 d 3,737
412 15 e 0 p 3.906
413 11 _ 0 t 3.468
414 4 e 0 d 3.361
415 10 a 1 t 3,421
416 16 g 0 p 3.552
417 21 c 1 p 3.839
418 5 b 1 d 3.]52
9
Vl : 1 - 254 count/m1 x 10
Mean/S.E.M.
Orbit \ Type d p
0 3.45/0.177 . 3.93/0.177
1 3.60/0.177 3.49/0.177
V2
7.84
]4.02
12.66
67.62
14.26
13.46
14.56
21.06
10.76
16.88
21.64
18.58
12.90
8.74
10.28
10.52
10.80
4.58
v_A
110
108
106
140
106
106
110
112
105
I10
112
111
108
108
I00
106
108
100
V4
1.564
0.491
1.315
1.735
1.331
1.271
1.257
1.633
1.377
1.357
1.552
1.346
1.321
1.374
1.339
1.321
1.539
1.642
t
3.40/0.177
3.46/0.177
3.59/0.102
3.52/0.102
V2 = > 254
Mean/S.E.M.
Orbit \ Tvoe
3.52/0.125 3.71/0.125
7
, count/ml x i0
d m
3.43/0.125
t
0 I4.61/7.747 32.24/7.747 14.15/7.747 20.33/4.g73
1 13.2.2,/7.747 9.80/7.747 13.03/7.747
13.92/5.478 21.02/5.478 13.59/5.478
V3 : Peak Channel
Mean/S.E.M.
Orbit \ Type d P
12. (12,/4. 477
t
0 109.33/0.177 119.00/0.177 108.00/0.177
1 lO_.O0/O. 177 107.67/0.177 105.33/0.177
107.67/0.125 113.33/0.125 106.67/0.125
112. 11,/0. 102
106.33,',3. 102
V4 : Delay Factor - not analysed
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Jacobson I - White Blood Ceils
Samole Bacj Dewar Orbit=l Type Vl V2 V3
871 22 a 1 d 6.945
872 35 b I t 7.073
873 3] g 0 t 7.092
874 24 £ 0 d 6.965
875 39 c 1 p 7.051
876 40 e 0 p 7.093
877 25 g 0 d 6.931
878 32 e 0 t 7.]01
879 29 a 1 t 7.087
880 38 f 0 p 7.052
881 41 b 1 p 7.095
882 23 c ! d 6.893
883 37 a I p 7.03l
884 28 e 0 d 6.907
885 34 c I t 7.079
886 33 f 0 t 7.067
887 36 g 0 p 7.039
888 26 b ] d 6.930
42.2
25.5
23.9
38.7
27.9
24.9
41.5
22.0
24.5
24.5
24.6
44.5
28.8
42.2
25.5
23.8
26.5
42.4
228.1
263.7
259.4
220.5
259.1
255.3
220.5
263.4
252.6
269.9
236.5
226.6
261.5
225.5
259.0
248.0
253.2
240.7
Vl = pH
Mean/S.E.M.
Orbit \ Type d p t
0 6.93/0.0] 5 7.06/0.015 7.09/0.015
I 6.92/0.0]5 7.06/0.015 7.08/0.0]5
6.93/0.0|0 7.06/0.010 7.08/0.010
7.03/0.00_
7.02/0.00£
type p = 0.0001
V2 = PCO 2 - mm Hg
Me_n/S.E.M.
Orbit \
0
Type d p t
a0.00/0.835 25.30/0.835 23.23/0.835
43.03/0.835 27.10/0.835 25.17/0.835
41.92/0.590 26.20/0.590 24.20/0,590
29.77/0. _
31.77/0.4_2
type p = 0.000!
orbit p = 0.0]29
Pmge 27"
V3 = PO 2 - mm Hg
Mean/S.E.M.
Orbit \ Type d p
0 222.17/_.923 259.47/4.923
1 231.00/4.923 252.37/4.923
226.98/3.481 255.92/3.48I
t
256.93/4.923 2a6.]9/2._42
258.43/4.923 247.53/2.£42
257.68/3.48!
type p = 0.0001
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Jacobson 2 - Red Blood Cells
Sample B_@_q Dew3r Orbit=] Tv2ee
161 13 e 0 t
162 17 b 1 p
163 19 f 0 p
164 l g 0 d
165 6 a 1 d
166 14 c 1 t
167 3 c l d
168 9 g 0 t
169 8 b 1 t
170 2 F 0 d
171 15 e 0 p
172 20 a 1 p
173 4 e 0 d
174 16 g 0 p
175 5 b 1 d
176 11 f 0 t
177 21 c 1 p
178 I0 a 1 t
Vl = pH
Mean/S.E.M.
Vl
6.763
6.707
6.743
6.711
6.738
6.730
6.672
6.747
6.766
6.710
6.740
6.712
6.744
6.758
6.695
6.767
6.728
6.742
V2
134.5
133.8
155.2
149.4
133.9
169.8
128.2
129.0
157.5
134.3
143.4
145.8
132.1
161.2
126.0
143.5
134.1
Orbit \ Type d p t
0 6.72/0.011 6.75/0.QI[ 6.76/0.011
V3
52.4
49.9
50.1
37.0
36.6
48.2
34.1
48.8
49.8
36.4
45.8
51 .0
35.7
51.5
35.9
47.8
46.2
47.6
6.74/0.006
1 6.70/9.611 6.72/9.611 6.75/9.611
6.71/0.008 6.73/0.008 6.75/0.008
type p = 0.0099
orbit p : 0.0336
V2 = PCO 2 - mm Hg
Mean/S.E.M.
Orbit \ Type d p t
0 152.83/3.243 133.40/3.243 125.43/3.243
! 160.13/3.243 140.47/3.2a3 132.33/3.243
156.48/2.293 136.93/2.293
type p : 0.0001
orbit p : 0.0201
6.72/0.006
128.88/2.293
137.22/1.872
144.31/1.872
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V3 : PO 2 - mm Hg
Mean/S.E.M.
Orbit \ Type d
0 ..... 36.37/I.164
! 3B.53/I.164
35.95/0.823
P
49. 1311. 164
49.03/1.164
49.08/0.823
t
49.67/I.164
48.53/1.164
49.10/0.823
45.06/0.672
44.37/0.672
type p : 0.000!
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Jacobson 3 - Platelets
Sammle Ba_ Dewar Orbit=l Tvoe Vl V2 V3
140 61 d l p 5.811 20.3 170.7
I41 48 d 1 d 5.663 10.8 185.2
142 50 h 0 t 5.833 7.3 221.9
143 56 d ] t 6.544 22.6 ]86.9
I44 60 h 0 p 5.880 11.5 202.1
145 45 h 0 d 5.712 9.2 195.3
146 54 d 1 t 6.237 29.9 145.5
147 55 h 0 t 5.748 7.2 201.4
148 43 d l d 5.659 8.7 194.2
|49 47 h 0 d 5.734 8.9 207.6
150 62 d 1 p 5.814 18.3 189.1
15] 59 h 0 p 5.826 8.0 214.2
152 51 h 0 t 5.732 6.8 21].0
153 63 h 0 p 5.722 6.4 206.8
154 58 d 1 p 5.729 10.6 203.4
155 44 d l d 5.662 10.8 184.8
156 53 d ] t 5.781 12.1 191.6
157 46 h 0 d 5.680 8.6 203.5
158 99 d I t 5.763 12.5 189.7
159 98 h 0 t 5.753 6.5 205.0
Vl : pH
Mean/S.E.M.
Orbit \ Type d p t
0 5.71/0.104 5.81/0.104 5.77/0.090 5.76/0.057
1 5.66/0.104 5.78/0. 104 6.08/0.090 5.87/0.0E7
5.69/0.074 5.80/0.074 5.92/0.064
omitting bag number 56:
Mean/S.E.M.
Orbit \ TvDe d p t
0 5.71/0.066 5.81/0.066 5.77/0.QE7 5.76/0.03A
I 5.66/0.066 5.78/0.066 5.93/0.066 5.79/0.078
5.80/0.047 5.84/0.0435.69/0.047
V2 = PCO 2 - mm Hg
Mean/S.E.M.
Orbit \ Tyoe d p t
0 8.90/2.632 8.63/2.632 6.95/2.279 8.0a/l.a43
1 10.10/2.632 16.40/2.632 19.28/2.279 15.6G'].4J3
9.5011.861 12.52/I.86t 13.11/1.612
. N _orbit p : 0 0._L
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omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d p t
0 8.90/2,661 8.63/2,661 6.95/2,305
I I0.I0/2,661 16.40/2.66i I8. 17/2.279
8,04/].458
14.89/[.53(_
9.50/1.882
orbit p = 0.0065
V3 = PO 2 - mm Hg
12.52/1.882
Mean/S.E.M.
Orbit \ Type d p
0 202.13/7.630 207.7.0/7.630
I 188.07/7.63.0 187.73/7.630
195.10/5,395 197.72/5.395
orbit p : 0.0018
omitting bag number 56:
Mean/S.E.M.
1t.76/1.742
t
209.83/6.607 206.88/4.179
178.42/6.607 18a.11/4. ]79
194.13/4.672
Orbit \ Tyoe d p t
0 202.13/7.76] 207.70/7.762 209.83/6.72]
l 188.07/7.76]
195.10/5.488
187.73/7,761
197.72/5.488
") I'_. °_0. 88/4 25]
175.60/7.761
195.16/5.081
183._0/4.48i
orbit p : 0.0025
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dacobson 4
Sample Ba_ Dewar Orbit:l Tvoe
81 13 e 0
82 1 g 0
B3 6 a !
84 19 g 0
B5 17 b !
86 14 c I
87 8 b I
88 15 e 0
89 9 g 0
90 3 c I
91 20 a I
92 2 F 0
93 5 b 1
94 10 a 1
95 21 c 1
96 16 g 0
97 II g 0
98 4 e 0
Vl = Plasma Hemoglobin mg/dl
Mean/S.E.M.
Orb(t \ Type d p
0 8.00/0.892 8.67/0.892
I 8.33/0.892 8.33/0.892
8.I7/0.631 8.50/0.631
Vl
t I0.0
0 7.0
d 7.0
p 8.0
p 7.0
t 10.0
t I0.0
p 8.0
t IO.O
d 8.0
p 8.O
d I0.0
d 10.0
t 14.0
p I0.0
p lO.O
t i0.0
d 7.0
t
10.00/0.892 8.89/0.515
II.33/0.892 9.33/0.515
10.67/0.631
type p = 0.0324
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dacobson 5 - Red Blood Cells
Samole _ Dewar Orbit=l Type V___l V2 V3 V4 V5
61 1 g 0 d 4.1 3.1 306.7
62 14 c l t 3.8 1.8 310.7
63 6 a l d 4.2 3.1 323.5
64 19 f 0 p 3.8 3.1 308.0
65 13 e 0 t 3.8 3.8 304.5
66 17 b 1 p 3.8 2.5 313.5
67 3 c I d 3.8 3. I 312.7
68 2 F 0 d 3.8 4.9 298.0
69 20 a 1 p 3.8 3.8 304.7
70 8 b I t 3.5 I .9 307.0
71 13 e 0 t 3.8 2.5 302.0
72 15 e 0 p 3.5 4.4 300.0
73 16 g 0 p 3.8 1.9 302.0
74 5 b I d 3.8 2.5 298.7
75 I0 a 1 t 3.8 3.8 305.0
76 II f 0 t 3.4 1.9 321.3
77 4 e 0 d 4.2 3.1 337.0
78 2I c 1 p 4.2 3.1 317.0
38.6
38.2
38.5
38.3
38.5
38.4
38.1
38.6
38.3
38.0
38.5
38.5
38.2
38.5
38.2
38.2
38.1
38.2
Iii.0
Iii.0
112.0
112.0
I12.0
I12.0
112.0
112.0
112.0
lll.O
112.0
112.0
111.0
1t2.0
III.0
III.0
I12.0
III.0
Vl = ATP umoles / gm hgb
Mean/S.E.M.
Orbit \ Type d p t
0 4.03/0.121 3.70/0.121 3.67/0.121
I 3.93/0.121 I 3.93/0.121 3.70/0.121
3.98/0.086 3.82/0.086 3.68/0.086
3.80/0.070
3.86/0.070
V2 : 2,3DPG umoles / gm hgb
Mean/S.E.M.
Orbit \ Type d p t
0 3.70/0.548 3.1310.548 2.73/0.548
l 2.90/0.548 3.13/0.5a8 2.50/0.5a8
3.30/0.387 3.13/0.387 2.62/0.387
3.1910.316
2.84./0.3]6
V3 : Glucose mg/dl
Mean/S.E.M.
Orbit \ Tyoe d p
0 313.90/6.aSa 303.33/6.454
l 311.63/6.454 311.73/6.454
312.77/4.564 307.53/4.564
309.27/6.454
307.57/6.454
308.42/4.564
308.83/3.72_
• 310.31/3.726
(Continued next page)
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Va = Potassium mlq/l_ter
Mean/S.E.M.
Orbit \ Type d p t
0 38.43/0.109 3B.33/0.I09 38.40/0.109
| 38.37/0.I09 38.39/0.109 38.13/0.I09
38.40/0.077 3B.32/0.077 38.27/0.077
V5 = 5odium m]q/]_ter
Mean/S.E.M.
Orbit \,Type d p t
38.39/0.063
38.27/0.063
0 Iii.67/0.272 111.67/0.272
112.00/0.272 111.67/0.272
!11.67/0.272 IlI.67/0. 157
t11.00/0.272 III.5A/O. 157
111.83/0.192 111.67/0.192 111.33/0.192
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Jacobson 6 - Red Blood Cells
Sampl e Bacj Dewar Orblt:l _ Vl V2 V3
81 13 e 0 t 10.0
82 I g 0 d 7.0
83 6 a I d 7.0
B4 19 f 0 D B.O
85 17 b I p 7.0
86 14 c I t 10.0
87 8 b I t I0.0
88 15 e 0 p 8.0
89 9 g 0 t I0.0
90 3 c 1 d 8.0
91 20 a 1 p 8.0
92 2 £ 0 d 10.0
93 5 b I d I0.0
94 lO a l t 14.0
95 21 c I p I0.0
96 16 g 0 p I0.0
97 I l _ 0 t I0.0
98 4 e 0 d 7.0
12.0
II.7
12.7
11.7
12.2
11.8
12.8
11.8
II.8
12.1
12.0
11.7
ii.9
12.3
12.6
12.5
12.6
12.5
167.0
167.0
168.0
167.0
168.0
169.0
166.5
168.0
169.0
168.0
169.0
169.0
169.0
168.0
168.0
169.0
169.0
169.0
Vl = Plasma Hemoglobin rags 7.
Mean/S.E.M.
Orbit \ Type d p t
0 8,00/0.892 8.67/0.892 10,00/0,892
l 8.33/0.892 8.33/0,892 II.33/0.892
8.17/0.631 B.50/0,631 I0.67/0.631
8.8910,515
9.3310.515
type p = 0.0324
V2 = Plasma Potassium mlq/liter
MeBn/S.E.M.
Orbit X Type d _ t
0 11.97/0.246 12.00/0.246
l 12.23/0.246 12.27/0.246
12.10/0.174 12.13/0.174
V3 = Plasma Sodium mlqlliter
MeanlS.E.M.
Orbit \ Tyoe d
0 168.33/0.573
1 168.33/0.573
168.33/0.405
12.13/0.246
12.30/0.246
12.22/0.174
12.0310.142
12.2710.142
P
168.o0/0.573
168.3310.573
168.1710.405
t
168.33/0.573 168.22/0.331
167.83/0.573 168.17/0.331
168.08/0.405
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Jacobson 13 Red Cells Phospholipids and Cholesterol
Sample
21 14
22 17
23 6
24 13
25 1
26 19
27 3
28 15
29 8
30 9
31 20
32 2
33 4
34 16
35 11
36 I0
37 21
38 5
Vl = PhospholiDids
Dewar Orbit:l T_y_p_e Vl V2
c 1 t lost lost
b 1 p 21.84 11.99
a 1 d 21.20 11.65
e 0 t 22.01 11.72
g 0 d 22.25 10.99
g 0 p 22.46 10.97
c 1 d 21.43 10.94
e 0 p 23.42 13.82
b 1 t 23.05 13.16
g 0 t 22.40 12.65
a I p 21.87 12.38
£ 0 d 24.45 12.83
e 0 d 23.17 13.32
g 0 p 26.09 13.32
f 0 t 24.43 11.51
a I t 26.68 12.04
c I p 21.00 12.21
b 1 d 21.96 11.02
_gP/]0 8 cells
Mean/S.E.M.
Orbit \ Type d p t
0 23.29/0.784 23.99/0.784 22.95/0.784
I 21.53/0.784 21.57/0.784 24.87/0.960
22.41/0.554 22.79/0.554 23.71/0.607
V2 = Cholesterol ug /
8
i0 cel Is
23.41/0.453
22.38/0.480
Mean/S.E.M.
Orbit \ Type d
0 12.38/0.533
1 11.20/0.533
II.79/0.377
P
12.70/0.533
12.19/0.533
12.45/0.377
t
11.96/0.533
12.60/0.653
12.22/0.413
12.35/0. 308
11.92/0.327
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Jacobson 14 Plasma Phospholipids and Cholesterol
Sample Baa
1 13
2 17
3 19
4 I
5 6
6 14
7 3
8 9
9 8
10 2
11 15
12 20
13 4
14 16
15 5
16 11
17 21
18 10
Dewar Orbit:l Type Vl V2
e 0 t 1. 18 1 .48
b I p 1. 19 1 .45
£ 0 p 1 .27 I .43
g 0 d 1 .22 I .37
a I cl 1 .24 1 .46
c 1 t 1 .20 1 .42
c 1 d 1.20 1 .45
g 0 t I .20 1.51
b 1 t 1.19 1.51
£ 0 d 1.25 I .52
e 0 p 1.37 ! .34
a 1 p 1.50 1.36
e 0 d I .45 I .31
g 0 p 1 .33 1. 19
b 1 d I .27 I .31
0 t i .36 1 .43
c I p I. 19 I .23
a 1 t 1 .33 1 .31
8
ugP/lO cellsVl = Phosphollpids
Mean/S.E.M.
Orb]t\ Type d
0 1.31/0.061
P
I .32/0.061
t
I .25/0.061
V2
1.29/0.035
1 1.24/0.061 1.29/0.061 1.24/0.061 !.26/0.035
1.27/0.043
= Cholesterol _g / lO
1.31/0.043
8
cells
1.24/0.043
Mean/S.E.M.
Orbit
0
\ Tyoe d
1.40/0.056
l 1.4l/0.056
1.40/0.040
P
1.32/0.056
1.35/0.056
t
1.47/0.056
1.41/0.056
l. 40/0. O23
1.39/0.022
1.33/0.040 1.44/0.040
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Jacobson 15 Plasticizer DEHP
Sammle _ Dewar Orbft:l Type
4 1 g 0 d
5 6 a 1 d
7 3 c 1 d
10 2 f 0 d
13 4 e 0 d
15 5 b 1 d
V1
4.65
4.30
4.45
4.25
4.90
4.85
Vl = Plasticizer mg/lOOml plasma
Mean (Standard Error o£ the Mean)
Orbit
0 : 4.60 (.177) 1 : 4.53 (.177)
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Kenney 1 Surface Proteins - P]ate]ets
Sample _ Dewar Orbit=l
500 50 h 0
501 60 h 0
502 56 d i
503 61 d l
504 48 d I
505 45 h 0
506 59 h 0
507 43 d 1
508 54 d 1
509 62 d 1
510 47 h 0
511 55 h 0
Vl : 125I - Membrane Proteins
Type V__2 V__2 V__3
t 5.8 5.8 5.9
p 5.5 5.7 6.0
t 2.2 3.2 2.7
p 3.5 2.0 2.9
d 10.8 10.1 9.9
d 10.8 9.8 11.0
p 8.5 9.4 9.4
d 10.3 10.1 9.5
t 1.0 1.0 1.5
p 4.5 3.8 3.0
d 7.7]0.0 9.9
t 7.3 6.7 6.3
Mean/S.E.M.
Orbit \ Type d p
0 9.25/1.419 .7.00/!.419
! 10.55/1.419 4.00/I.419
9.90/1.004 5.50/1.004
t
6.55/1.419
1.60/1.419
4.07/1.004
7.60/0.819
5.38/0.8!9
type p = 0.0085
omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d p t
0 9.25,/1.051 7.00/1.051 6.55/1.051
1 10.55/].051 4.00/1.051 1.00/1.487
9.90/0.743 5.50/0.743 4.70/0.858
7.60/0.607
6.02/0. 665
type p = 0.0088
V2 = 3H - Membrane Glycoproteins
Mean/S.E.M.
Orbit \ Type d p t
0 9.90/1.263 7.55/1.263 6.25/1.263
1 10.10/1.263 2.90/1.263 2.10/1.263
10.00/0.893 5.23/0.893 4.17/0.893
7.90/0.729
5.03/0.739
type p = 0.0038
orbit p = 0.0240
omitting bag
Mean/S.E.M.
Orbit \ Type
0
I
number 56:
d
9.90/0.943
I0.]0/0.9a3
10.00/0.667
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P t
type p : 0.0038
orbit p : 0.0270
7.55/0.943
2.90/0.943
5.23/0,667
6.25/0.943
].00/1.333
4.50/0.770
7.90/0.544
5.40/0.596
V3 = Cytoskeleton
Mean/S.E.M.
Orbit \ Type d p t
0 10.45/1.0t0 7.70/1.010 6.10/1.010
I 9.70/1.010 2.95/].010 2.IO/l.OlO
|0.08/0.7|4 5.33/0.714 4. 10/0.7]4
8.08/0.583
4.92/0.5_3
type p = 0.0008
orbit p = 0.0049
omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d P t
0 I0.45/0.809 7.70/0.809 6. I0/0.809 8.08/0.467
1 9.70/0.809 2.95/0.809 1.50,/1.145 5.36/0.512
!0.08/0.572
type p = 0.0019
orbit p = 0.01|!
5.33/0.572 4.57/0.661
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Kevy I - Red Cell Osmotic Fragility
Sammle Bag Dewar Orbit=! Type Vl V2 V3
121 19 f 0 p 2.85
122 14 c I t 2.94
123 13 e 0 t 1.40
124 17 b I p 2.63
125 I g 0 d 2.85
126 6 a ] d 4.34
127 2 _ 0 d 2.94
]28 9 g 0 t 4.34
129 3 c I d 2.85
130 8 b l t 4.41
131 15 e 0 p 1.47
132 20 a I p 1.47
133 10 a 1 t 8.57
134 5 b 1 d 6.84
135 16 g 0 p 2.89
136 4 e 0 d 0.59
137 21 c 1 p 1.49
138 11 f 0 t 1.21
7.14
7.35
5.63
7.89
8.57
7.24
4.41
7.24
7.14
7.35
8.23
4.41
10.00
10.95
7.24
5.97
2.98
1.51
27.14
26.47
22.53
28.94
31.42
27.53
35.29
28.98
34.28
32.35
36.76
32.35
45.71
38.35
36.23
32.83
29.85
28.78
Vl = Percent Hemolysis, 0.6% Saline
Mean/S.E.M.
Orbit \ Type d p t
0 2.13/1.015 2.40/1.015 2.32/I.015
l 4.68/1.015 1.86/1.015 5.31/1.015
3.40/0.718 2.13/0.718 3.81/0.718
2.28/0.586
3.95/0.586
V2 : Percent Hemolysis, 0.55% Saline
Mean/S.E.M.
Orbit \ Type d p
0 6.32/1.22a 7.54/1.224
1 8.44/1.224 5.09/1.224
7.38/0.865 6.32/0.865
4.79/I . 2_4
8.2,3/1.224
6.51/0.865
6.22/0.70,_
7.26/0.70_
V3 : Percent Hemolysis, 0.5% Saline
Mean/S.E.M.
Orbit \ Type d p t
0 33.18/3.133 33.38/3.133 26.76/3.133
I 33.39/3.133 30.38/3.133 34.8.4/3.133
33.28/2.216 31.88/2.216 30.80/2.216
31.11/1.809
32.87/l.809
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Lionetti 1 - White Ceils Recovery and Viability
Sample Baq Dewar Orbit=] Type Vl V2 v_ 3
801 22 a I d 9.7 52.9 89
802 35 b I t 12.1 66.0 83
803 31 g 0 t 9.3 50.7 84
804 24 f 0 d 8.3 45.3 82
805 39 c I p II.8 64.4 90
806 40 e 0 p 9.1 49.6 93
807 25 g 0 d 13.6 74.2 12
808 32 e 0 t 11.0 60.0 79
809 29 a 1 t 10.6 57.8 85
810 38 f 0 p 11.3 61.6 89
811 41 b 1 p 8.0 43.6 77
812 23 c I d 12.3 67.1 88
813 37 a I p 10.7 58.4 80
814 28 e 0 d 12.4 67.7 67
815 33 _ 0 t 11.9 64.9 77
816 34 c 1 t 11.3 61.6 56
817 36 g 0 p 12.8 69.8 78
818 26 b I d 9.6 52.4 73
Vl = count x 10 6 ceils / mI - not analysed
V2 = % recovery
Mean/S.E.M.
Orbit \ Type d p t
0 62.40/5.707 60.33/5.707 58.53/5.707 60.42/3._.5
I 57.47/5.707 55.47/5.707
59.93/4.035 57.90/4.035
V3 = viability _ FDA positive
Mean/S.E.M.
3rbit \ Tyoe d
0 53.67/I0.057
I 83.33/10.057
68.50/7.112
61.80/5.707
60.17/4.035
58.24/3.295
p. t
86.67/I0.057
82.33/10.057
8o.o9/1o.o57
74.67/1o.o57
73.44/5.807
80.11/6.807
84.50/7.112 77.33/7.112
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Lfonetti 2 - White Cells Phagocytic Index
5amole Baq Dewar Orbit:l Tvme V___[] V___22
801 22 a I d 147 141
802 35 b I t 142 143
803 31 g 0 t ]75 195
804 24 F 0 d 171 184
805 39 c I p 143 I46
806 40 e 0 p 159 178
807 25 g 0 d 147 174
808 32 e 0 t 157 148
809 29 a l t 147 I54
810 38 F 0 p ]48 ]33
811 41 b 1 P 155 178
812 23 c I d 123 130
813 37 a 1 p 141 I42
814 28 e 0 d 156 116
815 33 F 0 t 147 154
816 34 c ] t ]63 170
817 36 g 0 p 155 162
818 26 b 1 d 149 149
Vl = Ingestion of
determination I
125
I Staph A, _ oF N-Ethylmaleimide treated controls,
Mean/S.E.M.
Orbit \ Type d p t
0 158.00/6.525 154.00/6,525 159.67/6,525
1 139.67/6.525 146.33/6.525 150.67/6,525
148.83/4.614 150.17/4.614 |55.17/4.614
157.22/3.767
145.55/3.767
orbit p = 0.0490
V2 = Ingestion oF
determ_nation 2
125
I Staph A, % oF N-Ethylmalefmide treated controls,
Mean/S.E.M.
Orbit \ Tyoe d o t
158.00/13,307
140.00/13,307
149.00/9.408
157.67/13,307
155.33/13,307
156.50/9.408
165.67/13.307 160.d4/'7.6_3
[55.67/13.307 150.33/7.683
160.67/9.408
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Lionetti 3 - White Cell Glucose Oxidation
Samote Bag Dewar Orbit=l Type V___!_ V____2
801 22 a 1 d 260 90
802 35 b ] t 290 90
803 31 g 0 t 320 II0
804 24 f 0 d 320 120
805 39 c 1 p 280 I00
806 40 e 0 p 410 120
807 25 g 0 d 190 80
808 32 e 0 t 340 130
809 29 a I t 290 100
810 38 f 0 p 3i0 120
811 41 b l p 390 II0
812 23 c 1 d 200 60
813 37 a I p 320 100
814 28 e 0 d 260 90
815 33 g 0 t 360 120
816 34 C ] t 440 90
817 36 g 0 p 370 110
818 26 b l d 280 90
V] : 14C Glucose Oxidation, Stimulated by PMA, _ over background
Mean/S.E.M.
Orbit \ Type d p
0 256.67/32.914 363.33/32.9]4
1 246.67/32.914 330.00/32.914
251.67/23.274 346.67/23.274
t
340.00/32.914
340.00/32.914
340.00/23.274
320.00/19.003
305.56/i9.003
type p : 0.0237
V2 = 14C Glucose Oxidation, Stimulated by FMLP, % over background
Mean/S.E.M.
Orbit h Type d p
0 96.67/7.201 116.67/7.201
l 80.00/7.201 10.3.33/7.201
t
120.00/7.201
93.33/7.201
111.11/a.157
92.22/4.157
88.33/5.092
type p = 0.0230
orbit p = 0.0075
110.00/5.092 106.67/5.092
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Szymanski I - Red Cells Agglutination
Sample Bag Dewar Orbit=l Ty.oe Vl
201 19 F 0 p 14.08
202 6 a 1 d 14.20
203 17 b I p 14.50
204 14 c I t 14.18
205 I g 0 d 14.48
206 13 e 0 t 13.95
207 2 f 0 d 14.20
208 3 c I d 12.28
209 9 g 0 t 14.33
210 20 a 1 p 14.70
211 8 b I t 13.83
212 15 e 0 p 14.38
213 4 e 0 d 14.90
214 11 f 0 t 16.40
215 21 c 1 p 16.25
216 5 b I d 16.63
217 16 g 0 p 16.30
218 I0 a I t 16.60
Vl = IgG on intact cells, molecules / cell
Mean/S.E.M.
V2
106.8
72.5
73.8
69.0
73.0
65.2
56.3
74.4
64.6
58.1
63.0
53.9
60.5
71.8
75.2
69.4
62.2
76.3
Orbit \ Type d p t
V3
8.35
8.58
8.58
7.95
6.78
6.93
6.73
7.28
7.13
7.85
8.93
8.63
9.13
9.25
9.25
8.85
9.15
8.68
V4
115.75
116.25
116.25
123.50
103.67
110.33
99.50
98.67
96.25
94.50
99.75
99.00
99.25
94.75
94.25
93.25
96.50
91.00
0 14.53/0.791 14.92/0.791 14.89/0.791
I 14.37/0.791 15.15/0.791 14.87/0.791
14.45/0.559 15.04/0.559 14.88/0.559
V2 = IgG inside cells,
Mean/S.E.M.
Orbit \ Type d
0 63.27/7.607
I
14.78/0.457
14.8010.457
molecules/cell
P
74.30/7.607
72.10,/7.607 69.03/7.607
t
67.20/7.607
69 4317.607
68 2614 3¢2. . ° -
70.!9/4.302
67.68/5.379 71.67/5.379 68.32/5.379
V3 : C3c on intact cells, molecules/cell
Mean/S.E.H.
Orbit \ Type d p t
0 7.55/0.535 8.71/0.535 7.77/0.535
1 8.23/0.535 8.56/0.535 8.52/0.535
7.89/0.378 8.64/0.378 8.15/0.378
8.01/0. 309
8.44/0.30_
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V4 = C3d on intact ceils, molecules/cell
Mean/S.E.M.
Orbit \ Type d p
0 |00.8]/6.568 103.75/6.568
! 102.72/6.568 101.67/6.568
101.77/4.644 102.71/4.644
Mean (Standard Error of the Mean)
Type
d : 101.77 (3.20) p : 102.71 (4.26)
Orbit
0 : 101.67 (2.35) I : 103.05 (4.06)
100.44/6.568
10d.75/6.568
102.60/4.644
101.67/3.792
103.05/3.792
t : 102.60 (4.97)
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Szymanski 2 - Red Ce]]s Agglutination
Sample Ba____a Dewar Orbit=] Type Vl V2 V3 V4
201 19 f 0 p 21.90
202 6 a 1 d 21.25
203 17 b 1 p 18.25
204 14 c 1 t 16.30
205 1 g 0 d 22.25
206 13 e 0 t 21.35
207 2 f 0 d 21.60
208 3 c ] d 22.20
209 9 g 0 t 14.35
210 20 a 1 p 16.80
211 8 b I t 27.85
212 15 e 0 p 22.]0
213 4 e 0 d 26.55
214 11 f 0 t 23.85
215 21 c I p 26.50
216 5 b 1 d 24.60
217 ]6 g 0 p 26.30
218 I0 a l t 20.90
48.85
47.10
44.30
40.40
57.40
48.60
46.95
48.30
39.00
42.20
54.90
50.15
54.85
50.75
52.55
51.30
51.65
48.15
76.30
73.10
73.30
72.95
77.25
76.00
74.60
75.35
73.00
72.80
78.00
77.40
77.80
77.25
76.95
76.55
76.90
76.20
54.85
50.45
50.55
50.45
56.35
55.70
54.70
53.60
49.65
49.60
56.15
56.80
56.95
56.80
56.00
56.90
56.60
54.40
Vl = % Agglutination with anti-C3a
MeBn/S.E.M.
Orbit \,Type d p
0 23.47/2.378 23.43/2.378
1 22.68/2.378 20.52/2.378
23.08/1.682 21.98/1.682
t
19.85/2.378
21.68/2.378
20.77/1.682
22.2.5/1.373
21.63/1.373
V2 = % Agglutination with anti-C3c
Mean/S.E.M.
Drbit \.,Type d p t
0 53.07/2.963 50.22/2.963 46.12/2.963
I 48.90/2.963 46.35/2.963 47.82/2.963
50.98/2.095 48.28/2.095 46.97/2.095
49.8011.71!
47.69/I.711
J3 = % Agglutination with antf-C3d
_ean/S.E.M.
)rbit \ Type d p t
76.55/1.124 76.87/1.124 75.42/1.124
75.00/1.124 74.35/1.124 75.7.2/1.124
75.78/0.795 75.6]/0.795 75.57/0.795
76.28/0.649
75.02/0.64_
V4 = _ Agglutination with
Mean/S.E.M.
Orbit \
0
i
ant_-IgG
Page 48
Type d p t
56.00/1.636 56.08/1.636 54.05/1.636
53.65/1.636 52.05/1.636 53.67/1.646
54.83/|.157 54.07/|.157 53.86/I.157
55.3_/0.945
53.12/0.945
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Szymanski 3 - Platelets
Sample Bag Dewar Orbit=l Type Vl V2 V3
600 60 h 0 p 4018 2085 2049
601 45 h 0 d 6611 2198 2123
602 50 h 0 t ]597 2041 2002
603 61 d 1 p 2840 ]574 1840
604 48 d I d 6374 2181 2750
605 56 d 1 t 2997 1218 1200
606 54 d 1 t 1844 1148 1207
607 62 d 1 p 2488 1478 1934
608 43 d I d 5855 2312 2783
609 47 h 0 d 5425 2302 2560
610 59 h 0 p 5059 2164 2461
611 55 h 0 t 5902 2132 2400
612 46 h 0 d 5656 2030 2324
613 53 d ] t 2147 1561 1719
614 63 h 0 p 4208 2013 2218
615 51 h 0 t 4355 1775 2412
616 58 d 1 p 5433 1715 2273
617 44 d I d 6586 2130 2775
Vl : Molecules of bound IgG/platelet
Mean/S.E.M.
OrbTt \ Type d p t
0 5897/688.9 4428/688.9 3951/688.9
1 6271/688.9 3587/688.9 2329/688.9
6084/487.2 4007/487.2 3140/487.2
4759/397.8
4062/397.8
type p : 0.0032
Dmitting bag number 56:
_ean/5.E.M.
]rbit \ Type d p
0 5897/705.4 4428/705.4
I..... 6271/705.4 3587/705.4
6084/498.8 4007/498.8
t
3951/705.4
1995/862.9
3169/546.4
4759/407.2
4195/4Sl.9
:ype p = 0.0052
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V2 = Number oF C3d molecules/platelet
Mean/S.E.M.
Orbit \ Type d p
0 2]76/85.26 2087/85.26
1 2207/85.26 1589/85.26
2192/60.29 1838/60.29
type p : 0.0001
orbit p = 0.0001
interaction p = 0.0037
t
1982/85.26 2082/49.22
1309/85.26 1701/49.22
1645/60.29
omitting bag number 56:
Mean/S.E.M.
Orbit \TvDe d p t
0 2]76/86.9] 2087/86.9] 1982/86.9]
1 2207/86.91 1589/86.91 1354/]06.4
2192/61.45 1838/61.45 1731/67.32
type p = 0.0005
orbit p = 0.001!
interaction p = 0.0085
2082/50.l£
]762/53.22
v3 = Number oF C3c molecules/platelet
Mean/S.E.M.
Orbit \ Type d p t
0 2335/126.0 2242/126.0 2271/126.0
i 2769/]26.0 2015/126.0 1375/126.0
2552/89.12 2129/89.12 1823/89.12
type p = 0.0003
orbit p = 0.0454
interaction p = 0.0007
2283/72.77
2053/72.77
omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d p t
0 2335/]26.2 224,2/126.2 2271/126.2
1 2769/126.2 2015/126.2 1463/154.6
2552/89.25 2129/89.25 1948/97.77
22£3/72.8S
2160/77.30
type p = 0.0019
interaction p = 0.0025
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Szymanski - Platelets
Sample _ Dewar Orbit:] Type V__]
600 60 h 0 p 37122
601 45 h 0 d 52517
602 50 h 0 t 30479
603 61 d 1 p 28264
604 48 d l d 47284
605 56 d ! t 16298
606 54 d l t 16234
607 62 d 1 p 26533
608 43 d 1 d 54000
609 47 h 0 d 47809
610 59 h 0 p 37094
611 55 h 0 t 33935
612 46 h 0 d 44638
613 53 d 1 t 24738
614 63 h 0 p 36985
615 51 h 0 t 39813
616 58 d 1 p 42508
617 44 d 1 d 55841
V2
33104
45906
29382
25424
40910
13301
14390
24045
48145
42384
32035
28033
38982
22591
32777
35458
36978
49255
Vl Total Platelet IgG (molecules/platelet)
Hean/S.E.H.
Orbit \ Type d p t
0 48321/2972 37067/2972 34742/2972
l 52375/2972 32a35/2972 19090/2972
50348/2101 34751/2t01 26916/2101
40043/1716
34633/1716
type p = 0.0001
orbit p = 0.0457
interaction p = 0.0200
omitting bag number 56:
Mean/S.E.M.
3rbit \ Type d
0 48321/3047
! 52375/3,047
50348/2154
P
37067/3047
32435/3047
3475|/2154
t
34742/3047
18490/3732
29039/2360
40043/1759
36925118_5
type p = 0.0001
fnteraction p = 0.0342
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V2 Total Eree IgG in Frozen - Thawed platelets (molecules/platelet)
Mean/S.E.M.
Orbit \Tvpe d p t
0 42424/2632 32629/2632 30957/2632, , 35340/1520
! 46103/2632 28816/2632 16761/2632 30560/]520
44264/186] 30727/1861 23859/1861
type p = 0.0001
orbit p = 0.046|
interaction p = 0.017]
omitting bag number 56:
Mean/S.E.M.
Orbit \ Type d D t
0 42424/2648 32629/2648 30957/2648 35340/1519
I 46103/2648 288}6/2648 ]8491/3243
44264/1873 30727/]873 25970/205]
type p = 0.000]
interaction p = 0.0327
32717/]622
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Taylor White Cells
Sample BaQ Dewar Orbit=l Type
901 22 a l Q
904 40 e 0 p
910 29 a 1 t
9]2 32 e 0 t
913 37 a ] p
918 28 e 0 d
Vl : % viability
Mean/S.E.M.
9rblt \ Txpe d p
0 95.00/2.887 98.00/2.887
I 94.00/2.887 98.00/2.887
94.50/2.041 98.00/2.041
V2 = % Viability - 72 hours
Mean/S.E.M.
V_l v_£ vj_3 v4 v__5_sv6 v7 v8
94 95 38.2 41.5 16.9 27.0 38.6
98 95 38.4 30.0 36.3 79.8 55.1 0.78
91 90 52.9 75.9 47.1 98.7 88.4 0.72
94 97 15.6 23.4 26.0 80.3 81.0 2.06
98 97 17.1 21.0 22.8 115.5 94.9 1.15
95 98 19.5 26.8 60.4 79.7 74.8 4.98
95.67/1.667
94.33/1.667
t
94.00/2.887
91.00/2.887
92.50/2.041
3rblt \ TYRe d p t
0 Ill 98.0Q/2.261 95.00/2.261 97.00/2.26]
1 94.00/2.26! 97.00/2.261 90.00/2.261
96.50/1.985 96.00/1.985 93.50/].985
_3 = Protein Synthesis wlo MItogen
4ean/S.E.M.
]rbtt \ Type d p t
0 19.50/15.37 38.40/15.37 15.60/15.37
1 38.20/15.37 17.10/15.37 52.90/15.37
28.85/10.87 27.75/10.87 34.25/10.87
14 = Protein Synthesis In response to phytohemagglutfnin
P
30.00/19.75
21.00/19.75
25.50/]3.97
t
23.40/19.75
75.90/19.75
49.65/13.97
lean/S.E.M.
)rbit \ Type d
0 26.80/19.75
l 41.50/19.75
34.15/13.97
iContinued on next page)
96.67/1.599
94.33/1.599
24.50/8.874
36.07/8.874
26.73/11.41
46.13/11.41
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/5 = Blastogenesfs w/o Mitogen
4ean/S. E. M.
)rb_t \ Type d p. t
0 60.40/16.85 36.30/16.85 26.00/16.85
] ]6.90/]6.85 22.80/]6.85 47.]0/]6.85
38.65/11.92 29.55/11.92 53.86/11.92
16 = B1astogenesls In response to PHA
lean/S.E.M.
)rbit \ Type d p
0 79.70/34.23 79.80/34.23
I 27.00/34.23 I]5.5/34.23
53.35/23.50 97.65/23.50
40.90/9.729
28.93/9.729
t
80.30/34.23
98.70/34.23
89.50/23.50
79.93/19.]9
80.40/19.19
17 = B1astogenesls In response to Pokeweed mltogen
_ean/S.E.M.
)rb|t \ Type d p t
0 74.80/23.78 55.]0/23.78 81.00/23.78
! 38.60/23.78 94.90/23.78 88_40/23.78
56.70/16.82 75.00/16.82 84.70/16.82
70.30/13.73
73.97/13.73
'8 = Flow cytometry - phycoerythrIn controls
lean/S.E.M.
- % autoflourescence
)rbtt \ Type d p t
0 4.98/1.766 0.78/].766
l . / . ].I5/1.766
4.98/1.766 0.97/].249
2.06/1.766
0.72/1.766
1.39/1.249
2.61/].020
0.94/1.249
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Addendum to Statistical Report
It was suggested by Dr. Surgenor that certain of the measured
variables fell into natural clusters, and that It mlght be
helpful to attempt to analyse the Influence of the experimental
factors on these groups as a whole. The clusters suggested by
Dr. Surgenor were analysed using multivariate analysis of
variance methods. The SAS procedure GLM was again used,
utilizing the MANOVA option.
The first group analysed was a white cell group consisting of
the followlng varlables:
Variable Table In original report
pH
pCO 2
PO 2
viability, % FDA positive
Phagocytic index I
Phagocytic index 2
Glucose oxidation, PMA
Glucose oxidation, FMLP
Jacobson l
,t
tl
L ionett i I
L ionett i 2
tl
Lionett i 3
wt
For thls cluster, the orbit factor was not significant at the 5%
level (p = .09), the bag type factor was significant (p = .0002)
and there was no significant interaction effect.
The second group was a red cell metabolism group:
Variable Table in original report
pH Jacobson 2
It
PCO 2
ATP Jacobson 5
2,3DPG "
G 1ucose "
For this cluster, the orbit factor was not significant, the bag
type factor was slgnificant (p = .002) and there was no
significant interaction effect.
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The third cluster was a red ce]] structure group:
Variable Table in original report
Cell Potassium
Cell Sodium
Plasma Potassium
Plasma Sodium
Plasma hemoglobin
Osmotic Fragility
.5%, .55%, and .6% saline
Phospholipids
Cholesterol
Jacobson 5
l!
Jacobson 6
@!
tt
Kevy l
Jacobson ]3
tt
None of the Factors were significant for this cluster.
The Fourth cluster was a red cell membrane binding group:
Variable Table in origfnal report
IgG on Intact ceils
IgG (nside ceils
C3c on intact cells
C3c inside ceils
Agglutination with anti-C3a
Agglutinat|on with antI-C3c
Agglutlnatfon with anti-C3d
Agg]utlnation with antI-IgG
Szymanski I
tP
fl
ff
Szyrnanski 2
el
@@
It
None oF the Factors were significant for this cluster.
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The fifth cluster was a plate]et metabolism group:
Variable Table in oriofnal report
Glucose Chao ]3
pH Jacobson 3
pCO 2 "
pO 2 "
Lactate Chao 12
P1atelet count Chao !
Mean platelet volume Chao 3
The orbit factor was significant (p = .03) as was bag type
(p = .0002).
The sixth cluster was a plate]et structure group:
Varlab]e Table in original remort
Membrane protein Kenney !
* Membrane g|ycoprote_ns
" Cytoske]eton "
Bound IgG Szymansk| 3
Bound C3d
Bound C3c "
Average transmission
electron microscopy score Ausprunk
" dropped from the analysis due to missTng data.
The orbit factor was s_gniFicant (p = .033) as was the bag type
(p = .048) .
P3ge 4
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The final cluster was a platelet Function group:
Variable Table In oriqinal report
The above together with:
Aggregat{on by collagen
Aggregation by ADP
ATP release
Serotonin uptake
8 - Thrombog]obulin
Thromboxane 8 2
Chao 4
Chao 5
Chao 6
Chao 8
Chao 10
Chao 11
None of the factors were significant for this group.
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June 27,1987
Dr. Douglas Surgenor
The Center for Blood Research
800 Huntington Avenue
Boston, MA 02115
Dear Doug,
Here is a report on the analysis of the data on position of
storage of the samples, As you can see, some of the signicance of
the orbit or bag type effects change, and there is some effect of
position on many but not most of the measured outcomes. I don't
know if these effects are consistent or random, but they definitely
exist. Taking them into account in the analysis lends somewhat more
weight to our conclusions, and it seems obvious that it would be
_ell worth some effort in any future experiments to attempt to
dampen these effects, either by designing the storage system to some
way reduce the effects and/or by carefully matching on storage
position in the design.
I am going to be out of the country during the entire month
of July. I hope Nan can clear up any questions you may have until
then, and I will be in touch with you when I return.
cerely,
Donald K. Blevins, Ph.D.
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T_SE
W_ ,:ill a_gcuss in this report, nn additional analysis which
,._ hav_ rerT_;'med on the data from the Initial Blood Storage
_vr_r4ment. This annlysis was an attempt to evaluate the effect if
an_" of the physical location of storage of the blood bags in the
storage module.
There were identical storage modules for the orbiter and on
Earth. In each of these, the red and white cell bags w_re._tored in
_I,'Q L+ .
three different Dewars, labeled a, b, and c in for t_e _4_e_e_ unit
and correspondingly labeled e, f, and g in the _ unit. Within
each Dewar, the bags were stored in one of three positions - front,
middle or back (see diagram I). The platelet bags were all stored
in one Dewar, labeled d and h respectively, in each storage unit.
Five platelet bags were stored in front and five in back. We
therefor introduced for red and white cells two new factors, Dewar
and position, and for platelets one new factor, position (front or
back). We included these factors together with the previous factors
of bag type and orbital status in an analysis of variance as
before. Due to the larger number of experimental factors, there was
now insufficient data to include any interaction effects, so we used
only a main effects model. In the majority of cases, the inclusion
of these factors caused no significant change in the conclusions of
the previous analyses, but as will be described in the following, in
a number of cases one or both of the following effects were noted.
First, for some of the experimental variables, the Dewar and/or
position in which the sample was stored had a statistically
significant effect on the outcome. Second, the inclusion these new
factors in the model in some cases changed the significance levels
of the original factors. This can occur if the changes in the
experimental variable due to the new factors was large enough to
partially mask the change caused by the others.
Following is a summary of the new results. Any variables not
noted were not significantly changed in this analyses as compared to
the previous analysis. (page numbers refer to the previously
distributed complete report)
Ausprunk - Transmission Electron Microscopy Data - Red Cells
V1 Total Number of Cells Counted - orbit p : 0.0459
Ausprunk - Transmission Electron Microscopy Data - White Cells
(page 6) V5 Average Ranking - orbit p : 0.0565
Chao 4 (page 12)
Vl Aggregation (by collagen) - orbit p = 0.0202
position p = 0.0195
Chao 5 (page 13)
V1 Aggregation (by ADP) - type p : 0.0634
position p : 0.0206
_,i_!_l. PAGE IS
OF POOR QUALITY
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Chao 6 (page 14)
VI ATP Release - orbit p = 0.0692
position p = 0.0464
Chao 8 (page 16)
V1Serotonin Uptake - position p = 0.0506
Chao 13 (page 21)
V1 Glucose - position p = 0.0344
Curby 2 - White Cell Distribution
V1 - Dewar p = 0.0032
V2 - Dewar p = 0.0006
V3 Peak Channel - type p = 0.0049
Dewar p = 0.0049
Jacobson 1 White Blood Cells (page 26)
V1 pH - type p = 0.0001
position p = 0.0001
Dewar p = 0.0677
V2 pCO 2 - orbit p = 0.0001
type p = 0.0001
position p = 0.0016
Dewar p = 0.0044
Jacobson 2 - Red Blood Cells (page 28)
V1 pH - type p = 0.0001
orbit p = 0.0005
position p = 0.0004
Dewar p = 0.0428
V2 pCO 2 - orbit p = 0.0060
type p = 0.0001
Jacobson 3 - Platelets (page 30)
Vl pH - type p = 0.0589
position p = 0.0277
Jacobson 5 - Red Blood Cells (page 33)
V3 Glucose - position p = 0.0359
Jacobson 6 - Red Blood Cells (page 35)
V2 Plasma Potassium - orbit p : 0.0006
position p = 0.0001
V3 Plasma Sodium - position p = 0.0548
Lionetti 1 - White Cells Recovery and Viability (page 42)
V1 Count - position p = 0.0010
Dewar p = 0.0250
V2 % recovery - position p = 0.0010
Dewar p = 0.0249
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Lionetti 2 -
V!
V2
White Cells Phagocytic Index (page 43)
orbit p = 0.0104
position p = 0.0079
position p = 0.0090
Lionetti 3
V1
V2
White Cells Glucose Oxidation (page 44)
14C Glucose Oxidation, Stimulated by PMA -
type p = 0.0068
position p = 0.0370
14C Glucose Oxidation, Stimulated by FMLP -
type p = 0.0018
orbit p = 0.0005
position p = 0.0764
Dewar p = 0.0114
Szymanski 1 - Ned Cells Agglutination (page 45)
V11EG on intact cells - position p = 0.0099
Szymanski 2 - Red Cells Agglutination
V1% agglutination with anti-C3a
V2 % agglutination with anti-C3c
(page 47)
- position = 0.0171
- position = 0.0595
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Dr. Douglas Surgenor
The Center for Blood Research
BOO Huntington Avenue
Boston, MA 02115
September 8, 19B?
Dear Doug;
Here ts the analysis of the TOTM piatelet bags that Nan said
you were Interested In. I think It Is self explanatory, but as
usual feel free to cll me If you have questions.
Blevtns, Ph.D.
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We have done an analysls of the effect of mlcrogravilty
versus controls considering only the platelet bags of type PVC
TOTM. Since the only variable factor was the two level
earth/orblt factor, a slmple t-test suffices for the analysis.
The SAS TTEST procedure was used. A basic assumption of the t-
test Is that the underlying populatlon of each of the two groups
are normally distributed with equal variances. If the equal
variance assumption Is not satisfied an approximate t-test can be
used. The SAS procedure TTEST reports both results together wlth
a test statistic for the equal variance assu_tlon. For these
data, the assumption of equal variance was statistically
acceptable (p > .10) except for a few of the outcome variables.
Therefor tn the following summary, we will report only the
results of the standard t-test except for those Few Items, for
which we will report both the standard statistic and the
approximate statistic. Unless otherwise noted the degree of
freedom for the t-test Is 5. The degree of freedom for the
approximate t-test depends on the calculated sample variances.
Results
Ausprunk data:
Psuedopocls
Aggregated
Oegranulated
Swollen/Ruptured
Average Score
Chao data:
Platelet count
Hypotonlc stress
Mean volume
T - -2.39, p = 0.06
T - 0.85, p = 0.44
T -- 1.20, p -- 0.29
T = 2.07, p - 0.09
T - 1.66, p " 0.16
T " 5.16, p = 0.0036
T = -].41, p = 0.22
T = 9.07, p - 0.0003
Aggregation (collagen)
T = -2.59, p = 0.0489
Aggregation (ADP) T = -I.94. p = 0.11
(Unequal var. p = 0.0626, approx. T = -1.66, p = 0.23)
ATP release T = -!.38, p = 0.23
Russell's Viper venom time
T = 1.20, p = 0.29
Serotonin uptake T - -1.46, p - 0.20
(Unequal var. p - 0.0105, approx. T s -I.23, p = 0.34)
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Serotontn release T = -1.20, p = 0.29
I_-Thromboglobin T = !.40, p - 0.22
Thromboxane B2 T = !.88, p = 0.12
(Unequal var. p = O. 0025, approx. T = 2.22, p = O. ! ! )
Lactate T = 2.07, p = 0.09
Glucose T = -0.83, p = 0.45
(Unequal var. p = 0.0318, approx. T = -0.70, p = 0.55)
Curby data :
1-254/ml x 109 T = 0.80, p = 0.46
> 254/m1 x 109 T = -0.19, p = 0.86
Peak channel T = -0.33, p = 0.75
Delay factor T = -1.10, p = 0.3Z
Jacobson data :
pH T = -1.21, p = 0.28
(Unequal ver. p = 0.0165, apprx. T = -1.02, p = 0.41)
pCO 2 T = -2.28, p = 0.07
(Unequal var. p = 0.0001, approx. T = -1.91, p = 0.20)
pO 2 T = 2.50, p = 0.0543
Kenney data:
125! _ membrane protein
T = 4.27 df = l, p = 0.14
3H - membrane gl ycoprotel n
T = 6.74 df = l, p = 0.09
Cytoskeleton T = 13.28 df = I, p = 0.0479
5zymansk ! data:
Bound l gG T = 1.20 (:If = 3, p = 0.32
C3d molecules / platelet
T = 3.03 df = 3, p = 0.0560
C3c molecules / platelet
T = 3.13 df = 3, p = 0.0520
Total IgG T = 3.01 df = 3, p = 0.0572
Total free lgG !n frozen - thawed plate!ets
T = 2.94 dF = 3, p = 0.06
